bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
TCR repertoire is a protein_family_or_group, Epstein - Barr virus - encoded transactivator protein is a protein_family_or_group, BZLF1 is a protein_molecule, CD8 + cytotoxic T lymphocytes is a cell_type	55581_task1	Sentence: Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Instructions: please typing these entity words according to sentence: TCR repertoire, Epstein - Barr virus - encoded transactivator protein, BZLF1, CD8 + cytotoxic T lymphocytes Options: cell_type, protein_family_or_group, protein_molecule	[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "O", "O" ]	Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.	[ "Selection", "of", "a", "diverse", "TCR", "repertoire", "in", "response", "to", "an", "Epstein", "-", "Barr", "virus", "-", "encoded", "transactivator", "protein", "BZLF1", "by", "CD8", "+", "cytotoxic", "T", "lymphocytes", "during", "primary", "and", "persistent", "infection", "." ]	[ "cell_line", "protein_family_or_group", "multi_cell", "cell_type", "(AND virus virus)", "other_name", "(OR other_name other_name)", "peptide", "(AND cell_line cell_line)", "virus", "protein_domain_or_region", "RNA_molecule", "", "protein_subunit", "DNA_domain_or_region", "protein_molecule" ]
TCR repertoire, Epstein - Barr virus - encoded transactivator protein, BZLF1, CD8 + cytotoxic T lymphocytes	55581_task2	Sentence: Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "O", "O" ]	Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.	[ "Selection", "of", "a", "diverse", "TCR", "repertoire", "in", "response", "to", "an", "Epstein", "-", "Barr", "virus", "-", "encoded", "transactivator", "protein", "BZLF1", "by", "CD8", "+", "cytotoxic", "T", "lymphocytes", "during", "primary", "and", "persistent", "infection", "." ]	[ "cell_line", "protein_family_or_group", "multi_cell", "cell_type", "(AND virus virus)", "other_name", "(OR other_name other_name)", "peptide", "(AND cell_line cell_line)", "virus", "protein_domain_or_region", "RNA_molecule", "", "protein_subunit", "DNA_domain_or_region", "protein_molecule" ]
GM - CSF is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, p50 is a Protein, p65 is a Protein, GM - CSF is a Protein, enhancers is a Entity, p50 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, KBF1 is a Protein, p50 is a Protein, GM - CSF is a Protein, GM - CSF is a Protein	293_task0	Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.	[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]	[ "Protein", "Entity" ]
GM - CSF is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, p50 is a Protein, p65 is a Protein, GM - CSF is a Protein, enhancers is a Entity, p50 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, KBF1 is a Protein, p50 is a Protein, GM - CSF is a Protein, GM - CSF is a Protein	293_task1	Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please typing these entity words according to sentence: GM - CSF, granulocyte - macrophage colony - stimulating factor, GM - CSF, GM - CSF, GM - CSF, p50, p65, GM - CSF, enhancers, p50, p50, p65, p65, KBF1, p50, GM - CSF, GM - CSF Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.	[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]	[ "Protein", "Entity" ]
GM - CSF, granulocyte - macrophage colony - stimulating factor, GM - CSF, GM - CSF, GM - CSF, p50, p65, GM - CSF, enhancers, p50, p50, p65, p65, KBF1, p50, GM - CSF, GM - CSF	293_task2	Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.	[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]	[ "Protein", "Entity" ]
hydrocortisone is a lipid, chemotactic migration is an other_name, human leukocytes is a cell_type	97938_task0	Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, lipid, other_name	[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]	[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]	[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]	[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]
hydrocortisone is a lipid, chemotactic migration is an other_name, human leukocytes is a cell_type	97938_task1	Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please typing these entity words according to sentence: hydrocortisone, chemotactic migration, human leukocytes Options: cell_type, lipid, other_name	[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]	[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]	[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]	[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]
hydrocortisone, chemotactic migration, human leukocytes	97938_task2	Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]	[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]	[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]	[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]
tumor necrosis factor receptor - associated factor 6 is a Protein, TRAF6 is a Protein, MyD88 is a Protein, Tumor necrosis factor receptor - activated factor 6 is a Protein, TRAF6 is a Protein, nuclear factor kappaB ( NF - kappaB)-inducing kinase is a Protein, NIK is a Protein, TRAF6 is a Protein	823_task0	Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.	[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]	[ "Protein" ]
tumor necrosis factor receptor - associated factor 6 is a Protein, TRAF6 is a Protein, MyD88 is a Protein, Tumor necrosis factor receptor - activated factor 6 is a Protein, TRAF6 is a Protein, nuclear factor kappaB ( NF - kappaB)-inducing kinase is a Protein, NIK is a Protein, TRAF6 is a Protein	823_task1	Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please typing these entity words according to sentence: tumor necrosis factor receptor - associated factor 6, TRAF6, MyD88, Tumor necrosis factor receptor - activated factor 6, TRAF6, nuclear factor kappaB ( NF - kappaB)-inducing kinase, NIK, TRAF6 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.	[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]	[ "Protein" ]
tumor necrosis factor receptor - associated factor 6, TRAF6, MyD88, Tumor necrosis factor receptor - activated factor 6, TRAF6, nuclear factor kappaB ( NF - kappaB)-inducing kinase, NIK, TRAF6	823_task2	Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.	[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]	[ "Protein" ]
new capsule - type colon specific drug delivery system is a Intervention_Pharmacological, healthy volunteers . is a Participant_Condition, Colonic drug delivery is a Intervention_Physical, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) is a Intervention_Physical	91759_task0	Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Pharmacological, Participant_Condition	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .	[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]	[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
new capsule - type colon specific drug delivery system is a Intervention_Pharmacological, healthy volunteers . is a Participant_Condition, Colonic drug delivery is a Intervention_Physical, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) is a Intervention_Physical	91759_task1	Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please typing these entity words according to sentence: new capsule - type colon specific drug delivery system, healthy volunteers ., Colonic drug delivery, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) Options: Intervention_Physical, Intervention_Pharmacological, Participant_Condition	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .	[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]	[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
new capsule - type colon specific drug delivery system, healthy volunteers ., Colonic drug delivery, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule )	91759_task2	Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .	[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]	[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]
glycyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N, glycyl - tRNA synthetase is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, aminoacyl - tRNA synthetases is a GENE-N, amino acids is a CHEMICAL, GARS is a GENE-Y, glycine is a CHEMICAL, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, tRNA synthetase is a GENE-N, YARS is a GENE-Y, tyrosyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N	3722_task0	Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.	[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glycyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N, glycyl - tRNA synthetase is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, aminoacyl - tRNA synthetases is a GENE-N, amino acids is a CHEMICAL, GARS is a GENE-Y, glycine is a CHEMICAL, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, tRNA synthetase is a GENE-N, YARS is a GENE-Y, tyrosyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N	3722_task1	Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please typing these entity words according to sentence: glycyl - tRNA synthetase, tRNA - charging enzymes, glycyl - tRNA synthetase, GARS, GARS, aminoacyl - tRNA synthetases, amino acids, GARS, glycine, GARS, GARS, GARS, GARS, GARS, tRNA synthetase, YARS, tyrosyl - tRNA synthetase, tRNA - charging enzymes Options: CHEMICAL, GENE-Y, GENE-N	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.	[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
glycyl - tRNA synthetase, tRNA - charging enzymes, glycyl - tRNA synthetase, GARS, GARS, aminoacyl - tRNA synthetases, amino acids, GARS, glycine, GARS, GARS, GARS, GARS, GARS, tRNA synthetase, YARS, tyrosyl - tRNA synthetase, tRNA - charging enzymes	3722_task2	Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.	[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
TCR is a Entity, response genes is a Entity, TCR gene is a Entity, loci is a Entity, TCR gamma loci is a Entity, TCR beta is a Entity, cellular response gene is a Entity, IL-2 is a Protein, chromatin is a Entity, genes is a Entity, IL-2R alpha is a Protein, IL-2 is a Protein, IL-2R beta chain is a Protein, Bcl-2 is a Protein	759_task0	Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .	[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]	[ "Entity", "Protein" ]
TCR is a Entity, response genes is a Entity, TCR gene is a Entity, loci is a Entity, TCR gamma loci is a Entity, TCR beta is a Entity, cellular response gene is a Entity, IL-2 is a Protein, chromatin is a Entity, genes is a Entity, IL-2R alpha is a Protein, IL-2 is a Protein, IL-2R beta chain is a Protein, Bcl-2 is a Protein	759_task1	Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please typing these entity words according to sentence: TCR, response genes, TCR gene, loci, TCR gamma loci, TCR beta, cellular response gene, IL-2, chromatin, genes, IL-2R alpha, IL-2, IL-2R beta chain, Bcl-2 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .	[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]	[ "Entity", "Protein" ]
TCR, response genes, TCR gene, loci, TCR gamma loci, TCR beta, cellular response gene, IL-2, chromatin, genes, IL-2R alpha, IL-2, IL-2R beta chain, Bcl-2	759_task2	Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .	[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]	[ "Entity", "Protein" ]
ASIC2 is a GENE-Y, amiloride is a CHEMICAL	16704974_task0	Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.	[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ASIC2 is a GENE-Y, amiloride is a CHEMICAL	16704974_task1	Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please typing these entity words according to sentence: ASIC2, amiloride Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.	[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ASIC2, amiloride	16704974_task2	Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.	[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
chronic lymphocytic leukemia is a Participant_Condition, rituximab ( R ) to fludarabine and cyclophosphamide is a Intervention_Pharmacological, FC is a Intervention_Pharmacological, patient outcomes is a Outcome_Physical, CLL is a Participant_Condition, genome - wide expression is a Outcome_Physical, 300 is a Participant_Sample-size, 552 is a Participant_Sample-size, R - FC is a Intervention_Pharmacological, progression - free survival is a Outcome_Mortality, R - dependent cell death is a Outcome_Physical	66009_task0	Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .	[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]
chronic lymphocytic leukemia is a Participant_Condition, rituximab ( R ) to fludarabine and cyclophosphamide is a Intervention_Pharmacological, FC is a Intervention_Pharmacological, patient outcomes is a Outcome_Physical, CLL is a Participant_Condition, genome - wide expression is a Outcome_Physical, 300 is a Participant_Sample-size, 552 is a Participant_Sample-size, R - FC is a Intervention_Pharmacological, progression - free survival is a Outcome_Mortality, R - dependent cell death is a Outcome_Physical	66009_task1	Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please typing these entity words according to sentence: chronic lymphocytic leukemia, rituximab ( R ) to fludarabine and cyclophosphamide, FC, patient outcomes, CLL, genome - wide expression, 300, 552, R - FC, progression - free survival, R - dependent cell death Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .	[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]
chronic lymphocytic leukemia, rituximab ( R ) to fludarabine and cyclophosphamide, FC, patient outcomes, CLL, genome - wide expression, 300, 552, R - FC, progression - free survival, R - dependent cell death	66009_task2	Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .	[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]	[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]
Echinococcus is an umlsterm, Larvenstadium is an umlsterm, menschlichen Koerpers is an umlsterm, Leber is an umlsterm, Knochenbefall is an umlsterm, Becken- is an umlsterm, Hueftgelenks is an umlsterm, Os pubis is an umlsterm, Hueftgelenk- is an umlsterm, Beckenteilresektion is an umlsterm, Rezidiv is an umlsterm, Femur is an umlsterm, Chemotherapie is an umlsterm, Mebendazol is an umlsterm	DerChirurg.70680832.ger.abstr_task0	Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .	[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]	[ "umlsterm" ]
Echinococcus is an umlsterm, Larvenstadium is an umlsterm, menschlichen Koerpers is an umlsterm, Leber is an umlsterm, Knochenbefall is an umlsterm, Becken- is an umlsterm, Hueftgelenks is an umlsterm, Os pubis is an umlsterm, Hueftgelenk- is an umlsterm, Beckenteilresektion is an umlsterm, Rezidiv is an umlsterm, Femur is an umlsterm, Chemotherapie is an umlsterm, Mebendazol is an umlsterm	DerChirurg.70680832.ger.abstr_task1	Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please typing these entity words according to sentence: Echinococcus, Larvenstadium, menschlichen Koerpers, Leber, Knochenbefall, Becken-, Hueftgelenks, Os pubis, Hueftgelenk-, Beckenteilresektion, Rezidiv, Femur, Chemotherapie, Mebendazol Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .	[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]	[ "umlsterm" ]
Echinococcus, Larvenstadium, menschlichen Koerpers, Leber, Knochenbefall, Becken-, Hueftgelenks, Os pubis, Hueftgelenk-, Beckenteilresektion, Rezidiv, Femur, Chemotherapie, Mebendazol	DerChirurg.70680832.ger.abstr_task2	Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .	[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]	[ "umlsterm" ]
cancer is a Disease, new malignancies is a Disease, tobacco is a Plant, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, Tobacco is a Plant, cancers is a Disease, acute myeloid leukemia is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, tobacco is a Plant, cancer is a Disease	22706885_task0	Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]	INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.	[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]	[ "Disease", "Plant" ]
cancer is a Disease, new malignancies is a Disease, tobacco is a Plant, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, Tobacco is a Plant, cancers is a Disease, acute myeloid leukemia is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, tobacco is a Plant, cancer is a Disease	22706885_task1	Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please typing these entity words according to sentence: cancer, new malignancies, tobacco, cancer, tobacco, cancer, cancer, tobacco, cancer, cancer, tobacco, Tobacco, cancers, acute myeloid leukemia, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, tobacco, tobacco, cancer Options: Disease, Plant	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]	INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.	[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]	[ "Disease", "Plant" ]
cancer, new malignancies, tobacco, cancer, tobacco, cancer, cancer, tobacco, cancer, cancer, tobacco, Tobacco, cancers, acute myeloid leukemia, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, tobacco, tobacco, cancer	22706885_task2	Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]	INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.	[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]	[ "Disease", "Plant" ]
pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, cutaneous lesions is a ADVERSE, weakness is a ADVERSE, fever is a ADVERSE, poor appetite is a ADVERSE, nausea is a ADVERSE, vomiting is a ADVERSE, painful lesions is a ADVERSE, cutaneous ulceration is a ADVERSE, pancytopenia is a ADVERSE, abnormal coagulation is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, pancytopenia is a ADVERSE, renal insufficiency is a ADVERSE, hypoalbuminemia is a ADVERSE, concomitant infections is a ADVERSE, pancytopenia is a ADVERSE, rheumatoid arthritis is a DISEASE	example-313_task0	Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE	[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]	Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.	[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]	[ "ADVERSE", "DISEASE" ]
pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, cutaneous lesions is a ADVERSE, weakness is a ADVERSE, fever is a ADVERSE, poor appetite is a ADVERSE, nausea is a ADVERSE, vomiting is a ADVERSE, painful lesions is a ADVERSE, cutaneous ulceration is a ADVERSE, pancytopenia is a ADVERSE, abnormal coagulation is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, pancytopenia is a ADVERSE, renal insufficiency is a ADVERSE, hypoalbuminemia is a ADVERSE, concomitant infections is a ADVERSE, pancytopenia is a ADVERSE, rheumatoid arthritis is a DISEASE	example-313_task1	Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please typing these entity words according to sentence: pancytopenia, skin ulcer, Pancytopenia, pancytopenia, cutaneous lesions, weakness, fever, poor appetite, nausea, vomiting, painful lesions, cutaneous ulceration, pancytopenia, abnormal coagulation, Pancytopenia, pancytopenia, skin ulcer, pancytopenia, renal insufficiency, hypoalbuminemia, concomitant infections, pancytopenia, rheumatoid arthritis Options: ADVERSE, DISEASE	[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]	Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.	[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]	[ "ADVERSE", "DISEASE" ]
pancytopenia, skin ulcer, Pancytopenia, pancytopenia, cutaneous lesions, weakness, fever, poor appetite, nausea, vomiting, painful lesions, cutaneous ulceration, pancytopenia, abnormal coagulation, Pancytopenia, pancytopenia, skin ulcer, pancytopenia, renal insufficiency, hypoalbuminemia, concomitant infections, pancytopenia, rheumatoid arthritis	example-313_task2	Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]	Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.	[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]	[ "ADVERSE", "DISEASE" ]
Patienten is an umlsterm, chronischer Niereninsuffizienz is an umlsterm, Skelettveraenderungen is an umlsterm, Knochenmasseveraenderungen is an umlsterm, Wirbelsaeule is an umlsterm, Haemodialyse is an umlsterm, Autopsiefaellen is an umlsterm, Dialysedauer is an umlsterm, Wirbelsaeulen is an umlsterm, skelettgesunde is an umlsterm, Autopsiefaelle is an umlsterm, Beckenkammbiopsie is an umlsterm, Biopsieort is an umlsterm, Wirbelsaeule is an umlsterm, Praeparationstechnik is an umlsterm, Analyse is an umlsterm, Wirbelkoerperhoehen is an umlsterm, Knochenvolumen is an umlsterm, Wirbelkoerperfrakturen is an umlsterm, Osteopathie is an umlsterm, Knochenvolumens is an umlsterm, Normalbereich is an umlsterm, skelettgesunden is an umlsterm, Wirbelsaeule is an umlsterm, Beckenkammbiopsie is an umlsterm, Haemodialyse is an umlsterm, Geschlecht is an umlsterm, Analyse is an umlsterm, Architektur is an umlsterm, Patienten is an umlsterm, Haemodialyse is an umlsterm	DerPathologe.40150015.ger.abstr_task0	Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .	[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]	[ "umlsterm" ]
Patienten is an umlsterm, chronischer Niereninsuffizienz is an umlsterm, Skelettveraenderungen is an umlsterm, Knochenmasseveraenderungen is an umlsterm, Wirbelsaeule is an umlsterm, Haemodialyse is an umlsterm, Autopsiefaellen is an umlsterm, Dialysedauer is an umlsterm, Wirbelsaeulen is an umlsterm, skelettgesunde is an umlsterm, Autopsiefaelle is an umlsterm, Beckenkammbiopsie is an umlsterm, Biopsieort is an umlsterm, Wirbelsaeule is an umlsterm, Praeparationstechnik is an umlsterm, Analyse is an umlsterm, Wirbelkoerperhoehen is an umlsterm, Knochenvolumen is an umlsterm, Wirbelkoerperfrakturen is an umlsterm, Osteopathie is an umlsterm, Knochenvolumens is an umlsterm, Normalbereich is an umlsterm, skelettgesunden is an umlsterm, Wirbelsaeule is an umlsterm, Beckenkammbiopsie is an umlsterm, Haemodialyse is an umlsterm, Geschlecht is an umlsterm, Analyse is an umlsterm, Architektur is an umlsterm, Patienten is an umlsterm, Haemodialyse is an umlsterm	DerPathologe.40150015.ger.abstr_task1	Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please typing these entity words according to sentence: Patienten, chronischer Niereninsuffizienz, Skelettveraenderungen, Knochenmasseveraenderungen, Wirbelsaeule, Haemodialyse, Autopsiefaellen, Dialysedauer, Wirbelsaeulen, skelettgesunde, Autopsiefaelle, Beckenkammbiopsie, Biopsieort, Wirbelsaeule, Praeparationstechnik, Analyse, Wirbelkoerperhoehen, Knochenvolumen, Wirbelkoerperfrakturen, Osteopathie, Knochenvolumens, Normalbereich, skelettgesunden, Wirbelsaeule, Beckenkammbiopsie, Haemodialyse, Geschlecht, Analyse, Architektur, Patienten, Haemodialyse Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .	[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]	[ "umlsterm" ]
Patienten, chronischer Niereninsuffizienz, Skelettveraenderungen, Knochenmasseveraenderungen, Wirbelsaeule, Haemodialyse, Autopsiefaellen, Dialysedauer, Wirbelsaeulen, skelettgesunde, Autopsiefaelle, Beckenkammbiopsie, Biopsieort, Wirbelsaeule, Praeparationstechnik, Analyse, Wirbelkoerperhoehen, Knochenvolumen, Wirbelkoerperfrakturen, Osteopathie, Knochenvolumens, Normalbereich, skelettgesunden, Wirbelsaeule, Beckenkammbiopsie, Haemodialyse, Geschlecht, Analyse, Architektur, Patienten, Haemodialyse	DerPathologe.40150015.ger.abstr_task2	Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .	[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]	[ "umlsterm" ]
Interleukin-4 is a Protein, IL-4 is a Protein, interleukin-12 is a Entity, IL-12 is a Entity, tyrosine residues is a Entity, intracellular domain is a Entity, phosphotyrosines is a Entity, docking sites is a Entity, src homology 2 ( SH2 ) domain is a Entity, intracellular domain is a Entity, phosphotyrosine residue is a Entity, amino acid residues is a Entity, phosphotyrosine is a Entity, docking sites is a Entity	186_task0	Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.	[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]	[ "Entity", "Protein" ]
Interleukin-4 is a Protein, IL-4 is a Protein, interleukin-12 is a Entity, IL-12 is a Entity, tyrosine residues is a Entity, intracellular domain is a Entity, phosphotyrosines is a Entity, docking sites is a Entity, src homology 2 ( SH2 ) domain is a Entity, intracellular domain is a Entity, phosphotyrosine residue is a Entity, amino acid residues is a Entity, phosphotyrosine is a Entity, docking sites is a Entity	186_task1	Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please typing these entity words according to sentence: Interleukin-4, IL-4, interleukin-12, IL-12, tyrosine residues, intracellular domain, phosphotyrosines, docking sites, src homology 2 ( SH2 ) domain, intracellular domain, phosphotyrosine residue, amino acid residues, phosphotyrosine, docking sites Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.	[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]	[ "Entity", "Protein" ]
Interleukin-4, IL-4, interleukin-12, IL-12, tyrosine residues, intracellular domain, phosphotyrosines, docking sites, src homology 2 ( SH2 ) domain, intracellular domain, phosphotyrosine residue, amino acid residues, phosphotyrosine, docking sites	186_task2	Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.	[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]	[ "Entity", "Protein" ]
fimbrin is a protein, actin is a protein	1.0alpha7.train.1315_task0	Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.	[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]	[ "protein" ]
fimbrin is a protein, actin is a protein	1.0alpha7.train.1315_task1	Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please typing these entity words according to sentence: fimbrin, actin Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.	[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]	[ "protein" ]
fimbrin, actin	1.0alpha7.train.1315_task2	Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.	[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]	[ "protein" ]
Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase is a GENE-Y	16532449_task0	Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.	[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]	[ "GENE-Y", "CHEMICAL" ]
Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase is a GENE-Y	16532449_task1	Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please typing these entity words according to sentence: Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.	[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]	[ "GENE-Y", "CHEMICAL" ]
Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase	16532449_task2	Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]	Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.	[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]	[ "GENE-Y", "CHEMICAL" ]
complication probability modeling is a Intervention_Other, after radiotherapy is a Participant_Condition, prostate cancer is a Participant_Condition, 512 is a Participant_Sample-size, 284 is a Participant_Sample-size, 228 is a Participant_Sample-size, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model is a Intervention_Other, High stool frequency is a Outcome_Physical	50694_task0	Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Other, Outcome_Physical, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .	[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]	[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
complication probability modeling is a Intervention_Other, after radiotherapy is a Participant_Condition, prostate cancer is a Participant_Condition, 512 is a Participant_Sample-size, 284 is a Participant_Sample-size, 228 is a Participant_Sample-size, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model is a Intervention_Other, High stool frequency is a Outcome_Physical	50694_task1	Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please typing these entity words according to sentence: complication probability modeling, after radiotherapy, prostate cancer, 512, 284, 228, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model, High stool frequency Options: Intervention_Other, Outcome_Physical, Participant_Condition, Participant_Sample-size	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .	[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]	[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
complication probability modeling, after radiotherapy, prostate cancer, 512, 284, 228, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model, High stool frequency	50694_task2	Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .	[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]	[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]
evolutional process is a Outcome_Other, language therapeutic interventions is a Intervention_Educational, the extension and the speed of the evolutional process is a Outcome_Mental, direct and indirect interventions is a Intervention_Educational, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention is a Intervention_Physical, Autism Behavior Checklist ( ABC ) to interview the mothers is a Intervention_Educational, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) is a Intervention_Educational, speed and extension in the evolutional process is a Outcome_Other, Autism Behavior Checklist ( total and partial scores ) is a Outcome_Mental, performance is a Outcome_Mental, adaptive functioning is a Outcome_Mental	50196_task0	Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Educational, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .	[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]	[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]
evolutional process is a Outcome_Other, language therapeutic interventions is a Intervention_Educational, the extension and the speed of the evolutional process is a Outcome_Mental, direct and indirect interventions is a Intervention_Educational, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention is a Intervention_Physical, Autism Behavior Checklist ( ABC ) to interview the mothers is a Intervention_Educational, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) is a Intervention_Educational, speed and extension in the evolutional process is a Outcome_Other, Autism Behavior Checklist ( total and partial scores ) is a Outcome_Mental, performance is a Outcome_Mental, adaptive functioning is a Outcome_Mental	50196_task1	Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please typing these entity words according to sentence: evolutional process, language therapeutic interventions, the extension and the speed of the evolutional process, direct and indirect interventions, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention, Autism Behavior Checklist ( ABC ) to interview the mothers, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ), speed and extension in the evolutional process, Autism Behavior Checklist ( total and partial scores ), performance, adaptive functioning Options: Intervention_Physical, Intervention_Educational, Outcome_Other, Outcome_Mental	[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .	[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]	[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]
evolutional process, language therapeutic interventions, the extension and the speed of the evolutional process, direct and indirect interventions, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention, Autism Behavior Checklist ( ABC ) to interview the mothers, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ), speed and extension in the evolutional process, Autism Behavior Checklist ( total and partial scores ), performance, adaptive functioning	50196_task2	Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .	[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]	[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]
Methoden is an umlsterm, Therapieverfahren is an umlsterm, Behandlung is an umlsterm, Kniegelenks is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Knorpelveraenderungen is an umlsterm, Holmium is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Brancheninstrumente is an umlsterm, Knorpellaesionen is an umlsterm, Knorpellaesion is an umlsterm, Geschlechtsverteilung is an umlsterm, Behandlung is an umlsterm, Patientengruppen is an umlsterm, Patienten is an umlsterm, Fragebogen is an umlsterm, Schmerzauspraegung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Laserpatienten is an umlsterm, Schmerzwahrnehmung is an umlsterm, Fragebogens is an umlsterm, Lasergruppe is an umlsterm, Schmerzwahrnehmung is an umlsterm	Arthroskopie.80110291.ger.abstr_task0	Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .	[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]	[ "umlsterm" ]
Methoden is an umlsterm, Therapieverfahren is an umlsterm, Behandlung is an umlsterm, Kniegelenks is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Knorpelveraenderungen is an umlsterm, Holmium is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Brancheninstrumente is an umlsterm, Knorpellaesionen is an umlsterm, Knorpellaesion is an umlsterm, Geschlechtsverteilung is an umlsterm, Behandlung is an umlsterm, Patientengruppen is an umlsterm, Patienten is an umlsterm, Fragebogen is an umlsterm, Schmerzauspraegung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Laserpatienten is an umlsterm, Schmerzwahrnehmung is an umlsterm, Fragebogens is an umlsterm, Lasergruppe is an umlsterm, Schmerzwahrnehmung is an umlsterm	Arthroskopie.80110291.ger.abstr_task1	Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please typing these entity words according to sentence: Methoden, Therapieverfahren, Behandlung, Kniegelenks, Patienten, Patienten, Knorpelveraenderungen, Holmium, Patienten, Instrumente, Brancheninstrumente, Knorpellaesionen, Knorpellaesion, Geschlechtsverteilung, Behandlung, Patientengruppen, Patienten, Fragebogen, Schmerzauspraegung, Patienten, Patienten, Laserpatienten, Schmerzwahrnehmung, Fragebogens, Lasergruppe, Schmerzwahrnehmung Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .	[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]	[ "umlsterm" ]
Methoden, Therapieverfahren, Behandlung, Kniegelenks, Patienten, Patienten, Knorpelveraenderungen, Holmium, Patienten, Instrumente, Brancheninstrumente, Knorpellaesionen, Knorpellaesion, Geschlechtsverteilung, Behandlung, Patientengruppen, Patienten, Fragebogen, Schmerzauspraegung, Patienten, Patienten, Laserpatienten, Schmerzwahrnehmung, Fragebogens, Lasergruppe, Schmerzwahrnehmung	Arthroskopie.80110291.ger.abstr_task2	Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .	[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]	[ "umlsterm" ]
Age is a Person, 65 - 79 is a Value, History is a Observation, coronary artery disease is a Condition, MI / heart attack , stroke , heart failure , or peripheral artery disease is a Scope, Cancer is a Condition, no is a Negation, active treatment is a Procedure, in the last year is a Temporal, MCI is a Condition, MoCA > 18<26 is a Scope, Decline physical function is a Condition, walking speed < 1 m / s is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hypertension is a Condition, treated or resting blood pressure > 140/90 is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hyperlipidemia is a Condition, treated or fasting total cholesterol > 240 is a Scope, English literacy is a Observation, Willing to is a Mood, provide informed consent is a Observation	NCT02986659_inc_task0	Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Observation, Procedure, Negation, Scope, Mood	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]	Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent	[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]
Age is a Person, 65 - 79 is a Value, History is a Observation, coronary artery disease is a Condition, MI / heart attack , stroke , heart failure , or peripheral artery disease is a Scope, Cancer is a Condition, no is a Negation, active treatment is a Procedure, in the last year is a Temporal, MCI is a Condition, MoCA > 18<26 is a Scope, Decline physical function is a Condition, walking speed < 1 m / s is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hypertension is a Condition, treated or resting blood pressure > 140/90 is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hyperlipidemia is a Condition, treated or fasting total cholesterol > 240 is a Scope, English literacy is a Observation, Willing to is a Mood, provide informed consent is a Observation	NCT02986659_inc_task1	Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please typing these entity words according to sentence: Age, 65 - 79, History, coronary artery disease, MI / heart attack , stroke , heart failure , or peripheral artery disease, Cancer, no, active treatment, in the last year, MCI, MoCA > 18<26, Decline physical function, walking speed < 1 m / s, Abdominal obesity, > 88 cm women , > 102 cm men, hypertension, treated or resting blood pressure > 140/90, Abdominal obesity, > 88 cm women , > 102 cm men, hyperlipidemia, treated or fasting total cholesterol > 240, English literacy, Willing to, provide informed consent Options: Temporal, Condition, Value, Person, Observation, Procedure, Negation, Scope, Mood	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]	Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent	[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]
Age, 65 - 79, History, coronary artery disease, MI / heart attack , stroke , heart failure , or peripheral artery disease, Cancer, no, active treatment, in the last year, MCI, MoCA > 18<26, Decline physical function, walking speed < 1 m / s, Abdominal obesity, > 88 cm women , > 102 cm men, hypertension, treated or resting blood pressure > 140/90, Abdominal obesity, > 88 cm women , > 102 cm men, hyperlipidemia, treated or fasting total cholesterol > 240, English literacy, Willing to, provide informed consent	NCT02986659_inc_task2	Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please extract entity words from the input sentence	[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]	Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent	[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]
profilin is a Individual_protein, actin is a Individual_protein, extracellular matrix proteins is a Individual_protein	290_task0	Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.	[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]	[ "Individual_protein" ]
profilin is a Individual_protein, actin is a Individual_protein, extracellular matrix proteins is a Individual_protein	290_task1	Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please typing these entity words according to sentence: profilin, actin, extracellular matrix proteins Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.	[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]	[ "Individual_protein" ]
profilin, actin, extracellular matrix proteins	290_task2	Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.	[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]	[ "Individual_protein" ]
cytochrome P450 1 is a GENE-N, Cyp1 is a GENE-N, vanadium is a CHEMICAL	23423713_task0	Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.	[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
cytochrome P450 1 is a GENE-N, Cyp1 is a GENE-N, vanadium is a CHEMICAL	23423713_task1	Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please typing these entity words according to sentence: cytochrome P450 1, Cyp1, vanadium Options: GENE-N, CHEMICAL	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.	[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
cytochrome P450 1, Cyp1, vanadium	23423713_task2	Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.	[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Pneumonien is an umlsterm	DerAnaesthesist.80470925.ger.abstr_task0	Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .	[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]	[ "umlsterm" ]
Pneumonien is an umlsterm	DerAnaesthesist.80470925.ger.abstr_task1	Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please typing these entity words according to sentence: Pneumonien Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .	[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]	[ "umlsterm" ]
Pneumonien	DerAnaesthesist.80470925.ger.abstr_task2	Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .	[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]	[ "umlsterm" ]
Dokumentation is an umlsterm, Lymphknotenbefundes is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm, thoraxchirurgischen is an umlsterm, Gesellschaft is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten - Sampling is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm	DerChirurg.70680601.ger.abstr_task0	Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .	[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]	[ "umlsterm" ]
Dokumentation is an umlsterm, Lymphknotenbefundes is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm, thoraxchirurgischen is an umlsterm, Gesellschaft is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten - Sampling is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm	DerChirurg.70680601.ger.abstr_task1	Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please typing these entity words according to sentence: Dokumentation, Lymphknotenbefundes, Lymphknotendokumentation, Lymphadenektomie, thoraxchirurgischen, Gesellschaft, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten - Sampling, Lymphknotendokumentation, Lymphadenektomie Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .	[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]	[ "umlsterm" ]
Dokumentation, Lymphknotenbefundes, Lymphknotendokumentation, Lymphadenektomie, thoraxchirurgischen, Gesellschaft, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten - Sampling, Lymphknotendokumentation, Lymphadenektomie	DerChirurg.70680601.ger.abstr_task2	Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .	[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]	[ "umlsterm" ]
E2F - HDAC is a Complex, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone H3 is a Gene_or_gene_product, lysine 9 is a Simple_chemical, histone H3 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, 6 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, chromatin is a Cellular_component, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone deacetylase is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, trichostatin A is a Simple_chemical, TSA is a Simple_chemical, ARHI is a Gene_or_gene_product, luciferase is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, TSA is a Simple_chemical, E2F - HDAC is a Complex, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, retinoblastoma protein is a Gene_or_gene_product, pRB is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F4 is a Gene_or_gene_product, pRB is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, ARHI is a Gene_or_gene_product	148_task0	Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component	[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]	E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]
E2F - HDAC is a Complex, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone H3 is a Gene_or_gene_product, lysine 9 is a Simple_chemical, histone H3 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, 6 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, chromatin is a Cellular_component, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone deacetylase is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, trichostatin A is a Simple_chemical, TSA is a Simple_chemical, ARHI is a Gene_or_gene_product, luciferase is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, TSA is a Simple_chemical, E2F - HDAC is a Complex, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, retinoblastoma protein is a Gene_or_gene_product, pRB is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F4 is a Gene_or_gene_product, pRB is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, ARHI is a Gene_or_gene_product	148_task1	Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please typing these entity words according to sentence: E2F - HDAC, ARHI, ARHI, ARHI, histone H3, lysine 9, histone H3, ARHI, ARHI, E2F, E2F1, 4, E2F2, 6, E2F, E2F1, 4, E2F, chromatin, E2F1, 4, ARHI, histone deacetylase, HDAC, trichostatin A, TSA, ARHI, luciferase, E2F, E2F1, 4, ARHI, TSA, E2F - HDAC, E2F1, 4, retinoblastoma protein, pRB, ARHI, E2F1, E2F4, pRB, E2F1, 4, HDAC, ARHI Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component	[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]	E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]
E2F - HDAC, ARHI, ARHI, ARHI, histone H3, lysine 9, histone H3, ARHI, ARHI, E2F, E2F1, 4, E2F2, 6, E2F, E2F1, 4, E2F, chromatin, E2F1, 4, ARHI, histone deacetylase, HDAC, trichostatin A, TSA, ARHI, luciferase, E2F, E2F1, 4, ARHI, TSA, E2F - HDAC, E2F1, 4, retinoblastoma protein, pRB, ARHI, E2F1, E2F4, pRB, E2F1, 4, HDAC, ARHI	148_task2	Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please extract entity words from the input sentence	[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]	E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.	[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]	[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]
woman is an umlsterm, blood loss is an umlsterm, injuries is an umlsterm, PTT is an umlsterm, factor XII is an umlsterm, deficiency is an umlsterm, symptoms is an umlsterm, von Willebrands disease is an umlsterm, patient is an umlsterm, protein C is an umlsterm, concentration is an umlsterm, homocysteine is an umlsterm, blood plasma is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, mutation is an umlsterm, methylenetetrahydrofolate reductase is an umlsterm, -gene is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, point mutation is an umlsterm, promoter region is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, factor XII is an umlsterm, woman is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, mutation is an umlsterm, women is an umlsterm, old is an umlsterm, blood loss is an umlsterm, coagulation is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, von Willebrands disease is an umlsterm, factor XII is an umlsterm, factor XII deficiency is an umlsterm, APC resistance is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, Mother is an umlsterm, father is an umlsterm, factor XII deficiency is an umlsterm, mutation is an umlsterm, gene is an umlsterm, mother is an umlsterm, mutation is an umlsterm, factor V is an umlsterm, gene is an umlsterm, family members is an umlsterm, D - dimer is an umlsterm, concentrations is an umlsterm, plasma is an umlsterm	MonatsschriftKinderheilkunde.91470104.eng.abstr_task0	Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .	[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]	[ "umlsterm" ]
woman is an umlsterm, blood loss is an umlsterm, injuries is an umlsterm, PTT is an umlsterm, factor XII is an umlsterm, deficiency is an umlsterm, symptoms is an umlsterm, von Willebrands disease is an umlsterm, patient is an umlsterm, protein C is an umlsterm, concentration is an umlsterm, homocysteine is an umlsterm, blood plasma is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, mutation is an umlsterm, methylenetetrahydrofolate reductase is an umlsterm, -gene is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, point mutation is an umlsterm, promoter region is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, factor XII is an umlsterm, woman is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, mutation is an umlsterm, women is an umlsterm, old is an umlsterm, blood loss is an umlsterm, coagulation is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, von Willebrands disease is an umlsterm, factor XII is an umlsterm, factor XII deficiency is an umlsterm, APC resistance is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, Mother is an umlsterm, father is an umlsterm, factor XII deficiency is an umlsterm, mutation is an umlsterm, gene is an umlsterm, mother is an umlsterm, mutation is an umlsterm, factor V is an umlsterm, gene is an umlsterm, family members is an umlsterm, D - dimer is an umlsterm, concentrations is an umlsterm, plasma is an umlsterm	MonatsschriftKinderheilkunde.91470104.eng.abstr_task1	Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please typing these entity words according to sentence: woman, blood loss, injuries, PTT, factor XII, deficiency, symptoms, von Willebrands disease, patient, protein C, concentration, homocysteine, blood plasma, factor V, mutation, mutation, methylenetetrahydrofolate reductase, -gene, analysis, factor XII, gene, point mutation, promoter region, mutation, factor XII, gene, factor XII, woman, mutation, factor XII, gene, mutation, women, old, blood loss, coagulation, analysis, factor XII, von Willebrands disease, factor XII, factor XII deficiency, APC resistance, factor V, mutation, Mother, father, factor XII deficiency, mutation, gene, mother, mutation, factor V, gene, family members, D - dimer, concentrations, plasma Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .	[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]	[ "umlsterm" ]
woman, blood loss, injuries, PTT, factor XII, deficiency, symptoms, von Willebrands disease, patient, protein C, concentration, homocysteine, blood plasma, factor V, mutation, mutation, methylenetetrahydrofolate reductase, -gene, analysis, factor XII, gene, point mutation, promoter region, mutation, factor XII, gene, factor XII, woman, mutation, factor XII, gene, mutation, women, old, blood loss, coagulation, analysis, factor XII, von Willebrands disease, factor XII, factor XII deficiency, APC resistance, factor V, mutation, Mother, father, factor XII deficiency, mutation, gene, mother, mutation, factor V, gene, family members, D - dimer, concentrations, plasma	MonatsschriftKinderheilkunde.91470104.eng.abstr_task2	Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .	[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]	[ "umlsterm" ]
Differentialdiagnose is an umlsterm, pulmonaler Rundherde is an umlsterm, Metastasen is an umlsterm, Tuberkulose is an umlsterm, Sarkoidose is an umlsterm, Silikose is an umlsterm, Amyloidtumoren is an umlsterm, Diagnosefindung is an umlsterm, radiologischer is an umlsterm, Aetiologie is an umlsterm	DerPathologe.60170301.ger.abstr_task0	Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .	[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]	[ "umlsterm" ]
Differentialdiagnose is an umlsterm, pulmonaler Rundherde is an umlsterm, Metastasen is an umlsterm, Tuberkulose is an umlsterm, Sarkoidose is an umlsterm, Silikose is an umlsterm, Amyloidtumoren is an umlsterm, Diagnosefindung is an umlsterm, radiologischer is an umlsterm, Aetiologie is an umlsterm	DerPathologe.60170301.ger.abstr_task1	Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please typing these entity words according to sentence: Differentialdiagnose, pulmonaler Rundherde, Metastasen, Tuberkulose, Sarkoidose, Silikose, Amyloidtumoren, Diagnosefindung, radiologischer, Aetiologie Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .	[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]	[ "umlsterm" ]
Differentialdiagnose, pulmonaler Rundherde, Metastasen, Tuberkulose, Sarkoidose, Silikose, Amyloidtumoren, Diagnosefindung, radiologischer, Aetiologie	DerPathologe.60170301.ger.abstr_task2	Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .	[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]	[ "umlsterm" ]
RelA is a Protein, c - Rel is a Protein, I kappa B alpha is a Protein, IL-2 is a Protein, IL-2R alpha is a Protein, IL-4 is a Protein, IL-10 is a Protein, IFN - gamma is a Protein, IL-2 is a Protein	187_task0	Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.	[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]	[ "Protein" ]
RelA is a Protein, c - Rel is a Protein, I kappa B alpha is a Protein, IL-2 is a Protein, IL-2R alpha is a Protein, IL-4 is a Protein, IL-10 is a Protein, IFN - gamma is a Protein, IL-2 is a Protein	187_task1	Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please typing these entity words according to sentence: RelA, c - Rel, I kappa B alpha, IL-2, IL-2R alpha, IL-4, IL-10, IFN - gamma, IL-2 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.	[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]	[ "Protein" ]
RelA, c - Rel, I kappa B alpha, IL-2, IL-2R alpha, IL-4, IL-10, IFN - gamma, IL-2	187_task2	Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.	[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]	[ "Protein" ]
Laila is a NOMBRE_SUJETO_ASISTENCIA, Alonso Lestayo is a NOMBRE_SUJETO_ASISTENCIA, 736980 is a ID_SUJETO_ASISTENCIA, Barakaldo is a TERRITORIO, 48903 is a TERRITORIO, 15/08/2015 is a FECHAS, España is a PAIS, 16 meses is a EDAD_SUJETO_ASISTENCIA, 13/12/2015 is a FECHAS, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, 48 48 46560 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, hijo is a FAMILIARES_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, abuelo materno is a FAMILIARES_SUJETO_ASISTENCIA, Padre is a FAMILIARES_SUJETO_ASISTENCIA, Primo de rama paterna is a FAMILIARES_SUJETO_ASISTENCIA, 7 meses is a EDAD_SUJETO_ASISTENCIA, 14 meses is a EDAD_SUJETO_ASISTENCIA, 10 meses is a EDAD_SUJETO_ASISTENCIA, 15 meses is a EDAD_SUJETO_ASISTENCIA, 16 meses is a EDAD_SUJETO_ASISTENCIA, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, Hospital de Cruces is a HOSPITAL, Plaza de Cruces , s / n is a CALLE, 48903 is a TERRITORIO, Cruces is a TERRITORIO, Barakaldo is a TERRITORIO, España is a PAIS, mariasanlo@terra.es is a CORREO_ELECTRONICO	201_task0	Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Laila is a NOMBRE_SUJETO_ASISTENCIA, Alonso Lestayo is a NOMBRE_SUJETO_ASISTENCIA, 736980 is a ID_SUJETO_ASISTENCIA, Barakaldo is a TERRITORIO, 48903 is a TERRITORIO, 15/08/2015 is a FECHAS, España is a PAIS, 16 meses is a EDAD_SUJETO_ASISTENCIA, 13/12/2015 is a FECHAS, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, 48 48 46560 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, hijo is a FAMILIARES_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, abuelo materno is a FAMILIARES_SUJETO_ASISTENCIA, Padre is a FAMILIARES_SUJETO_ASISTENCIA, Primo de rama paterna is a FAMILIARES_SUJETO_ASISTENCIA, 7 meses is a EDAD_SUJETO_ASISTENCIA, 14 meses is a EDAD_SUJETO_ASISTENCIA, 10 meses is a EDAD_SUJETO_ASISTENCIA, 15 meses is a EDAD_SUJETO_ASISTENCIA, 16 meses is a EDAD_SUJETO_ASISTENCIA, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, Hospital de Cruces is a HOSPITAL, Plaza de Cruces , s / n is a CALLE, 48903 is a TERRITORIO, Cruces is a TERRITORIO, Barakaldo is a TERRITORIO, España is a PAIS, mariasanlo@terra.es is a CORREO_ELECTRONICO	201_task1	Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please typing these entity words according to sentence: Laila, Alonso Lestayo, 736980, Barakaldo, 48903, 15/08/2015, España, 16 meses, 13/12/2015, María Sánchez López, 48 48 46560, Mujer, hijo, padres, Madre, abuelo materno, Padre, Primo de rama paterna, 7 meses, 14 meses, 10 meses, 15 meses, 16 meses, María Sánchez López, Hospital de Cruces, Plaza de Cruces , s / n, 48903, Cruces, Barakaldo, España, mariasanlo@terra.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
Laila, Alonso Lestayo, 736980, Barakaldo, 48903, 15/08/2015, España, 16 meses, 13/12/2015, María Sánchez López, 48 48 46560, Mujer, hijo, padres, Madre, abuelo materno, Padre, Primo de rama paterna, 7 meses, 14 meses, 10 meses, 15 meses, 16 meses, María Sánchez López, Hospital de Cruces, Plaza de Cruces , s / n, 48903, Cruces, Barakaldo, España, mariasanlo@terra.es	201_task2	Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]	[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]
LEGO therapy is a Intervention_Psychological, social use of language programme is a Intervention_Psychological, social skills interventions is a Intervention_Psychological, children is a Participant_Age, high functioning autism is a Participant_Condition, Asperger Syndrome is a Participant_Condition, Social Use of Language Programme ( SULP ) is a Intervention_Psychological, 6 - 11 is a Participant_Age, no - intervention control group is a Intervention_Control, autism - specific social interaction scores ( Gilliam Autism Rating Scale ) is a Outcome_Mental, Maladaptive behaviour is a Outcome_Mental, communication and socialisation skills is a Outcome_Mental	36069_task0	Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Mental	[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]	LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .	[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]	[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]
LEGO therapy is a Intervention_Psychological, social use of language programme is a Intervention_Psychological, social skills interventions is a Intervention_Psychological, children is a Participant_Age, high functioning autism is a Participant_Condition, Asperger Syndrome is a Participant_Condition, Social Use of Language Programme ( SULP ) is a Intervention_Psychological, 6 - 11 is a Participant_Age, no - intervention control group is a Intervention_Control, autism - specific social interaction scores ( Gilliam Autism Rating Scale ) is a Outcome_Mental, Maladaptive behaviour is a Outcome_Mental, communication and socialisation skills is a Outcome_Mental	36069_task1	Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please typing these entity words according to sentence: LEGO therapy, social use of language programme, social skills interventions, children, high functioning autism, Asperger Syndrome, Social Use of Language Programme ( SULP ), 6 - 11, no - intervention control group, autism - specific social interaction scores ( Gilliam Autism Rating Scale ), Maladaptive behaviour, communication and socialisation skills Options: Intervention_Psychological, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Mental	[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]	LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .	[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]	[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]
LEGO therapy, social use of language programme, social skills interventions, children, high functioning autism, Asperger Syndrome, Social Use of Language Programme ( SULP ), 6 - 11, no - intervention control group, autism - specific social interaction scores ( Gilliam Autism Rating Scale ), Maladaptive behaviour, communication and socialisation skills	36069_task2	Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]	LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .	[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]	[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]
muscarinic M3 receptor is a GENE-Y	19498041_task0	Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.	[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
muscarinic M3 receptor is a GENE-Y	19498041_task1	Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please typing these entity words according to sentence: muscarinic M3 receptor Options: GENE-Y	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.	[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
muscarinic M3 receptor	19498041_task2	Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]	Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.	[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
polychlorinated biphenyl is a CHEMICAL	23147987_task0	Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.	[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]	[ "CHEMICAL" ]
polychlorinated biphenyl is a CHEMICAL	23147987_task1	Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please typing these entity words according to sentence: polychlorinated biphenyl Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.	[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]	[ "CHEMICAL" ]
polychlorinated biphenyl	23147987_task2	Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.	[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]	[ "CHEMICAL" ]
Lichtes is an umlsterm, Haut is an umlsterm, karzinogene is an umlsterm, DNS is an umlsterm, Tierexperimenten is an umlsterm, Plattenepithelkarzinomen is an umlsterm, Melanomen is an umlsterm, therapeutischen Anwendung is an umlsterm, maligner Melanome is an umlsterm, karzinogene is an umlsterm, Menschen is an umlsterm, Risiken is an umlsterm	DerHautarzt.40450517.ger.abstr_task0	Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .	[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]	[ "umlsterm" ]
Lichtes is an umlsterm, Haut is an umlsterm, karzinogene is an umlsterm, DNS is an umlsterm, Tierexperimenten is an umlsterm, Plattenepithelkarzinomen is an umlsterm, Melanomen is an umlsterm, therapeutischen Anwendung is an umlsterm, maligner Melanome is an umlsterm, karzinogene is an umlsterm, Menschen is an umlsterm, Risiken is an umlsterm	DerHautarzt.40450517.ger.abstr_task1	Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please typing these entity words according to sentence: Lichtes, Haut, karzinogene, DNS, Tierexperimenten, Plattenepithelkarzinomen, Melanomen, therapeutischen Anwendung, maligner Melanome, karzinogene, Menschen, Risiken Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .	[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]	[ "umlsterm" ]
Lichtes, Haut, karzinogene, DNS, Tierexperimenten, Plattenepithelkarzinomen, Melanomen, therapeutischen Anwendung, maligner Melanome, karzinogene, Menschen, Risiken	DerHautarzt.40450517.ger.abstr_task2	Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .	[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]	[ "umlsterm" ]
Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Kehlkopfentfernung is an umlsterm, Patienten is an umlsterm, Rachenhinterwandkarzinom is an umlsterm, Hypopharynx is an umlsterm, Tumorausdehnung is an umlsterm, kehlkopferhaltendes is an umlsterm, Patienten is an umlsterm, Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Unterarmlappen is an umlsterm, Duenndarmtransplantat is an umlsterm, Tumorausdehnungen is an umlsterm, Patienten is an umlsterm, Schluckfunktion is an umlsterm, Ernaehrung is an umlsterm, Patient is an umlsterm, Patient is an umlsterm, Aspirationen is an umlsterm, Nahrungsaufnahme is an umlsterm, Patienten is an umlsterm, Laryngektomie is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Rehabilitation is an umlsterm, Rachenhinterwandkarzinome is an umlsterm, Patienten is an umlsterm	HNO.80460135.ger.abstr_task0	Sentence: Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten .	[ "Bei", "der", "chirurgischen", "Entfernung", "von", "ausgedehnten", "Karzinomen", "der", "hypopharyngealen", "Rachenhinterwand", "stellt", "sich", "die", "Frage", "der", "Kehlkopfentfernung", "in", "erster", "Linie", "aus", "funktionellen", "Gruenden", ".", "Zwischen", "1994", "und", "1997", "wurde", "allen", "Patienten", "mit", "einem", "Rachenhinterwandkarzinom", "des", "Hypopharynx", "und", "einer", "geschaetzten", "Tumorausdehnung", "von", "mehr", "als", "6", "cm", "ein", "kehlkopferhaltendes", "chirurgisches", "Behandlungskonzept", "vorgeschlagen", ".", "Bei", "9", "Patienten", "mit", "T2", "(", "n=2", ")", "und", "T4", "(", "n=7", ")", "Karzinomen", "erfolgte", "nach", "lateraler", "Pharyngotomie", "eine", "Rekonstruktion", "der", "Rachenhinterwand", "mit", "freien", "Lappen", "(", "8", "Unterarmlappen", "und", "1", "Duenndarmtransplantat", ")", ".", "Die", "maximalen", "Tumorausdehnungen", "reichten", "von", "6,5", "-", "12,5", "cm", ".", "Bei", "der", "Praeparation", "wurde", "versucht", ",", "den", "N.", "laryngeus", "superior", "zu", "erhalten", "und", "bei", "der", "Einnaht", "der", "freien", "Lappen", "fand", "die", "exakte", "Anpassung", "des", "Lappens", "an", "den", "Defekt", "besondere", "Beachtung", ".", "Bei", "7", "Patienten", "war", "innerhalb", "von", "3", "Monaten", "die", "Schluckfunktion", "so", "wiederhergestellt", ",", "dass", "die", "Ernaehrung", "oral", "erfolgen", "konnte", ".", "Ein", "Patient", "benoetigte", "hierzu", "4", "Monate", "und", "ein", "Patient", "war", "12", "Monate", "postoperativ", "aufgrund", "von", "Aspirationen", "weiterhin", "nicht", "zur", "ausreichenden", "oralen", "Nahrungsaufnahme", "faehig", ",", "6", "Patienten", "wurden", "bisher", "dekanueliert", "und", "in", "keinem", "Fall", "war", "in", "der", "Beobachtungszeit", "eine", "Laryngektomie", "aufgrund", "von", "Komplikationen", "oder", "auf", "Wunsch", "des", "Patienten", "erforderlich", ".", "Die", "funktionelle", "Rehabilitation", "nach", "der", "Entfernung", "ausgedehnter", "Rachenhinterwandkarzinome", "gelingt", "mit", "Hilfe", "von", "freien", "Lappen", "bei", "einem", "Grossteil", "der", "Patienten", "." ]	[ "umlsterm" ]
Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Kehlkopfentfernung is an umlsterm, Patienten is an umlsterm, Rachenhinterwandkarzinom is an umlsterm, Hypopharynx is an umlsterm, Tumorausdehnung is an umlsterm, kehlkopferhaltendes is an umlsterm, Patienten is an umlsterm, Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Unterarmlappen is an umlsterm, Duenndarmtransplantat is an umlsterm, Tumorausdehnungen is an umlsterm, Patienten is an umlsterm, Schluckfunktion is an umlsterm, Ernaehrung is an umlsterm, Patient is an umlsterm, Patient is an umlsterm, Aspirationen is an umlsterm, Nahrungsaufnahme is an umlsterm, Patienten is an umlsterm, Laryngektomie is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Rehabilitation is an umlsterm, Rachenhinterwandkarzinome is an umlsterm, Patienten is an umlsterm	HNO.80460135.ger.abstr_task1	Sentence: Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten . Instructions: please typing these entity words according to sentence: Karzinomen, Rachenhinterwand, Kehlkopfentfernung, Patienten, Rachenhinterwandkarzinom, Hypopharynx, Tumorausdehnung, kehlkopferhaltendes, Patienten, Karzinomen, Rachenhinterwand, Unterarmlappen, Duenndarmtransplantat, Tumorausdehnungen, Patienten, Schluckfunktion, Ernaehrung, Patient, Patient, Aspirationen, Nahrungsaufnahme, Patienten, Laryngektomie, Komplikationen, Patienten, Rehabilitation, Rachenhinterwandkarzinome, Patienten Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten .	[ "Bei", "der", "chirurgischen", "Entfernung", "von", "ausgedehnten", "Karzinomen", "der", "hypopharyngealen", "Rachenhinterwand", "stellt", "sich", "die", "Frage", "der", "Kehlkopfentfernung", "in", "erster", "Linie", "aus", "funktionellen", "Gruenden", ".", "Zwischen", "1994", "und", "1997", "wurde", "allen", "Patienten", "mit", "einem", "Rachenhinterwandkarzinom", "des", "Hypopharynx", "und", "einer", "geschaetzten", "Tumorausdehnung", "von", "mehr", "als", "6", "cm", "ein", "kehlkopferhaltendes", "chirurgisches", "Behandlungskonzept", "vorgeschlagen", ".", "Bei", "9", "Patienten", "mit", "T2", "(", "n=2", ")", "und", "T4", "(", "n=7", ")", "Karzinomen", "erfolgte", "nach", "lateraler", "Pharyngotomie", "eine", "Rekonstruktion", "der", "Rachenhinterwand", "mit", "freien", "Lappen", "(", "8", "Unterarmlappen", "und", "1", "Duenndarmtransplantat", ")", ".", "Die", "maximalen", "Tumorausdehnungen", "reichten", "von", "6,5", "-", "12,5", "cm", ".", "Bei", "der", "Praeparation", "wurde", "versucht", ",", "den", "N.", "laryngeus", "superior", "zu", "erhalten", "und", "bei", "der", "Einnaht", "der", "freien", "Lappen", "fand", "die", "exakte", "Anpassung", "des", "Lappens", "an", "den", "Defekt", "besondere", "Beachtung", ".", "Bei", "7", "Patienten", "war", "innerhalb", "von", "3", "Monaten", "die", "Schluckfunktion", "so", "wiederhergestellt", ",", "dass", "die", "Ernaehrung", "oral", "erfolgen", "konnte", ".", "Ein", "Patient", "benoetigte", "hierzu", "4", "Monate", "und", "ein", "Patient", "war", "12", "Monate", "postoperativ", "aufgrund", "von", "Aspirationen", "weiterhin", "nicht", "zur", "ausreichenden", "oralen", "Nahrungsaufnahme", "faehig", ",", "6", "Patienten", "wurden", "bisher", "dekanueliert", "und", "in", "keinem", "Fall", "war", "in", "der", "Beobachtungszeit", "eine", "Laryngektomie", "aufgrund", "von", "Komplikationen", "oder", "auf", "Wunsch", "des", "Patienten", "erforderlich", ".", "Die", "funktionelle", "Rehabilitation", "nach", "der", "Entfernung", "ausgedehnter", "Rachenhinterwandkarzinome", "gelingt", "mit", "Hilfe", "von", "freien", "Lappen", "bei", "einem", "Grossteil", "der", "Patienten", "." ]	[ "umlsterm" ]

TCR repertoire is a protein_family_or_group, Epstein - Barr virus - encoded transactivator protein is a protein_family_or_group, BZLF1 is a protein_molecule, CD8 + cytotoxic T lymphocytes is a cell_type

55581_task1

Sentence: Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Instructions: please typing these entity words according to sentence: TCR repertoire, Epstein - Barr virus - encoded transactivator protein, BZLF1, CD8 + cytotoxic T lymphocytes Options: cell_type, protein_family_or_group, protein_molecule

[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "O", "O" ]

Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.

[ "Selection", "of", "a", "diverse", "TCR", "repertoire", "in", "response", "to", "an", "Epstein", "-", "Barr", "virus", "-", "encoded", "transactivator", "protein", "BZLF1", "by", "CD8", "+", "cytotoxic", "T", "lymphocytes", "during", "primary", "and", "persistent", "infection", "." ]

[ "cell_line", "protein_family_or_group", "multi_cell", "cell_type", "(AND virus virus)", "other_name", "(OR other_name other_name)", "peptide", "(AND cell_line cell_line)", "virus", "protein_domain_or_region", "RNA_molecule", "", "protein_subunit", "DNA_domain_or_region", "protein_molecule" ]

TCR repertoire, Epstein - Barr virus - encoded transactivator protein, BZLF1, CD8 + cytotoxic T lymphocytes

55581_task2

Sentence: Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "B-protein_molecule", "O", "B-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "I-cell_type", "O", "O", "O", "O", "O", "O" ]

Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection.

[ "Selection", "of", "a", "diverse", "TCR", "repertoire", "in", "response", "to", "an", "Epstein", "-", "Barr", "virus", "-", "encoded", "transactivator", "protein", "BZLF1", "by", "CD8", "+", "cytotoxic", "T", "lymphocytes", "during", "primary", "and", "persistent", "infection", "." ]

[ "cell_line", "protein_family_or_group", "multi_cell", "cell_type", "(AND virus virus)", "other_name", "(OR other_name other_name)", "peptide", "(AND cell_line cell_line)", "virus", "protein_domain_or_region", "RNA_molecule", "", "protein_subunit", "DNA_domain_or_region", "protein_molecule" ]

GM - CSF is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, p50 is a Protein, p65 is a Protein, GM - CSF is a Protein, enhancers is a Entity, p50 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, KBF1 is a Protein, p50 is a Protein, GM - CSF is a Protein, GM - CSF is a Protein

293_task0

Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.

[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]

[ "Protein", "Entity" ]

GM - CSF is a Protein, granulocyte - macrophage colony - stimulating factor is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, GM - CSF is a Protein, p50 is a Protein, p65 is a Protein, GM - CSF is a Protein, enhancers is a Entity, p50 is a Protein, p50 is a Protein, p65 is a Protein, p65 is a Protein, KBF1 is a Protein, p50 is a Protein, GM - CSF is a Protein, GM - CSF is a Protein

293_task1

Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please typing these entity words according to sentence: GM - CSF, granulocyte - macrophage colony - stimulating factor, GM - CSF, GM - CSF, GM - CSF, p50, p65, GM - CSF, enhancers, p50, p50, p65, p65, KBF1, p50, GM - CSF, GM - CSF Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.

[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]

[ "Protein", "Entity" ]

GM - CSF, granulocyte - macrophage colony - stimulating factor, GM - CSF, GM - CSF, GM - CSF, p50, p65, GM - CSF, enhancers, p50, p50, p65, p65, KBF1, p50, GM - CSF, GM - CSF

293_task2

Sentence: A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A nuclear factor NF-GM2 that interacts with a regulatory region of the GM-CSF gene essential for its induction in responses to T-cell activation: purification from human T-cell leukemia line Jurkat cells and similarity to NF-kappa B. Activation of T cells by antigen, lectin, or a combination of phorbol-12-myristate acetate (PMA) and calcium ionophore (A23187) leads to the induction of genes for a set of lymphokines, including granulocyte-macrophage colony-stimulating factor (GM-CSF). We demonstrated in earlier studies that the upstream region of the mouse GM-CSF promoter at positions between -95 and -73 is essential for transcriptional activation in response to PMA/A23187. This region contains two DNA-binding motifs, GM2 and GC-box. The GM2 sequence (GGTAGTTCCC) is recognized by an inducible factor NF-GM2; the other (CCGCCC) by constitutive factors A1, A2, and B. To elucidate the mechanism of GM-CSF gene activation, we have purified the inducible factor NF-GM2 from the nuclear extract of stimulated Jurkat cells on the basis of specific DNA-binding activity. The purified NF-GM2 consists of 50 (p50) and 65 kDa (p65) polypeptides and has a binding activity specific for both the GM-CSF and immunoglobulin kappa (GGAAAGTCCC) enhancers. Electrophoretically purified p50 alone can form a protein-DNA complex, but in the mixture, p50 associates preferentially with p65 to form the NF-GM2 complex. In addition, p65 gave per se, with low affinity, a protein-DNA complex that migrated more slowly than native NF-GM2 complex. Furthermore, an antiserum against KBF1 (identical to 50 kDa NF-kappa B protein) reacted with the p50 of NF-GM2, indicating that the NF-GM2 polypeptide cannot be immunologically differentiated from the 50 kDa subunit of NF-kappa B. The purified NF-GM2 activated in vitro transcription from the kappa B enhancer, while it failed to stimulate transcription from the GM-CSF promoter harboring the GM2 sequence. This suggests that the activation mechanism of the GM-CSF gene through the GM2/GC-box sequence is different from that of genes carrying the kappa B enhancer alone.

[ "A", "nuclear", "factor", "NF", "-", "GM2", "that", "interacts", "with", "a", "regulatory", "region", "of", "the", "GM", "-", "CSF", "gene", "essential", "for", "its", "induction", "in", "responses", "to", "T", "-", "cell", "activation", ":", "purification", "from", "human", "T", "-", "cell", "leukemia", "line", "Jurkat", "cells", "and", "similarity", "to", "NF", "-", "kappa", "B.", "\n", "Activation", "of", "T", "cells", "by", "antigen", ",", "lectin", ",", "or", "a", "combination", "of", "phorbol-12-myristate", "acetate", "(", "PMA", ")", "and", "calcium", "ionophore", "(", "A23187", ")", "leads", "to", "the", "induction", "of", "genes", "for", "a", "set", "of", "lymphokines", ",", "including", "granulocyte", "-", "macrophage", "colony", "-", "stimulating", "factor", "(", "GM", "-", "CSF", ")", ".", "We", "demonstrated", "in", "earlier", "studies", "that", "the", "upstream", "region", "of", "the", "mouse", "GM", "-", "CSF", "promoter", "at", "positions", "between", "-95", "and", "-73", "is", "essential", "for", "transcriptional", "activation", "in", "response", "to", "PMA", "/", "A23187", ".", "This", "region", "contains", "two", "DNA", "-", "binding", "motifs", ",", "GM2", "and", "GC", "-", "box", ".", "The", "GM2", "sequence", "(", "GGTAGTTCCC", ")", "is", "recognized", "by", "an", "inducible", "factor", "NF", "-", "GM2", ";", "the", "other", "(", "CCGCCC", ")", "by", "constitutive", "factors", "A1", ",", "A2", ",", "and", "B.", "To", "elucidate", "the", "mechanism", "of", "GM", "-", "CSF", "gene", "activation", ",", "we", "have", "purified", "the", "inducible", "factor", "NF", "-", "GM2", "from", "the", "nuclear", "extract", "of", "stimulated", "Jurkat", "cells", "on", "the", "basis", "of", "specific", "DNA", "-", "binding", "activity", ".", "The", "purified", "NF", "-", "GM2", "consists", "of", "50", "(", "p50", ")", "and", "65", "kDa", "(", "p65", ")", "polypeptides", "and", "has", "a", "binding", "activity", "specific", "for", "both", "the", "GM", "-", "CSF", "and", "immunoglobulin", "kappa", "(", "GGAAAGTCCC", ")", "enhancers", ".", "Electrophoretically", "purified", "p50", "alone", "can", "form", "a", "protein", "-", "DNA", "complex", ",", "but", "in", "the", "mixture", ",", "p50", "associates", "preferentially", "with", "p65", "to", "form", "the", "NF", "-", "GM2", "complex", ".", "In", "addition", ",", "p65", "gave", "per", "se", ",", "with", "low", "affinity", ",", "a", "protein", "-", "DNA", "complex", "that", "migrated", "more", "slowly", "than", "native", "NF", "-", "GM2", "complex", ".", "Furthermore", ",", "an", "antiserum", "against", "KBF1", "(", "identical", "to", "50", "kDa", "NF", "-", "kappa", "B", "protein", ")", "reacted", "with", "the", "p50", "of", "NF", "-", "GM2", ",", "indicating", "that", "the", "NF", "-", "GM2", "polypeptide", "cannot", "be", "immunologically", "differentiated", "from", "the", "50", "kDa", "subunit", "of", "NF", "-", "kappa", "B.", "The", "purified", "NF", "-", "GM2", "activated", "in", "vitro", "transcription", "from", "the", "kappa", "B", "enhancer", ",", "while", "it", "failed", "to", "stimulate", "transcription", "from", "the", "GM", "-", "CSF", "promoter", "harboring", "the", "GM2", "sequence", ".", "This", "suggests", "that", "the", "activation", "mechanism", "of", "the", "GM", "-", "CSF", "gene", "through", "the", "GM2", "/", "GC", "-", "box", "sequence", "is", "different", "from", "that", "of", "genes", "carrying", "the", "kappa", "B", "enhancer", "alone", "." ]

[ "Protein", "Entity" ]

hydrocortisone is a lipid, chemotactic migration is an other_name, human leukocytes is a cell_type

97938_task0

Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: cell_type, lipid, other_name

[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]

[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]

[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]

[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]

hydrocortisone is a lipid, chemotactic migration is an other_name, human leukocytes is a cell_type

97938_task1

Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please typing these entity words according to sentence: hydrocortisone, chemotactic migration, human leukocytes Options: cell_type, lipid, other_name

[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]

[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]

[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]

[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]

hydrocortisone, chemotactic migration, human leukocytes

97938_task2

Sentence: [The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes] Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-lipid", "O", "O", "B-other_name", "I-other_name", "O", "B-cell_type", "I-cell_type", "O" ]

[The inhibitory effect of hydrocortisone on the chemotactic migration of human leukocytes]

[ "[", "The", "inhibitory", "effect", "of", "hydrocortisone", "on", "the", "chemotactic", "migration", "of", "human", "leukocytes", "]" ]

[ "protein_domain_or_region", "other_name", "protein_family_or_group", "cell_type", "lipid", "other_organic_compound", "tissue" ]

tumor necrosis factor receptor - associated factor 6 is a Protein, TRAF6 is a Protein, MyD88 is a Protein, Tumor necrosis factor receptor - activated factor 6 is a Protein, TRAF6 is a Protein, nuclear factor kappaB ( NF - kappaB)-inducing kinase is a Protein, NIK is a Protein, TRAF6 is a Protein

823_task0

Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.

[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]

[ "Protein" ]

tumor necrosis factor receptor - associated factor 6 is a Protein, TRAF6 is a Protein, MyD88 is a Protein, Tumor necrosis factor receptor - activated factor 6 is a Protein, TRAF6 is a Protein, nuclear factor kappaB ( NF - kappaB)-inducing kinase is a Protein, NIK is a Protein, TRAF6 is a Protein

823_task1

Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please typing these entity words according to sentence: tumor necrosis factor receptor - associated factor 6, TRAF6, MyD88, Tumor necrosis factor receptor - activated factor 6, TRAF6, nuclear factor kappaB ( NF - kappaB)-inducing kinase, NIK, TRAF6 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.

[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]

[ "Protein" ]

tumor necrosis factor receptor - associated factor 6, TRAF6, MyD88, Tumor necrosis factor receptor - activated factor 6, TRAF6, nuclear factor kappaB ( NF - kappaB)-inducing kinase, NIK, TRAF6

823_task2

Sentence: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). The human homologue of Drosophila Toll (hToll) is a recently cloned receptor of the interleukin 1 receptor (IL-1R) superfamily, and has been implicated in the activation of adaptive immunity. Signaling by hToll is shown to occur through sequential recruitment of the adapter molecule MyD88 and the IL-1R-associated kinase. Tumor necrosis factor receptor-activated factor 6 (TRAF6) and the nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK) are both involved in subsequent steps of NF-kappaB activation. Conversely, a dominant negative version of TRAF6 failed to block hToll-induced activation of stress-activated protein kinase/c-Jun NH2-terminal kinases, thus suggesting an early divergence of the two pathways.

[ "The", "human", "toll", "signaling", "pathway", ":", "divergence", "of", "nuclear", "factor", "kappaB", "and", "JNK", "/", "SAPK", "activation", "upstream", "of", "tumor", "necrosis", "factor", "receptor", "-", "associated", "factor", "6", "(", "TRAF6", ")", ".", "\n", "The", "human", "homologue", "of", "Drosophila", "Toll", "(", "hToll", ")", "is", "a", "recently", "cloned", "receptor", "of", "the", "interleukin", "1", "receptor", "(", "IL-1R", ")", "superfamily", ",", "and", "has", "been", "implicated", "in", "the", "activation", "of", "adaptive", "immunity", ".", "Signaling", "by", "hToll", "is", "shown", "to", "occur", "through", "sequential", "recruitment", "of", "the", "adapter", "molecule", "MyD88", "and", "the", "IL-1R", "-", "associated", "kinase", ".", "Tumor", "necrosis", "factor", "receptor", "-", "activated", "factor", "6", "(", "TRAF6", ")", "and", "the", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB)-inducing", "kinase", "(", "NIK", ")", "are", "both", "involved", "in", "subsequent", "steps", "of", "NF", "-", "kappaB", "activation", ".", "Conversely", ",", "a", "dominant", "negative", "version", "of", "TRAF6", "failed", "to", "block", "hToll", "-", "induced", "activation", "of", "stress", "-", "activated", "protein", "kinase", "/", "c", "-", "Jun", "NH2-terminal", "kinases", ",", "thus", "suggesting", "an", "early", "divergence", "of", "the", "two", "pathways", "." ]

[ "Protein" ]

new capsule - type colon specific drug delivery system is a Intervention_Pharmacological, healthy volunteers . is a Participant_Condition, Colonic drug delivery is a Intervention_Physical, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) is a Intervention_Physical

91759_task0

Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Pharmacological, Participant_Condition

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .

[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]

[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

new capsule - type colon specific drug delivery system is a Intervention_Pharmacological, healthy volunteers . is a Participant_Condition, Colonic drug delivery is a Intervention_Physical, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) is a Intervention_Physical

91759_task1

Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please typing these entity words according to sentence: new capsule - type colon specific drug delivery system, healthy volunteers ., Colonic drug delivery, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule ) Options: Intervention_Physical, Intervention_Pharmacological, Participant_Condition

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .

[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]

[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

new capsule - type colon specific drug delivery system, healthy volunteers ., Colonic drug delivery, novel capsule - type colonic delivery system ( Colon - Targeted Delivery Capsule )

91759_task2

Sentence: Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Scintigraphic evaluation of a new capsule-type colon specific drug delivery system in healthy volunteers . Colonic drug delivery is intended for local or systemic therapies . The lack of predictive in vitro or animal model leads to considerable time delays in colonic product development . The objective of this scintigraphic study was to provide " proof of concept " for a novel capsule-type colonic delivery system ( Colon-Targeted Delivery Capsule ) in healthy volunteers . The human data validates the design concept behind the release mechanism , in that capsule disintegration , and hence drug release , did not start until 5 h after gastric emptying , irrespective of whether the product was administered to fasted or fed subjects . However , the potential for prolonged gastric residence for large enteric coated products intended for intestinal targeting was also observed ; overall , the study provides a focus for subsequent product development and highlights the role of scintigraphy in dynamically visualizing the drug delivery process .

[ "Scintigraphic", "evaluation", "of", "a", "new", "capsule", "-", "type", "colon", "specific", "drug", "delivery", "system", "in", "healthy", "volunteers", ".", "Colonic", "drug", "delivery", "is", "intended", "for", "local", "or", "systemic", "therapies", ".", "The", "lack", "of", "predictive", "in", "vitro", "or", "animal", "model", "leads", "to", "considerable", "time", "delays", "in", "colonic", "product", "development", ".", "The", "objective", "of", "this", "scintigraphic", "study", "was", "to", "provide", "\"", "proof", "of", "concept", "\"", "for", "a", "novel", "capsule", "-", "type", "colonic", "delivery", "system", "(", "Colon", "-", "Targeted", "Delivery", "Capsule", ")", "in", "healthy", "volunteers", ".", "The", "human", "data", "validates", "the", "design", "concept", "behind", "the", "release", "mechanism", ",", "in", "that", "capsule", "disintegration", ",", "and", "hence", "drug", "release", ",", "did", "not", "start", "until", "5", "h", "after", "gastric", "emptying", ",", "irrespective", "of", "whether", "the", "product", "was", "administered", "to", "fasted", "or", "fed", "subjects", ".", "However", ",", "the", "potential", "for", "prolonged", "gastric", "residence", "for", "large", "enteric", "coated", "products", "intended", "for", "intestinal", "targeting", "was", "also", "observed", ";", "overall", ",", "the", "study", "provides", "a", "focus", "for", "subsequent", "product", "development", "and", "highlights", "the", "role", "of", "scintigraphy", "in", "dynamically", "visualizing", "the", "drug", "delivery", "process", "." ]

[ "Intervention_Physical", "Intervention_Pharmacological", "Participant_Condition" ]

glycyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N, glycyl - tRNA synthetase is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, aminoacyl - tRNA synthetases is a GENE-N, amino acids is a CHEMICAL, GARS is a GENE-Y, glycine is a CHEMICAL, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, tRNA synthetase is a GENE-N, YARS is a GENE-Y, tyrosyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N

3722_task0

Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.

[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

glycyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N, glycyl - tRNA synthetase is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, aminoacyl - tRNA synthetases is a GENE-N, amino acids is a CHEMICAL, GARS is a GENE-Y, glycine is a CHEMICAL, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, GARS is a GENE-Y, tRNA synthetase is a GENE-N, YARS is a GENE-Y, tyrosyl - tRNA synthetase is a GENE-Y, tRNA - charging enzymes is a GENE-N

3722_task1

Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please typing these entity words according to sentence: glycyl - tRNA synthetase, tRNA - charging enzymes, glycyl - tRNA synthetase, GARS, GARS, aminoacyl - tRNA synthetases, amino acids, GARS, glycine, GARS, GARS, GARS, GARS, GARS, tRNA synthetase, YARS, tyrosyl - tRNA synthetase, tRNA - charging enzymes Options: CHEMICAL, GENE-Y, GENE-N

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.

[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

glycyl - tRNA synthetase, tRNA - charging enzymes, glycyl - tRNA synthetase, GARS, GARS, aminoacyl - tRNA synthetases, amino acids, GARS, glycine, GARS, GARS, GARS, GARS, GARS, tRNA synthetase, YARS, tyrosyl - tRNA synthetase, tRNA - charging enzymes

3722_task2

Sentence: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "B-GENE-Y", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. Charcot-Marie-Tooth disease type 2D (CMT2D) and distal spinal muscular atrophy type V (dSMA-V) are axonal neuropathies characterized by a phenotype that is more severe in the upper extremities. We previously implicated mutations in the gene encoding glycyl-tRNA synthetase (GARS) as the cause of CMT2D and dSMA-V. GARS is a member of the family of aminoacyl-tRNA synthetases responsible for charging tRNA with cognate amino acids; GARS ligates glycine to tRNA(Gly). Here, we present functional analyses of disease-associated GARS mutations and show that there are not any significant mutation-associated changes in GARS expression levels; that the majority of identified GARS mutations modeled in yeast severely impair viability; and that, in most cases, mutant GARS protein mislocalizes in neuronal cells. Indeed, four of the five mutations studied show loss-of-function features in at least one assay, suggesting that tRNA-charging deficits play a role in disease pathogenesis. Finally, we detected endogenous GARS-associated granules in the neurite projections of cultured neurons and in the peripheral nerve axons of normal human tissue. These data are particularly important in light of the recent identification of CMT-associated mutations in another tRNA synthetase gene [YARS (tyrosyl-tRNA synthetase gene)]. Together, these findings suggest that tRNA-charging enzymes play a key role in maintaining peripheral axons.

[ "Functional", "analyses", "of", "glycyl", "-", "tRNA", "synthetase", "mutations", "suggest", "a", "key", "role", "for", "tRNA", "-", "charging", "enzymes", "in", "peripheral", "axons", ".", "\n", "Charcot", "-", "Marie", "-", "Tooth", "disease", "type", "2D", "(", "CMT2D", ")", "and", "distal", "spinal", "muscular", "atrophy", "type", "V", "(", "dSMA", "-", "V", ")", "are", "axonal", "neuropathies", "characterized", "by", "a", "phenotype", "that", "is", "more", "severe", "in", "the", "upper", "extremities", ".", "We", "previously", "implicated", "mutations", "in", "the", "gene", "encoding", "glycyl", "-", "tRNA", "synthetase", "(", "GARS", ")", "as", "the", "cause", "of", "CMT2D", "and", "dSMA", "-", "V.", "GARS", "is", "a", "member", "of", "the", "family", "of", "aminoacyl", "-", "tRNA", "synthetases", "responsible", "for", "charging", "tRNA", "with", "cognate", "amino", "acids", ";", "GARS", "ligates", "glycine", "to", "tRNA(Gly", ")", ".", "Here", ",", "we", "present", "functional", "analyses", "of", "disease", "-", "associated", "GARS", "mutations", "and", "show", "that", "there", "are", "not", "any", "significant", "mutation", "-", "associated", "changes", "in", "GARS", "expression", "levels", ";", "that", "the", "majority", "of", "identified", "GARS", "mutations", "modeled", "in", "yeast", "severely", "impair", "viability", ";", "and", "that", ",", "in", "most", "cases", ",", "mutant", "GARS", "protein", "mislocalizes", "in", "neuronal", "cells", ".", "Indeed", ",", "four", "of", "the", "five", "mutations", "studied", "show", "loss", "-", "of", "-", "function", "features", "in", "at", "least", "one", "assay", ",", "suggesting", "that", "tRNA", "-", "charging", "deficits", "play", "a", "role", "in", "disease", "pathogenesis", ".", "Finally", ",", "we", "detected", "endogenous", "GARS", "-", "associated", "granules", "in", "the", "neurite", "projections", "of", "cultured", "neurons", "and", "in", "the", "peripheral", "nerve", "axons", "of", "normal", "human", "tissue", ".", "These", "data", "are", "particularly", "important", "in", "light", "of", "the", "recent", "identification", "of", "CMT", "-", "associated", "mutations", "in", "another", "tRNA", "synthetase", "gene", "[", "YARS", "(", "tyrosyl", "-", "tRNA", "synthetase", "gene", ")", "]", ".", "Together", ",", "these", "findings", "suggest", "that", "tRNA", "-", "charging", "enzymes", "play", "a", "key", "role", "in", "maintaining", "peripheral", "axons", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

TCR is a Entity, response genes is a Entity, TCR gene is a Entity, loci is a Entity, TCR gamma loci is a Entity, TCR beta is a Entity, cellular response gene is a Entity, IL-2 is a Protein, chromatin is a Entity, genes is a Entity, IL-2R alpha is a Protein, IL-2 is a Protein, IL-2R beta chain is a Protein, Bcl-2 is a Protein

759_task0

Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .

[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]

[ "Entity", "Protein" ]

TCR is a Entity, response genes is a Entity, TCR gene is a Entity, loci is a Entity, TCR gamma loci is a Entity, TCR beta is a Entity, cellular response gene is a Entity, IL-2 is a Protein, chromatin is a Entity, genes is a Entity, IL-2R alpha is a Protein, IL-2 is a Protein, IL-2R beta chain is a Protein, Bcl-2 is a Protein

759_task1

Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please typing these entity words according to sentence: TCR, response genes, TCR gene, loci, TCR gamma loci, TCR beta, cellular response gene, IL-2, chromatin, genes, IL-2R alpha, IL-2, IL-2R beta chain, Bcl-2 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .

[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]

[ "Entity", "Protein" ]

TCR, response genes, TCR gene, loci, TCR gamma loci, TCR beta, cellular response gene, IL-2, chromatin, genes, IL-2R alpha, IL-2, IL-2R beta chain, Bcl-2

759_task2

Sentence: The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The development of functionally responsive T cells. The work reviewed in this article separates T cell development into four phases. First is an expansion phase prior to TCR rearrangement, which appears to be correlated with programming of at least some response genes for inducibility. This phase can occur to some extent outside of the thymus. However, the profound T cell deficit of nude mice indicates that the thymus is by far the most potent site for inducing the expansion per se, even if other sites can induce some response acquisition. Second is a controlled phase of TCR gene rearrangement. The details of the regulatory mechanism that selects particular loci for rearrangement are still not known. It seems that the rearrangement of the TCR gamma loci in the gamma delta lineage may not always take place at a developmental stage strictly equivalent to the rearrangement of TCR beta in the alpha beta lineage, and it is not clear just how early the two lineages diverge. In the TCR alpha beta lineage, however, the final gene rearrangement events are accompanied by rapid proliferation and an interruption in cellular response gene inducibility. The loss of conventional responsiveness is probably caused by alterations at the level of signaling, and may be a manifestation of the physiological state that is a precondition for selection. Third is the complex process of selection. Whereas peripheral T cells can undergo forms of positive selection (by antigen-driven clonal expansion) and negative selection (by abortive stimulation leading to anergy or death), neither is exactly the same phenomenon that occurs in the thymic cortex. Negative selection in the cortex appears to be a suicidal inversion of antigen responsiveness: instead of turning on IL-2 expression, the activated cell destroys its own chromatin. The genes that need to be induced for this response are not yet identified, but it is unquestionably a form of activation. It is interesting that in humans and rats, cortical thymocytes undergoing negative selection can still induce IL-2R alpha expression and even be rescued in vitro, if exogenous IL-2 is provided. Perhaps murine thymocytes are denied this form of rescue because they shut off IL-2R beta chain expression at an earlier stage or because they may be uncommonly Bcl-2 deficient (cf. Sentman et al., 1991; Strasser et al., 1991). Even so, medullary thymocytes remain at least partially susceptible to negative selection even as they continue to mature .

[ "The", "development", "of", "functionally", "responsive", "T", "cells", ".", "\n", "The", "work", "reviewed", "in", "this", "article", "separates", "T", "cell", "development", "into", "four", "phases", ".", "First", "is", "an", "expansion", "phase", "prior", "to", "TCR", "rearrangement", ",", "which", "appears", "to", "be", "correlated", "with", "programming", "of", "at", "least", "some", "response", "genes", "for", "inducibility", ".", "This", "phase", "can", "occur", "to", "some", "extent", "outside", "of", "the", "thymus", ".", "However", ",", "the", "profound", "T", "cell", "deficit", "of", "nude", "mice", "indicates", "that", "the", "thymus", "is", "by", "far", "the", "most", "potent", "site", "for", "inducing", "the", "expansion", "per", "se", ",", "even", "if", "other", "sites", "can", "induce", "some", "response", "acquisition", ".", "Second", "is", "a", "controlled", "phase", "of", "TCR", "gene", "rearrangement", ".", "The", "details", "of", "the", "regulatory", "mechanism", "that", "selects", "particular", "loci", "for", "rearrangement", "are", "still", "not", "known", ".", "It", "seems", "that", "the", "rearrangement", "of", "the", "TCR", "gamma", "loci", "in", "the", "gamma", "delta", "lineage", "may", "not", "always", "take", "place", "at", "a", "developmental", "stage", "strictly", "equivalent", "to", "the", "rearrangement", "of", "TCR", "beta", "in", "the", "alpha", "beta", "lineage", ",", "and", "it", "is", "not", "clear", "just", "how", "early", "the", "two", "lineages", "diverge", ".", "In", "the", "TCR", "alpha", "beta", "lineage", ",", "however", ",", "the", "final", "gene", "rearrangement", "events", "are", "accompanied", "by", "rapid", "proliferation", "and", "an", "interruption", "in", "cellular", "response", "gene", "inducibility", ".", "The", "loss", "of", "conventional", "responsiveness", "is", "probably", "caused", "by", "alterations", "at", "the", "level", "of", "signaling", ",", "and", "may", "be", "a", "manifestation", "of", "the", "physiological", "state", "that", "is", "a", "precondition", "for", "selection", ".", "Third", "is", "the", "complex", "process", "of", "selection", ".", "Whereas", "peripheral", "T", "cells", "can", "undergo", "forms", "of", "positive", "selection", "(", "by", "antigen", "-", "driven", "clonal", "expansion", ")", "and", "negative", "selection", "(", "by", "abortive", "stimulation", "leading", "to", "anergy", "or", "death", ")", ",", "neither", "is", "exactly", "the", "same", "phenomenon", "that", "occurs", "in", "the", "thymic", "cortex", ".", "Negative", "selection", "in", "the", "cortex", "appears", "to", "be", "a", "suicidal", "inversion", "of", "antigen", "responsiveness", ":", "instead", "of", "turning", "on", "IL-2", "expression", ",", "the", "activated", "cell", "destroys", "its", "own", "chromatin", ".", "The", "genes", "that", "need", "to", "be", "induced", "for", "this", "response", "are", "not", "yet", "identified", ",", "but", "it", "is", "unquestionably", "a", "form", "of", "activation", ".", "It", "is", "interesting", "that", "in", "humans", "and", "rats", ",", "cortical", "thymocytes", "undergoing", "negative", "selection", "can", "still", "induce", "IL-2R", "alpha", "expression", "and", "even", "be", "rescued", "in", "vitro", ",", "if", "exogenous", "IL-2", "is", "provided", ".", "Perhaps", "murine", "thymocytes", "are", "denied", "this", "form", "of", "rescue", "because", "they", "shut", "off", "IL-2R", "beta", "chain", "expression", "at", "an", "earlier", "stage", "or", "because", "they", "may", "be", "uncommonly", "Bcl-2", "deficient", "(", "cf", ".", "Sentman", "et", "al", ".", ",", "1991", ";", "Strasser", "et", "al", ".", ",", "1991", ")", ".", "Even", "so", ",", "medullary", "thymocytes", "remain", "at", "least", "partially", "susceptible", "to", "negative", "selection", "even", "as", "they", "continue", "to", "mature", ".", "\n" ]

[ "Entity", "Protein" ]

ASIC2 is a GENE-Y, amiloride is a CHEMICAL

16704974_task0

Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.

[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ASIC2 is a GENE-Y, amiloride is a CHEMICAL

16704974_task1

Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please typing these entity words according to sentence: ASIC2, amiloride Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.

[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ASIC2, amiloride

16704974_task2

Sentence: Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Surface expression of ASIC2 inhibits the amiloride-sensitive current and migration of glioma cells.

[ "Surface", "expression", "of", "ASIC2", "inhibits", "the", "amiloride", "-", "sensitive", "current", "and", "migration", "of", "glioma", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

chronic lymphocytic leukemia is a Participant_Condition, rituximab ( R ) to fludarabine and cyclophosphamide is a Intervention_Pharmacological, FC is a Intervention_Pharmacological, patient outcomes is a Outcome_Physical, CLL is a Participant_Condition, genome - wide expression is a Outcome_Physical, 300 is a Participant_Sample-size, 552 is a Participant_Sample-size, R - FC is a Intervention_Pharmacological, progression - free survival is a Outcome_Mortality, R - dependent cell death is a Outcome_Physical

66009_task0

Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .

[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]

chronic lymphocytic leukemia is a Participant_Condition, rituximab ( R ) to fludarabine and cyclophosphamide is a Intervention_Pharmacological, FC is a Intervention_Pharmacological, patient outcomes is a Outcome_Physical, CLL is a Participant_Condition, genome - wide expression is a Outcome_Physical, 300 is a Participant_Sample-size, 552 is a Participant_Sample-size, R - FC is a Intervention_Pharmacological, progression - free survival is a Outcome_Mortality, R - dependent cell death is a Outcome_Physical

66009_task1

Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please typing these entity words according to sentence: chronic lymphocytic leukemia, rituximab ( R ) to fludarabine and cyclophosphamide, FC, patient outcomes, CLL, genome - wide expression, 300, 552, R - FC, progression - free survival, R - dependent cell death Options: Intervention_Pharmacological, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .

[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]

chronic lymphocytic leukemia, rituximab ( R ) to fludarabine and cyclophosphamide, FC, patient outcomes, CLL, genome - wide expression, 300, 552, R - FC, progression - free survival, R - dependent cell death

66009_task2

Sentence: PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia . Addition of rituximab ( R ) to fludarabine and cyclophosphamide ( FC ) has significantly improved patient outcomes in chronic lymphocytic leukemia ( CLL ) . Whether baseline gene expression can identify patients who will benefit from immunochemotherapy over chemotherapy alone has not been determined . We assessed genome-wide expression of 300 pretreatment specimens from a subset of 552 patients in REACH , a study of FC or R-FC in relapsed CLL . An independent test set was derived from 282 pretreatment specimens from CLL8 , a study of FC or R-FC in treatment-naïve patients . Genes specific for benefit from R-FC were determined by assessing treatment-gene interactions in Cox proportional hazards models . REACH patients with higher pretreatment protein tyrosine kinase 2 ( PTK2 ) messenger RNA levels derived greater benefit from R-FC , with significant improvements in progression-free survival , independent of known prognostic factors in a multivariate model . Examination of PTK2 gene expression in CLL8 patients yielded similar results . Furthermore , PTK2 inhibition blunted R-dependent cell death in vitro . This retrospective analysis from 2 independent trials revealed that increased PTK2 expression is associated with improved outcomes for CLL patients treated with R-FC vs FC . PTK2 expression may be a useful biomarker for patient selection in future trials . These trials were registered at www.clinicaltrials.gov as # NCT00090051 ( REACH ) and # NCT00281918 ( CLL8 ) .

[ "PTK2", "expression", "and", "immunochemotherapy", "outcome", "in", "chronic", "lymphocytic", "leukemia", ".", "Addition", "of", "rituximab", "(", "R", ")", "to", "fludarabine", "and", "cyclophosphamide", "(", "FC", ")", "has", "significantly", "improved", "patient", "outcomes", "in", "chronic", "lymphocytic", "leukemia", "(", "CLL", ")", ".", "Whether", "baseline", "gene", "expression", "can", "identify", "patients", "who", "will", "benefit", "from", "immunochemotherapy", "over", "chemotherapy", "alone", "has", "not", "been", "determined", ".", "We", "assessed", "genome", "-", "wide", "expression", "of", "300", "pretreatment", "specimens", "from", "a", "subset", "of", "552", "patients", "in", "REACH", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "relapsed", "CLL", ".", "An", "independent", "test", "set", "was", "derived", "from", "282", "pretreatment", "specimens", "from", "CLL8", ",", "a", "study", "of", "FC", "or", "R", "-", "FC", "in", "treatment", "-", "naïve", "patients", ".", "Genes", "specific", "for", "benefit", "from", "R", "-", "FC", "were", "determined", "by", "assessing", "treatment", "-", "gene", "interactions", "in", "Cox", "proportional", "hazards", "models", ".", "REACH", "patients", "with", "higher", "pretreatment", "protein", "tyrosine", "kinase", "2", "(", "PTK2", ")", "messenger", "RNA", "levels", "derived", "greater", "benefit", "from", "R", "-", "FC", ",", "with", "significant", "improvements", "in", "progression", "-", "free", "survival", ",", "independent", "of", "known", "prognostic", "factors", "in", "a", "multivariate", "model", ".", "Examination", "of", "PTK2", "gene", "expression", "in", "CLL8", "patients", "yielded", "similar", "results", ".", "Furthermore", ",", "PTK2", "inhibition", "blunted", "R", "-", "dependent", "cell", "death", "in", "vitro", ".", "This", "retrospective", "analysis", "from", "2", "independent", "trials", "revealed", "that", "increased", "PTK2", "expression", "is", "associated", "with", "improved", "outcomes", "for", "CLL", "patients", "treated", "with", "R", "-", "FC", "vs", "FC", ".", "PTK2", "expression", "may", "be", "a", "useful", "biomarker", "for", "patient", "selection", "in", "future", "trials", ".", "These", "trials", "were", "registered", "at", "www.clinicaltrials.gov", "as", "#", "NCT00090051", "(", "REACH", ")", "and", "#", "NCT00281918", "(", "CLL8", ")", "." ]

[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Mortality", "Outcome_Physical", "Participant_Sample-size" ]

Echinococcus is an umlsterm, Larvenstadium is an umlsterm, menschlichen Koerpers is an umlsterm, Leber is an umlsterm, Knochenbefall is an umlsterm, Becken- is an umlsterm, Hueftgelenks is an umlsterm, Os pubis is an umlsterm, Hueftgelenk- is an umlsterm, Beckenteilresektion is an umlsterm, Rezidiv is an umlsterm, Femur is an umlsterm, Chemotherapie is an umlsterm, Mebendazol is an umlsterm

DerChirurg.70680832.ger.abstr_task0

Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .

[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]

[ "umlsterm" ]

Echinococcus is an umlsterm, Larvenstadium is an umlsterm, menschlichen Koerpers is an umlsterm, Leber is an umlsterm, Knochenbefall is an umlsterm, Becken- is an umlsterm, Hueftgelenks is an umlsterm, Os pubis is an umlsterm, Hueftgelenk- is an umlsterm, Beckenteilresektion is an umlsterm, Rezidiv is an umlsterm, Femur is an umlsterm, Chemotherapie is an umlsterm, Mebendazol is an umlsterm

DerChirurg.70680832.ger.abstr_task1

Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please typing these entity words according to sentence: Echinococcus, Larvenstadium, menschlichen Koerpers, Leber, Knochenbefall, Becken-, Hueftgelenks, Os pubis, Hueftgelenk-, Beckenteilresektion, Rezidiv, Femur, Chemotherapie, Mebendazol Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .

[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]

[ "umlsterm" ]

Echinococcus, Larvenstadium, menschlichen Koerpers, Leber, Knochenbefall, Becken-, Hueftgelenks, Os pubis, Hueftgelenk-, Beckenteilresektion, Rezidiv, Femur, Chemotherapie, Mebendazol

DerChirurg.70680832.ger.abstr_task2

Sentence: Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Der Hundebandwurm , Echinococcus , kann in seinem Larvenstadium alle Teile des menschlichen Koerpers , zumeist die Leber , als Zwischenwirt befallen . Der primaere Knochenbefall ist mit weniger als 2 % aller Echinococcuslaesionen sehr selten . Wir berichten ueber einen Fall eines ausgedehnten linksseitigen Becken- und Femurbefalls . Die Destruktion des Hueftgelenks , des Os pubis sowie der ausgedehnte Befall des Os ileum und des proximalen Femurs machten eine Hueftgelenk- und Beckenteilresektion sowie den prothetischen Ersatz notwendig . Ein Rezidiv im Bereich der linken Leiste nach 5 Jahren , ausgehend vom proximalen Femur , wurde mit erneuter Resektion und Hueftprothesenwechsel behandelt . Der primaer eingebrachte Polyacetal-Beckenersatz musste dabei wegen Instabilitaet ebenfalls ausgetauscht werden . Ein sonderangefertigter CAD-Beckenersatz ( CAD = computer-aided designed " ) " wurde implantiert . Additiv wurde eine Chemotherapie mit Mebendazol durchgefuehrt . Die Radikalitaet der Resektion beim ossaeren Echinococcusbefall wird diskutiert .

[ "Zusammenfassung", ".", "Der", "Hundebandwurm", ",", "Echinococcus", ",", "kann", "in", "seinem", "Larvenstadium", "alle", "Teile", "des", "menschlichen", "Koerpers", ",", "zumeist", "die", "Leber", ",", "als", "Zwischenwirt", "befallen", ".", "Der", "primaere", "Knochenbefall", "ist", "mit", "weniger", "als", "2", "%", "aller", "Echinococcuslaesionen", "sehr", "selten", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "ausgedehnten", "linksseitigen", "Becken-", "und", "Femurbefalls", ".", "Die", "Destruktion", "des", "Hueftgelenks", ",", "des", "Os", "pubis", "sowie", "der", "ausgedehnte", "Befall", "des", "Os", "ileum", "und", "des", "proximalen", "Femurs", "machten", "eine", "Hueftgelenk-", "und", "Beckenteilresektion", "sowie", "den", "prothetischen", "Ersatz", "notwendig", ".", "Ein", "Rezidiv", "im", "Bereich", "der", "linken", "Leiste", "nach", "5", "Jahren", ",", "ausgehend", "vom", "proximalen", "Femur", ",", "wurde", "mit", "erneuter", "Resektion", "und", "Hueftprothesenwechsel", "behandelt", ".", "Der", "primaer", "eingebrachte", "Polyacetal", "-", "Beckenersatz", "musste", "dabei", "wegen", "Instabilitaet", "ebenfalls", "ausgetauscht", "werden", ".", "Ein", "sonderangefertigter", "CAD", "-", "Beckenersatz", "(", "CAD", "=", "computer", "-", "aided", "designed", "\"", ")", "\"", "wurde", "implantiert", ".", "Additiv", "wurde", "eine", "Chemotherapie", "mit", "Mebendazol", "durchgefuehrt", ".", "Die", "Radikalitaet", "der", "Resektion", "beim", "ossaeren", "Echinococcusbefall", "wird", "diskutiert", "." ]

[ "umlsterm" ]

cancer is a Disease, new malignancies is a Disease, tobacco is a Plant, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, Tobacco is a Plant, cancers is a Disease, acute myeloid leukemia is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, tobacco is a Plant, cancer is a Disease

22706885_task0

Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]

INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.

[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]

[ "Disease", "Plant" ]

cancer is a Disease, new malignancies is a Disease, tobacco is a Plant, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, tobacco is a Plant, Tobacco is a Plant, cancers is a Disease, acute myeloid leukemia is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, cancer is a Disease, cancer is a Disease, cancer is a Disease, tobacco is a Plant, tobacco is a Plant, cancer is a Disease

22706885_task1

Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please typing these entity words according to sentence: cancer, new malignancies, tobacco, cancer, tobacco, cancer, cancer, tobacco, cancer, cancer, tobacco, Tobacco, cancers, acute myeloid leukemia, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, tobacco, tobacco, cancer Options: Disease, Plant

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]

INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.

[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]

[ "Disease", "Plant" ]

cancer, new malignancies, tobacco, cancer, tobacco, cancer, cancer, tobacco, cancer, cancer, tobacco, Tobacco, cancers, acute myeloid leukemia, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, cancer, cancer, tobacco, cancer, cancer, cancer, tobacco, tobacco, cancer

22706885_task2

Sentence: INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "B-Disease", "O", "O" ]

INTRODUCTION: People who continue to smoke after a cancer diagnosis have an increased risk for recurrences or development of new malignancies. These risks may be even higher among tobacco-related cancer survivors (TRCS). We describe tobacco use behaviors among TRCS, other cancer survivors, and people without a history of cancer. METHODS: We used 2009 Behavioral Risk Factor Surveillance System data to describe demographic characteristics, smoking history, current smoking prevalence, and smokeless tobacco use among TRCS, other cancer survivors, and people without a history of cancer (cigarette smoking and smokeless tobacco use were calculated after adjusting for age, sex, race, and insurance status). Tobacco-related cancers were defined as lung/bronchial, pharyngeal, laryngeal, esophageal, stomach, pancreatic, kidney/renal, urinary bladder, cervical, and acute myeloid leukemia. RESULTS: A total of 20 % of all cancer survivors were TRCS. TRCS were primarily female (68 %) and white (78 %). Smoking prevalence was higher among TRCS (27 %) compared with other cancer survivors (16 %) and respondents without a history of cancer (18 %). Smokeless tobacco use was higher among respondents without a history of cancer (4 %) compared with TRCS (3 %) and other cancer survivors (3 %). CONCLUSIONS: The self-reported smoking prevalence among TRCS is higher than among other cancer survivors and people without a history of cancer. Targeted smoking prevention and cessation interventions are needed for cancer survivors, especially those diagnosed with a tobacco-related cancer. IMPLICATIONS FOR CANCER SURVIVORS: We recommend all cancer survivors be made aware of the health risks associated with smoking after a cancer diagnosis, and smoking cessation services be offered to those who currently smoke. We provide the first population-based report on demographic characteristics and tobacco use behaviors among self-reported tobacco-related cancer survivors.

[ "INTRODUCTION", ":", "People", "who", "continue", "to", "smoke", "after", "a", "cancer", "diagnosis", "have", "an", "increased", "risk", "for", "recurrences", "or", "development", "of", "new", "malignancies", ".", "These", "risks", "may", "be", "even", "higher", "among", "tobacco", "-", "related", "cancer", "survivors", "(", "TRCS", ")", ".", "We", "describe", "tobacco", "use", "behaviors", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", ".", "METHODS", ":", "We", "used", "2009", "Behavioral", "Risk", "Factor", "Surveillance", "System", "data", "to", "describe", "demographic", "characteristics", ",", "smoking", "history", ",", "current", "smoking", "prevalence", ",", "and", "smokeless", "tobacco", "use", "among", "TRCS", ",", "other", "cancer", "survivors", ",", "and", "people", "without", "a", "history", "of", "cancer", "(", "cigarette", "smoking", "and", "smokeless", "tobacco", "use", "were", "calculated", "after", "adjusting", "for", "age", ",", "sex", ",", "race", ",", "and", "insurance", "status", ")", ".", "Tobacco", "-", "related", "cancers", "were", "defined", "as", "lung", "/", "bronchial", ",", "pharyngeal", ",", "laryngeal", ",", "esophageal", ",", "stomach", ",", "pancreatic", ",", "kidney", "/", "renal", ",", "urinary", "bladder", ",", "cervical", ",", "and", "acute", "myeloid", "leukemia", ".", "RESULTS", ":", "A", "total", "of", "20", "%", "of", "all", "cancer", "survivors", "were", "TRCS", ".", "TRCS", "were", "primarily", "female", "(", "68", "%", ")", "and", "white", "(", "78", "%", ")", ".", "Smoking", "prevalence", "was", "higher", "among", "TRCS", "(", "27", "%", ")", "compared", "with", "other", "cancer", "survivors", "(", "16", "%", ")", "and", "respondents", "without", "a", "history", "of", "cancer", "(", "18", "%", ")", ".", "Smokeless", "tobacco", "use", "was", "higher", "among", "respondents", "without", "a", "history", "of", "cancer", "(", "4", "%", ")", "compared", "with", "TRCS", "(", "3", "%", ")", "and", "other", "cancer", "survivors", "(", "3", "%", ")", ".", "CONCLUSIONS", ":", "The", "self", "-", "reported", "smoking", "prevalence", "among", "TRCS", "is", "higher", "than", "among", "other", "cancer", "survivors", "and", "people", "without", "a", "history", "of", "cancer", ".", "Targeted", "smoking", "prevention", "and", "cessation", "interventions", "are", "needed", "for", "cancer", "survivors", ",", "especially", "those", "diagnosed", "with", "a", "tobacco", "-", "related", "cancer", ".", "IMPLICATIONS", "FOR", "CANCER", "SURVIVORS", ":", "We", "recommend", "all", "cancer", "survivors", "be", "made", "aware", "of", "the", "health", "risks", "associated", "with", "smoking", "after", "a", "cancer", "diagnosis", ",", "and", "smoking", "cessation", "services", "be", "offered", "to", "those", "who", "currently", "smoke", ".", "We", "provide", "the", "first", "population", "-", "based", "report", "on", "demographic", "characteristics", "and", "tobacco", "use", "behaviors", "among", "self", "-", "reported", "tobacco", "-", "related", "cancer", "survivors", "." ]

[ "Disease", "Plant" ]

pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, cutaneous lesions is a ADVERSE, weakness is a ADVERSE, fever is a ADVERSE, poor appetite is a ADVERSE, nausea is a ADVERSE, vomiting is a ADVERSE, painful lesions is a ADVERSE, cutaneous ulceration is a ADVERSE, pancytopenia is a ADVERSE, abnormal coagulation is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, pancytopenia is a ADVERSE, renal insufficiency is a ADVERSE, hypoalbuminemia is a ADVERSE, concomitant infections is a ADVERSE, pancytopenia is a ADVERSE, rheumatoid arthritis is a DISEASE

example-313_task0

Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE, DISEASE

[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]

Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.

[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]

[ "ADVERSE", "DISEASE" ]

pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, cutaneous lesions is a ADVERSE, weakness is a ADVERSE, fever is a ADVERSE, poor appetite is a ADVERSE, nausea is a ADVERSE, vomiting is a ADVERSE, painful lesions is a ADVERSE, cutaneous ulceration is a ADVERSE, pancytopenia is a ADVERSE, abnormal coagulation is a ADVERSE, Pancytopenia is a ADVERSE, pancytopenia is a ADVERSE, skin ulcer is a ADVERSE, pancytopenia is a ADVERSE, renal insufficiency is a ADVERSE, hypoalbuminemia is a ADVERSE, concomitant infections is a ADVERSE, pancytopenia is a ADVERSE, rheumatoid arthritis is a DISEASE

example-313_task1

Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please typing these entity words according to sentence: pancytopenia, skin ulcer, Pancytopenia, pancytopenia, cutaneous lesions, weakness, fever, poor appetite, nausea, vomiting, painful lesions, cutaneous ulceration, pancytopenia, abnormal coagulation, Pancytopenia, pancytopenia, skin ulcer, pancytopenia, renal insufficiency, hypoalbuminemia, concomitant infections, pancytopenia, rheumatoid arthritis Options: ADVERSE, DISEASE

[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]

Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.

[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]

[ "ADVERSE", "DISEASE" ]

pancytopenia, skin ulcer, Pancytopenia, pancytopenia, cutaneous lesions, weakness, fever, poor appetite, nausea, vomiting, painful lesions, cutaneous ulceration, pancytopenia, abnormal coagulation, Pancytopenia, pancytopenia, skin ulcer, pancytopenia, renal insufficiency, hypoalbuminemia, concomitant infections, pancytopenia, rheumatoid arthritis

example-313_task2

Sentence: Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "B-ADVERSE", "I-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DISEASE", "I-DISEASE", "O", "O" ]

Early-onset pancytopenia and skin ulcer following low-dose methotrexate therapy. Pancytopenia is a rare but serious adverse effect of low-dose methotrexate (MTX) sodium therapy, and this case report describes a very early-onset of pancytopenia and cutaneous lesions after three days of ingestion. A 64-year-old man was presented to Emergency Department with weakness, fever, poor appetite, nausea, and vomiting after he had had accidentally ingested MTX tablets (2.5 mg) twice a day for the last three days. On initial examination, several painful lesions in his oral mucosa and a cutaneous ulceration on his right foot were also observed. He had severe pancytopenia, poor kidney functions, and abnormal coagulation parameters. The blood level of MTX was found to be within therapeutic range. He was treated with leucovorine, intravenous antibiotics, and appropriate blood transfusions; he was discharged from hospital without any sequela. Pancytopenia associated with low-dose (cumulative dose of 15 mg in 3 days) MTX therapy had not been reported previously. The Naranjo probability scale showed pancytopenia and skin ulcer associated with low-dose MTX therapy as probable adverse reactions. Risk factors for pancytopenia such as renal insufficiency, hypoalbuminemia, low folate levels, concomitant infections, concomitant use of drugs, and folate supplementation were not identified in our patient. Although pancytopenia associated with low-dose MTX therapy is not expected as early as 3 days after initiation of the therapy, physicians should also be aware of this life threatening adverse effect during the very first days of MTX therapy for rheumatoid arthritis patients.

[ "Early", "-", "onset", "pancytopenia", "and", "skin", "ulcer", "following", "low", "-", "dose", "methotrexate", "therapy", ".", " ", "Pancytopenia", "is", "a", "rare", "but", "serious", "adverse", "effect", "of", "low", "-", "dose", "methotrexate", "(", "MTX", ")", "sodium", "therapy", ",", "and", "this", "case", "report", "describes", "a", "very", "early", "-", "onset", "of", "pancytopenia", "and", "cutaneous", "lesions", "after", "three", "days", "of", "ingestion", ".", "A", "64-year", "-", "old", "man", "was", "presented", "to", "Emergency", "Department", "with", "weakness", ",", "fever", ",", "poor", "appetite", ",", "nausea", ",", "and", "vomiting", "after", "he", "had", "had", "accidentally", "ingested", "MTX", "tablets", "(", "2.5", "mg", ")", "twice", "a", "day", "for", "the", "last", "three", "days", ".", "On", "initial", "examination", ",", "several", "painful", "lesions", "in", "his", "oral", "mucosa", "and", "a", "cutaneous", "ulceration", "on", "his", "right", "foot", "were", "also", "observed", ".", "He", "had", "severe", "pancytopenia", ",", "poor", "kidney", "functions", ",", "and", "abnormal", "coagulation", "parameters", ".", "The", "blood", "level", "of", "MTX", "was", "found", "to", "be", "within", "therapeutic", "range", ".", "He", "was", "treated", "with", "leucovorine", ",", "intravenous", "antibiotics", ",", "and", "appropriate", "blood", "transfusions", ";", "he", "was", "discharged", "from", "hospital", "without", "any", "sequela", ".", "Pancytopenia", "associated", "with", "low", "-", "dose", "(", "cumulative", "dose", "of", "15", "mg", "in", "3", "days", ")", "MTX", "therapy", "had", "not", "been", "reported", "previously", ".", "The", "Naranjo", "probability", "scale", "showed", "pancytopenia", "and", "skin", "ulcer", "associated", "with", "low", "-", "dose", "MTX", "therapy", "as", "probable", "adverse", "reactions", ".", "Risk", "factors", "for", "pancytopenia", "such", "as", "renal", "insufficiency", ",", "hypoalbuminemia", ",", "low", "folate", "levels", ",", "concomitant", "infections", ",", "concomitant", "use", "of", "drugs", ",", "and", "folate", "supplementation", "were", "not", "identified", "in", "our", "patient", ".", "Although", "pancytopenia", "associated", "with", "low", "-", "dose", "MTX", "therapy", "is", "not", "expected", "as", "early", "as", "3", "days", "after", "initiation", "of", "the", "therapy", ",", "physicians", "should", "also", "be", "aware", "of", "this", "life", "threatening", "adverse", "effect", "during", "the", "very", "first", "days", "of", "MTX", "therapy", "for", "rheumatoid", "arthritis", "patients", "." ]

[ "ADVERSE", "DISEASE" ]

Patienten is an umlsterm, chronischer Niereninsuffizienz is an umlsterm, Skelettveraenderungen is an umlsterm, Knochenmasseveraenderungen is an umlsterm, Wirbelsaeule is an umlsterm, Haemodialyse is an umlsterm, Autopsiefaellen is an umlsterm, Dialysedauer is an umlsterm, Wirbelsaeulen is an umlsterm, skelettgesunde is an umlsterm, Autopsiefaelle is an umlsterm, Beckenkammbiopsie is an umlsterm, Biopsieort is an umlsterm, Wirbelsaeule is an umlsterm, Praeparationstechnik is an umlsterm, Analyse is an umlsterm, Wirbelkoerperhoehen is an umlsterm, Knochenvolumen is an umlsterm, Wirbelkoerperfrakturen is an umlsterm, Osteopathie is an umlsterm, Knochenvolumens is an umlsterm, Normalbereich is an umlsterm, skelettgesunden is an umlsterm, Wirbelsaeule is an umlsterm, Beckenkammbiopsie is an umlsterm, Haemodialyse is an umlsterm, Geschlecht is an umlsterm, Analyse is an umlsterm, Architektur is an umlsterm, Patienten is an umlsterm, Haemodialyse is an umlsterm

DerPathologe.40150015.ger.abstr_task0

Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .

[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]

[ "umlsterm" ]

Patienten is an umlsterm, chronischer Niereninsuffizienz is an umlsterm, Skelettveraenderungen is an umlsterm, Knochenmasseveraenderungen is an umlsterm, Wirbelsaeule is an umlsterm, Haemodialyse is an umlsterm, Autopsiefaellen is an umlsterm, Dialysedauer is an umlsterm, Wirbelsaeulen is an umlsterm, skelettgesunde is an umlsterm, Autopsiefaelle is an umlsterm, Beckenkammbiopsie is an umlsterm, Biopsieort is an umlsterm, Wirbelsaeule is an umlsterm, Praeparationstechnik is an umlsterm, Analyse is an umlsterm, Wirbelkoerperhoehen is an umlsterm, Knochenvolumen is an umlsterm, Wirbelkoerperfrakturen is an umlsterm, Osteopathie is an umlsterm, Knochenvolumens is an umlsterm, Normalbereich is an umlsterm, skelettgesunden is an umlsterm, Wirbelsaeule is an umlsterm, Beckenkammbiopsie is an umlsterm, Haemodialyse is an umlsterm, Geschlecht is an umlsterm, Analyse is an umlsterm, Architektur is an umlsterm, Patienten is an umlsterm, Haemodialyse is an umlsterm

DerPathologe.40150015.ger.abstr_task1

Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please typing these entity words according to sentence: Patienten, chronischer Niereninsuffizienz, Skelettveraenderungen, Knochenmasseveraenderungen, Wirbelsaeule, Haemodialyse, Autopsiefaellen, Dialysedauer, Wirbelsaeulen, skelettgesunde, Autopsiefaelle, Beckenkammbiopsie, Biopsieort, Wirbelsaeule, Praeparationstechnik, Analyse, Wirbelkoerperhoehen, Knochenvolumen, Wirbelkoerperfrakturen, Osteopathie, Knochenvolumens, Normalbereich, skelettgesunden, Wirbelsaeule, Beckenkammbiopsie, Haemodialyse, Geschlecht, Analyse, Architektur, Patienten, Haemodialyse Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .

[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]

[ "umlsterm" ]

Patienten, chronischer Niereninsuffizienz, Skelettveraenderungen, Knochenmasseveraenderungen, Wirbelsaeule, Haemodialyse, Autopsiefaellen, Dialysedauer, Wirbelsaeulen, skelettgesunde, Autopsiefaelle, Beckenkammbiopsie, Biopsieort, Wirbelsaeule, Praeparationstechnik, Analyse, Wirbelkoerperhoehen, Knochenvolumen, Wirbelkoerperfrakturen, Osteopathie, Knochenvolumens, Normalbereich, skelettgesunden, Wirbelsaeule, Beckenkammbiopsie, Haemodialyse, Geschlecht, Analyse, Architektur, Patienten, Haemodialyse

DerPathologe.40150015.ger.abstr_task2

Sentence: Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Zusammenfassung . Bei Patienten mit chronischer Niereninsuffizienz kommt es zu charakteristischen Skelettveraenderungen . Das Ziel der vorliegenden Untersuchungen war es , die Knochenmasseveraenderungen der Wirbelsaeule bei langjaehriger Haemodialyse von C2 - L5 komplett zu erfassen . Von 9 Autopsiefaellen mit einer Dialysedauer von 4 bis 15 Jahren wurden Wirbelsaeulen komplett untersucht . Als altersentsprechendes Kontrollkollektiv dienten 26 skelettgesunde Autopsiefaelle . Eine Beckenkammbiopsie ermoeglichte den unmittelbaren Vergleich von diagnostischem Biopsieort und Wirbelsaeule . Mit einer neu entwickelten Praeparationstechnik ist die kombinierte zwei- und dreidimensionale Analyse moeglich , so dass neben dem histologischen Bild unmittelbar die zugrunde liegende dreidimensionale Struktur analysiert werden kann . Quantitativ ausgewertet wurden die Wirbelkoerperhoehen ( SDI ) , das Knochenvolumen ( BV/TV ) und die intertrabekulaere Verknuepfung ( TBPf ) . Der spine deformity index " ( " SDI ) zeigt Wirbelkoerperfrakturen bei den Typen I und II der renalen Osteopathie ( ROP ) , trotz eines trabekulaeren Knochenvolumens ( BV/TV ) im Normalbereich . BV/TV zeigt eine aus dem skelettgesunden Kontrollkollektiv bekannte Verteilung ueber die Wirbelsaeule . Der von der HWS zur LWS abnehmende plateauartige Kurvenverlauf liegt jedoch bei den ROP um 5% niedriger . Das BV/TV des 2. LWK betraegt zwischen 51,2% und 74,1% des in der korrespondierenden Beckenkammbiopsie gemessenen Wertes . Die Faelle mit laengerer Haemodialyse weisen unabhaengig von Lebensalter und Geschlecht hoehere BV/TV-Werte auf . Normales BV/TV ist nicht gleichbedeutend mit physiologischer Vernetzung der Spongiasa und funktioneller Statik . Die dreidimensionale Analyse bei ROP ergibt im Vergleich zu den Kontrollen eine sehr viel staerkere Umstrukturierung der Architektur als dies auf den 2-D-Schnittebenen und den trabekulaeren Knochenvolumina abgeleitet werden kann . Die Befunde unterstreichen die Bedeutung einer wirkungsvollen Prophylaxe zum Erhalt einer geordneten und somit funktionsfaehigen Spongiosaarchitektur bei Patienten unter chronischer Haemodialyse .

[ "Zusammenfassung", ".", "Bei", "Patienten", "mit", "chronischer", "Niereninsuffizienz", "kommt", "es", "zu", "charakteristischen", "Skelettveraenderungen", ".", "Das", "Ziel", "der", "vorliegenden", "Untersuchungen", "war", "es", ",", "die", "Knochenmasseveraenderungen", "der", "Wirbelsaeule", "bei", "langjaehriger", "Haemodialyse", "von", "C2", "-", "L5", "komplett", "zu", "erfassen", ".", "Von", "9", "Autopsiefaellen", "mit", "einer", "Dialysedauer", "von", "4", "bis", "15", "Jahren", "wurden", "Wirbelsaeulen", "komplett", "untersucht", ".", "Als", "altersentsprechendes", "Kontrollkollektiv", "dienten", "26", "skelettgesunde", "Autopsiefaelle", ".", "Eine", "Beckenkammbiopsie", "ermoeglichte", "den", "unmittelbaren", "Vergleich", "von", "diagnostischem", "Biopsieort", "und", "Wirbelsaeule", ".", "Mit", "einer", "neu", "entwickelten", "Praeparationstechnik", "ist", "die", "kombinierte", "zwei-", "und", "dreidimensionale", "Analyse", "moeglich", ",", "so", "dass", "neben", "dem", "histologischen", "Bild", "unmittelbar", "die", "zugrunde", "liegende", "dreidimensionale", "Struktur", "analysiert", "werden", "kann", ".", "Quantitativ", "ausgewertet", "wurden", "die", "Wirbelkoerperhoehen", "(", "SDI", ")", ",", "das", "Knochenvolumen", "(", "BV", "/", "TV", ")", "und", "die", "intertrabekulaere", "Verknuepfung", "(", "TBPf", ")", ".", "Der", "spine", "deformity", "index", "\"", "(", "\"", "SDI", ")", "zeigt", "Wirbelkoerperfrakturen", "bei", "den", "Typen", "I", "und", "II", "der", "renalen", "Osteopathie", "(", "ROP", ")", ",", "trotz", "eines", "trabekulaeren", "Knochenvolumens", "(", "BV", "/", "TV", ")", "im", "Normalbereich", ".", "BV", "/", "TV", "zeigt", "eine", "aus", "dem", "skelettgesunden", "Kontrollkollektiv", "bekannte", "Verteilung", "ueber", "die", "Wirbelsaeule", ".", "Der", "von", "der", "HWS", "zur", "LWS", "abnehmende", "plateauartige", "Kurvenverlauf", "liegt", "jedoch", "bei", "den", "ROP", "um", "5", "%", "niedriger", ".", "Das", "BV", "/", "TV", "des", "2", ".", "LWK", "betraegt", "zwischen", "51,2", "%", "und", "74,1", "%", "des", "in", "der", "korrespondierenden", "Beckenkammbiopsie", "gemessenen", "Wertes", ".", "Die", "Faelle", "mit", "laengerer", "Haemodialyse", "weisen", "unabhaengig", "von", "Lebensalter", "und", "Geschlecht", "hoehere", "BV", "/", "TV", "-", "Werte", "auf", ".", "Normales", "BV", "/", "TV", "ist", "nicht", "gleichbedeutend", "mit", "physiologischer", "Vernetzung", "der", "Spongiasa", "und", "funktioneller", "Statik", ".", "Die", "dreidimensionale", "Analyse", "bei", "ROP", "ergibt", "im", "Vergleich", "zu", "den", "Kontrollen", "eine", "sehr", "viel", "staerkere", "Umstrukturierung", "der", "Architektur", "als", "dies", "auf", "den", "2-D", "-", "Schnittebenen", "und", "den", "trabekulaeren", "Knochenvolumina", "abgeleitet", "werden", "kann", ".", "Die", "Befunde", "unterstreichen", "die", "Bedeutung", "einer", "wirkungsvollen", "Prophylaxe", "zum", "Erhalt", "einer", "geordneten", "und", "somit", "funktionsfaehigen", "Spongiosaarchitektur", "bei", "Patienten", "unter", "chronischer", "Haemodialyse", "." ]

[ "umlsterm" ]

Interleukin-4 is a Protein, IL-4 is a Protein, interleukin-12 is a Entity, IL-12 is a Entity, tyrosine residues is a Entity, intracellular domain is a Entity, phosphotyrosines is a Entity, docking sites is a Entity, src homology 2 ( SH2 ) domain is a Entity, intracellular domain is a Entity, phosphotyrosine residue is a Entity, amino acid residues is a Entity, phosphotyrosine is a Entity, docking sites is a Entity

186_task0

Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.

[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]

[ "Entity", "Protein" ]

Interleukin-4 is a Protein, IL-4 is a Protein, interleukin-12 is a Entity, IL-12 is a Entity, tyrosine residues is a Entity, intracellular domain is a Entity, phosphotyrosines is a Entity, docking sites is a Entity, src homology 2 ( SH2 ) domain is a Entity, intracellular domain is a Entity, phosphotyrosine residue is a Entity, amino acid residues is a Entity, phosphotyrosine is a Entity, docking sites is a Entity

186_task1

Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please typing these entity words according to sentence: Interleukin-4, IL-4, interleukin-12, IL-12, tyrosine residues, intracellular domain, phosphotyrosines, docking sites, src homology 2 ( SH2 ) domain, intracellular domain, phosphotyrosine residue, amino acid residues, phosphotyrosine, docking sites Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.

[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]

[ "Entity", "Protein" ]

Interleukin-4, IL-4, interleukin-12, IL-12, tyrosine residues, intracellular domain, phosphotyrosines, docking sites, src homology 2 ( SH2 ) domain, intracellular domain, phosphotyrosine residue, amino acid residues, phosphotyrosine, docking sites

186_task2

Sentence: Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Entity", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Interleukin-4 (IL-4) and interleukin-12 (IL-12) control the differentiation of T-helper cells. Here we summarize studies which investigate the mechanism by which these cytokines selectively reprogramme gene expression in T-lymphocytes. Cytokine stimulation leads to the phosphorylation of specific tyrosine residues within the intracellular domain of the corresponding cytokine receptor. These phosphotyrosines serve as docking sites for latent, cytoplasmic transcription factors known as signal transducers and activators of transcription (Stat) proteins. Receptor/Stat interaction is mediated by the src homology 2 (SH2) domain of the corresponding Stat protein. Although Stat binding to the intracellular domain of the cytokine receptor strongly depends on the phosphotyrosine residue, the recruitment of a specific Stat protein is dictated by amino acid residues C-terminal to the phosphotyrosine. Specific docking sites within individual cytokine receptors have been identified for almost all Stat proteins. The direct coupling between cytokine receptor and transcription factor helps to explain how different cytokines elicit distinct patterns of gene expression.

[ "Differentiation", "of", "T", "-", "helper", "lymphocytes", ":", "selective", "regulation", "by", "members", "of", "the", "STAT", "family", "of", "transcription", "factors", ".", "\n", "Interleukin-4", "(", "IL-4", ")", "and", "interleukin-12", "(", "IL-12", ")", "control", "the", "differentiation", "of", "T", "-", "helper", "cells", ".", "Here", "we", "summarize", "studies", "which", "investigate", "the", "mechanism", "by", "which", "these", "cytokines", "selectively", "reprogramme", "gene", "expression", "in", "T", "-", "lymphocytes", ".", "Cytokine", "stimulation", "leads", "to", "the", "phosphorylation", "of", "specific", "tyrosine", "residues", "within", "the", "intracellular", "domain", "of", "the", "corresponding", "cytokine", "receptor", ".", "These", "phosphotyrosines", "serve", "as", "docking", "sites", "for", "latent", ",", "cytoplasmic", "transcription", "factors", "known", "as", "signal", "transducers", "and", "activators", "of", "transcription", "(", "Stat", ")", "proteins", ".", "Receptor", "/", "Stat", "interaction", "is", "mediated", "by", "the", "src", "homology", "2", "(", "SH2", ")", "domain", "of", "the", "corresponding", "Stat", "protein", ".", "Although", "Stat", "binding", "to", "the", "intracellular", "domain", "of", "the", "cytokine", "receptor", "strongly", "depends", "on", "the", "phosphotyrosine", "residue", ",", "the", "recruitment", "of", "a", "specific", "Stat", "protein", "is", "dictated", "by", "amino", "acid", "residues", "C", "-", "terminal", "to", "the", "phosphotyrosine", ".", "Specific", "docking", "sites", "within", "individual", "cytokine", "receptors", "have", "been", "identified", "for", "almost", "all", "Stat", "proteins", ".", "The", "direct", "coupling", "between", "cytokine", "receptor", "and", "transcription", "factor", "helps", "to", "explain", "how", "different", "cytokines", "elicit", "distinct", "patterns", "of", "gene", "expression", ".", "\n" ]

[ "Entity", "Protein" ]

fimbrin is a protein, actin is a protein

1.0alpha7.train.1315_task0

Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.

[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]

[ "protein" ]

fimbrin is a protein, actin is a protein

1.0alpha7.train.1315_task1

Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please typing these entity words according to sentence: fimbrin, actin Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.

[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]

[ "protein" ]

fimbrin, actin

1.0alpha7.train.1315_task2

Sentence: The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The regular appearance of the crossbands within the arrays (slanted or straight) indicates that the binding of fimbrin to actin occurs only at very specific binding sites and not in a random manner.

[ "The", "regular", "appearance", "of", "the", "crossbands", "within", "the", "arrays", "(", "slanted", "or", "straight", ")", "indicates", "that", "the", "binding", "of", " ", "fimbrin", "to", " ", "actin", "occurs", "only", "at", "very", "specific", "binding", "sites", "and", "not", "in", "a", "random", "manner", "." ]

[ "protein" ]

Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase is a GENE-Y

16532449_task0

Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.

[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]

[ "GENE-Y", "CHEMICAL" ]

Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase is a GENE-Y

16532449_task1

Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please typing these entity words according to sentence: Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.

[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]

[ "GENE-Y", "CHEMICAL" ]

Bacillus circulans ssp . alkalophilus phosphoserine aminotransferase

16532449_task2

Sentence: Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O" ]

Effect of pH on the structure and stability of Bacillus circulans ssp. alkalophilus phosphoserine aminotransferase: thermodynamic and crystallographic studies.

[ "Effect", "of", "pH", "on", "the", "structure", "and", "stability", "of", "Bacillus", "circulans", "ssp", ".", "alkalophilus", "phosphoserine", "aminotransferase", ":", "thermodynamic", "and", "crystallographic", "studies", "." ]

[ "GENE-Y", "CHEMICAL" ]

complication probability modeling is a Intervention_Other, after radiotherapy is a Participant_Condition, prostate cancer is a Participant_Condition, 512 is a Participant_Sample-size, 284 is a Participant_Sample-size, 228 is a Participant_Sample-size, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model is a Intervention_Other, High stool frequency is a Outcome_Physical

50694_task0

Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Other, Outcome_Physical, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .

[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]

[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

complication probability modeling is a Intervention_Other, after radiotherapy is a Participant_Condition, prostate cancer is a Participant_Condition, 512 is a Participant_Sample-size, 284 is a Participant_Sample-size, 228 is a Participant_Sample-size, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model is a Intervention_Other, High stool frequency is a Outcome_Physical

50694_task1

Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please typing these entity words according to sentence: complication probability modeling, after radiotherapy, prostate cancer, 512, 284, 228, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model, High stool frequency Options: Intervention_Other, Outcome_Physical, Participant_Condition, Participant_Sample-size

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .

[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]

[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

complication probability modeling, after radiotherapy, prostate cancer, 512, 284, 228, Two traditional dose - based models ( Lyman - Kutcher - Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model, High stool frequency

50694_task2

Sentence: The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "B-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The benefits of including clinical factors in rectal normal tissue complication probability modeling after radiotherapy for prostate cancer . PURPOSE To study the impact of clinical predisposing factors on rectal normal tissue complication probability modeling using the updated results of the Dutch prostate dose-escalation trial . METHODS AND MATERIALS Toxicity data of 512 patients ( conformally treated to 68 Gy [ n = 284 ] and 78 Gy [ n = 228 ] ) with complete follow-up at 3 years after radiotherapy were studied . Scored end points were rectal bleeding , high stool frequency , and fecal incontinence . Two traditional dose-based models ( Lyman-Kutcher-Burman ( LKB ) and Relative Seriality ( RS ) and a logistic model were fitted using a maximum likelihood approach . Furthermore , these model fits were improved by including the most significant clinical factors . The area under the receiver operating characteristic curve ( AUC ) was used to compare the discriminating ability of all fits . RESULTS Including clinical factors significantly increased the predictive power of the models for all end points . In the optimal LKB , RS , and logistic models for rectal bleeding and fecal incontinence , the first significant ( p = 0.011-0.013 ) clinical factor was " previous abdominal surgery . " As second significant ( p = 0.012-0.016 ) factor , " cardiac history " was included in all three rectal bleeding fits , whereas including " diabetes " was significant ( p = 0.039-0.048 ) in fecal incontinence modeling but only in the LKB and logistic models . High stool frequency fits only benefitted significantly ( p = 0.003-0.006 ) from the inclusion of the baseline toxicity score . For all models rectal bleeding fits had the highest AUC ( 0.77 ) where it was 0.63 and 0.68 for high stool frequency and fecal incontinence , respectively . LKB and logistic model fits resulted in similar values for the volume parameter . The steepness parameter was somewhat higher in the logistic model , also resulting in a slightly lower D ( 50 ) . Anal wall DVHs were used for fecal incontinence , whereas anorectal wall dose best described the other two endpoints . CONCLUSIONS Comparable prediction models were obtained with LKB , RS , and logistic NTCP models . Including clinical factors improved the predictive power of all models significantly .

[ "The", "benefits", "of", "including", "clinical", "factors", "in", "rectal", "normal", "tissue", "complication", "probability", "modeling", "after", "radiotherapy", "for", "prostate", "cancer", ".", "PURPOSE", "To", "study", "the", "impact", "of", "clinical", "predisposing", "factors", "on", "rectal", "normal", "tissue", "complication", "probability", "modeling", "using", "the", "updated", "results", "of", "the", "Dutch", "prostate", "dose", "-", "escalation", "trial", ".", "METHODS", "AND", "MATERIALS", "Toxicity", "data", "of", "512", "patients", "(", "conformally", "treated", "to", "68", "Gy", "[", "n", "=", "284", "]", "and", "78", "Gy", "[", "n", "=", "228", "]", ")", "with", "complete", "follow", "-", "up", "at", "3", "years", "after", "radiotherapy", "were", "studied", ".", "Scored", "end", "points", "were", "rectal", "bleeding", ",", "high", "stool", "frequency", ",", "and", "fecal", "incontinence", ".", "Two", "traditional", "dose", "-", "based", "models", "(", "Lyman", "-", "Kutcher", "-", "Burman", "(", "LKB", ")", "and", "Relative", "Seriality", "(", "RS", ")", "and", "a", "logistic", "model", "were", "fitted", "using", "a", "maximum", "likelihood", "approach", ".", "Furthermore", ",", "these", "model", "fits", "were", "improved", "by", "including", "the", "most", "significant", "clinical", "factors", ".", "The", "area", "under", "the", "receiver", "operating", "characteristic", "curve", "(", "AUC", ")", "was", "used", "to", "compare", "the", "discriminating", "ability", "of", "all", "fits", ".", "RESULTS", "Including", "clinical", "factors", "significantly", "increased", "the", "predictive", "power", "of", "the", "models", "for", "all", "end", "points", ".", "In", "the", "optimal", "LKB", ",", "RS", ",", "and", "logistic", "models", "for", "rectal", "bleeding", "and", "fecal", "incontinence", ",", "the", "first", "significant", "(", "p", "=", "0.011", "-", "0.013", ")", "clinical", "factor", "was", "\"", "previous", "abdominal", "surgery", ".", "\"", "As", "second", "significant", "(", "p", "=", "0.012", "-", "0.016", ")", "factor", ",", "\"", "cardiac", "history", "\"", "was", "included", "in", "all", "three", "rectal", "bleeding", "fits", ",", "whereas", "including", "\"", "diabetes", "\"", "was", "significant", "(", "p", "=", "0.039", "-", "0.048", ")", "in", "fecal", "incontinence", "modeling", "but", "only", "in", "the", "LKB", "and", "logistic", "models", ".", "High", "stool", "frequency", "fits", "only", "benefitted", "significantly", "(", "p", "=", "0.003", "-", "0.006", ")", "from", "the", "inclusion", "of", "the", "baseline", "toxicity", "score", ".", "For", "all", "models", "rectal", "bleeding", "fits", "had", "the", "highest", "AUC", "(", "0.77", ")", "where", "it", "was", "0.63", "and", "0.68", "for", "high", "stool", "frequency", "and", "fecal", "incontinence", ",", "respectively", ".", "LKB", "and", "logistic", "model", "fits", "resulted", "in", "similar", "values", "for", "the", "volume", "parameter", ".", "The", "steepness", "parameter", "was", "somewhat", "higher", "in", "the", "logistic", "model", ",", "also", "resulting", "in", "a", "slightly", "lower", "D", "(", "50", ")", ".", "Anal", "wall", "DVHs", "were", "used", "for", "fecal", "incontinence", ",", "whereas", "anorectal", "wall", "dose", "best", "described", "the", "other", "two", "endpoints", ".", "CONCLUSIONS", "Comparable", "prediction", "models", "were", "obtained", "with", "LKB", ",", "RS", ",", "and", "logistic", "NTCP", "models", ".", "Including", "clinical", "factors", "improved", "the", "predictive", "power", "of", "all", "models", "significantly", "." ]

[ "Intervention_Other", "Outcome_Physical", "Participant_Condition", "Intervention_Physical", "Participant_Sample-size" ]

evolutional process is a Outcome_Other, language therapeutic interventions is a Intervention_Educational, the extension and the speed of the evolutional process is a Outcome_Mental, direct and indirect interventions is a Intervention_Educational, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention is a Intervention_Physical, Autism Behavior Checklist ( ABC ) to interview the mothers is a Intervention_Educational, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) is a Intervention_Educational, speed and extension in the evolutional process is a Outcome_Other, Autism Behavior Checklist ( total and partial scores ) is a Outcome_Mental, performance is a Outcome_Mental, adaptive functioning is a Outcome_Mental

50196_task0

Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Educational, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .

[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]

[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]

evolutional process is a Outcome_Other, language therapeutic interventions is a Intervention_Educational, the extension and the speed of the evolutional process is a Outcome_Mental, direct and indirect interventions is a Intervention_Educational, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention is a Intervention_Physical, Autism Behavior Checklist ( ABC ) to interview the mothers is a Intervention_Educational, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) is a Intervention_Educational, speed and extension in the evolutional process is a Outcome_Other, Autism Behavior Checklist ( total and partial scores ) is a Outcome_Mental, performance is a Outcome_Mental, adaptive functioning is a Outcome_Mental

50196_task1

Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please typing these entity words according to sentence: evolutional process, language therapeutic interventions, the extension and the speed of the evolutional process, direct and indirect interventions, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention, Autism Behavior Checklist ( ABC ) to interview the mothers, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ), speed and extension in the evolutional process, Autism Behavior Checklist ( total and partial scores ), performance, adaptive functioning Options: Intervention_Physical, Intervention_Educational, Outcome_Other, Outcome_Mental

[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .

[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]

[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]

evolutional process, language therapeutic interventions, the extension and the speed of the evolutional process, direct and indirect interventions, Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention, Autism Behavior Checklist ( ABC ) to interview the mothers, the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ), speed and extension in the evolutional process, Autism Behavior Checklist ( total and partial scores ), performance, adaptive functioning

50196_task2

Sentence: Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Comparison of the evolutional process of children with autism spectrum disorders in different language therapeutic interventions . PURPOSE To analyze and compare the extension and the speed of the evolutional process of children with Autism Spectrum Disorders in direct and indirect interventions as opposed to only indirect intervention . METHODS The design of this study is a clinical trial . The sample was composed of 11 children diagnosed with Autism ( n=6 ) and Asperger syndrome ( n=5 ) by a multidisciplinary team , that attended specialized speech-language pathology therapy at the institution were the study was carried out . These children were randomly divided into two groups : Therapy Group ( TG ) - composed by six subjects receiving both direct and indirect intervention ; and Orientation Group ( OG ) - constituted by five subjects receiving exclusively indirect intervention . It was used the Autism Behavior Checklist ( ABC ) to interview the mothers , and the Sample of Vocal Behavior ( SVB ) , in three occasions : at the beginning of the intervention process ( time 0 ) , six months later ( time 1 ) and 12 months later ( time 2 ) . RESULTS It was observed greater speed and extension in the evolutional process of the TG Group , both in the analysis of the Autism Behavior Checklist ( total and partial scores ) and the Sample of Vocal Behavior , especially in the item Full Language . The performance of children with Asperger syndrome was considered more positive when compared to that of children with autism . There was greater evolution in younger children and with normal , mild , and moderate adaptive functioning . CONCLUSION The tendency towards better performance of the children attending direct and indirect intervention showed that this association is fundamental in the therapeutic process of children with Autism Spectrum Disorders .

[ "Comparison", "of", "the", "evolutional", "process", "of", "children", "with", "autism", "spectrum", "disorders", "in", "different", "language", "therapeutic", "interventions", ".", "PURPOSE", "To", "analyze", "and", "compare", "the", "extension", "and", "the", "speed", "of", "the", "evolutional", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "in", "direct", "and", "indirect", "interventions", "as", "opposed", "to", "only", "indirect", "intervention", ".", "METHODS", "The", "design", "of", "this", "study", "is", "a", "clinical", "trial", ".", "The", "sample", "was", "composed", "of", "11", "children", "diagnosed", "with", "Autism", "(", "n=6", ")", "and", "Asperger", "syndrome", "(", "n=5", ")", "by", "a", "multidisciplinary", "team", ",", "that", "attended", "specialized", "speech", "-", "language", "pathology", "therapy", "at", "the", "institution", "were", "the", "study", "was", "carried", "out", ".", "These", "children", "were", "randomly", "divided", "into", "two", "groups", ":", "Therapy", "Group", "(", "TG", ")", "-", "composed", "by", "six", "subjects", "receiving", "both", "direct", "and", "indirect", "intervention", ";", "and", "Orientation", "Group", "(", "OG", ")", "-", "constituted", "by", "five", "subjects", "receiving", "exclusively", "indirect", "intervention", ".", "It", "was", "used", "the", "Autism", "Behavior", "Checklist", "(", "ABC", ")", "to", "interview", "the", "mothers", ",", "and", "the", "Sample", "of", "Vocal", "Behavior", "(", "SVB", ")", ",", "in", "three", "occasions", ":", "at", "the", "beginning", "of", "the", "intervention", "process", "(", "time", "0", ")", ",", "six", "months", "later", "(", "time", "1", ")", "and", "12", "months", "later", "(", "time", "2", ")", ".", "RESULTS", "It", "was", "observed", "greater", "speed", "and", "extension", "in", "the", "evolutional", "process", "of", "the", "TG", "Group", ",", "both", "in", "the", "analysis", "of", "the", "Autism", "Behavior", "Checklist", "(", "total", "and", "partial", "scores", ")", "and", "the", "Sample", "of", "Vocal", "Behavior", ",", "especially", "in", "the", "item", "Full", "Language", ".", "The", "performance", "of", "children", "with", "Asperger", "syndrome", "was", "considered", "more", "positive", "when", "compared", "to", "that", "of", "children", "with", "autism", ".", "There", "was", "greater", "evolution", "in", "younger", "children", "and", "with", "normal", ",", "mild", ",", "and", "moderate", "adaptive", "functioning", ".", "CONCLUSION", "The", "tendency", "towards", "better", "performance", "of", "the", "children", "attending", "direct", "and", "indirect", "intervention", "showed", "that", "this", "association", "is", "fundamental", "in", "the", "therapeutic", "process", "of", "children", "with", "Autism", "Spectrum", "Disorders", "." ]

[ "Intervention_Physical", "Intervention_Educational", "Outcome_Mental", "Outcome_Other" ]

Methoden is an umlsterm, Therapieverfahren is an umlsterm, Behandlung is an umlsterm, Kniegelenks is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Knorpelveraenderungen is an umlsterm, Holmium is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Brancheninstrumente is an umlsterm, Knorpellaesionen is an umlsterm, Knorpellaesion is an umlsterm, Geschlechtsverteilung is an umlsterm, Behandlung is an umlsterm, Patientengruppen is an umlsterm, Patienten is an umlsterm, Fragebogen is an umlsterm, Schmerzauspraegung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Laserpatienten is an umlsterm, Schmerzwahrnehmung is an umlsterm, Fragebogens is an umlsterm, Lasergruppe is an umlsterm, Schmerzwahrnehmung is an umlsterm

Arthroskopie.80110291.ger.abstr_task0

Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .

[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]

[ "umlsterm" ]

Methoden is an umlsterm, Therapieverfahren is an umlsterm, Behandlung is an umlsterm, Kniegelenks is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Knorpelveraenderungen is an umlsterm, Holmium is an umlsterm, Patienten is an umlsterm, Instrumente is an umlsterm, Brancheninstrumente is an umlsterm, Knorpellaesionen is an umlsterm, Knorpellaesion is an umlsterm, Geschlechtsverteilung is an umlsterm, Behandlung is an umlsterm, Patientengruppen is an umlsterm, Patienten is an umlsterm, Fragebogen is an umlsterm, Schmerzauspraegung is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Laserpatienten is an umlsterm, Schmerzwahrnehmung is an umlsterm, Fragebogens is an umlsterm, Lasergruppe is an umlsterm, Schmerzwahrnehmung is an umlsterm

Arthroskopie.80110291.ger.abstr_task1

Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please typing these entity words according to sentence: Methoden, Therapieverfahren, Behandlung, Kniegelenks, Patienten, Patienten, Knorpelveraenderungen, Holmium, Patienten, Instrumente, Brancheninstrumente, Knorpellaesionen, Knorpellaesion, Geschlechtsverteilung, Behandlung, Patientengruppen, Patienten, Fragebogen, Schmerzauspraegung, Patienten, Patienten, Laserpatienten, Schmerzwahrnehmung, Fragebogens, Lasergruppe, Schmerzwahrnehmung Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .

[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]

[ "umlsterm" ]

Methoden, Therapieverfahren, Behandlung, Kniegelenks, Patienten, Patienten, Knorpelveraenderungen, Holmium, Patienten, Instrumente, Brancheninstrumente, Knorpellaesionen, Knorpellaesion, Geschlechtsverteilung, Behandlung, Patientengruppen, Patienten, Fragebogen, Schmerzauspraegung, Patienten, Patienten, Laserpatienten, Schmerzwahrnehmung, Fragebogens, Lasergruppe, Schmerzwahrnehmung

Arthroskopie.80110291.ger.abstr_task2

Sentence: In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

In der vorliegenden Untersuchung werden die Ergebnisse konventionell mechanischer Methoden mit lasergestuetzen Therapieverfahren in der arthroskopischen Behandlung der Chondropathie des Kniegelenks verglichen . 102 Patienten konnten randomisiert in 2 Gruppen unterteilt werden : In der 1. Gruppe ( n = 52 Patienten ) wurden die Knorpelveraenderungen mittels eines Holmium : YAG-Lasers behandelt . In der 2. Gruppe ( n = 50 Patienten ) wurden konventionell mechanische Instrumente ( Fraesen , starre Schneide- und Brancheninstrumente ) verwandt . Einschlusskriterien in die Studie waren degenerativ oder traumatisch bedingte Knorpellaesionen . Hinsichtlich der Schwere der Knorpellaesion , der Lokalisation , der Alters- und Geschlechtsverteilung , der Operationsdauer und der perioperativen Behandlung ergab sich zwischen beiden Patientengruppen kein Unterschied . Nach einem mittleren Nachuntersuchungszeitraum von 21 Monaten postoperativ wurde bei allen Patienten standardisiert ein Fragebogen , u.a. mit den Kriterien des Lysholm-Scores , erhoben ; die Schmerzauspraegung wurde mit Hilfe einer visuellen Analogskala ermittelt . In Gruppe 1 konnten 49 Patienten und in Gruppe 2 45 Patienten klinisch standardisiert nachuntersucht werden . Hinsichtlich der objektivierbaren Untersuchungsbefunde ergab sich zwischen beiden Gruppen kein signifikanter Unterschied . Ein signifikant guenstigeres Ergebnis der Laserpatienten fand sich in der Schmerzwahrnehmung , gemessen mit der visuellen Analogskala . Die subjektiven anamnestischen Daten , erhoben mittels des Lysholm-Scores bzw. eines individuell erstellten Fragebogens , zeigten in einigen Kriterien statistisch signifikant bessere Ergebnisse in der Lasergruppe ( Gesamtwert des Lysholm-Scores , schmerzfreies Treppensteigen , subjektive Schmerzwahrnehmung , Bereitschaft zur Operationswiederholung ) .

[ "In", "der", "vorliegenden", "Untersuchung", "werden", "die", "Ergebnisse", "konventionell", "mechanischer", "Methoden", "mit", "lasergestuetzen", "Therapieverfahren", "in", "der", "arthroskopischen", "Behandlung", "der", "Chondropathie", "des", "Kniegelenks", "verglichen", ".", "102", "Patienten", "konnten", "randomisiert", "in", "2", "Gruppen", "unterteilt", "werden", ":", "In", "der", "1", ".", "Gruppe", "(", "n", "=", "52", "Patienten", ")", "wurden", "die", "Knorpelveraenderungen", "mittels", "eines", "Holmium", ":", "YAG", "-", "Lasers", "behandelt", ".", "In", "der", "2", ".", "Gruppe", "(", "n", "=", "50", "Patienten", ")", "wurden", "konventionell", "mechanische", "Instrumente", "(", "Fraesen", ",", "starre", "Schneide-", "und", "Brancheninstrumente", ")", "verwandt", ".", "Einschlusskriterien", "in", "die", "Studie", "waren", "degenerativ", "oder", "traumatisch", "bedingte", "Knorpellaesionen", ".", "Hinsichtlich", "der", "Schwere", "der", "Knorpellaesion", ",", "der", "Lokalisation", ",", "der", "Alters-", "und", "Geschlechtsverteilung", ",", "der", "Operationsdauer", "und", "der", "perioperativen", "Behandlung", "ergab", "sich", "zwischen", "beiden", "Patientengruppen", "kein", "Unterschied", ".", "Nach", "einem", "mittleren", "Nachuntersuchungszeitraum", "von", "21", "Monaten", "postoperativ", "wurde", "bei", "allen", "Patienten", "standardisiert", "ein", "Fragebogen", ",", "u.a", ".", "mit", "den", "Kriterien", "des", "Lysholm", "-", "Scores", ",", "erhoben", ";", "die", "Schmerzauspraegung", "wurde", "mit", "Hilfe", "einer", "visuellen", "Analogskala", "ermittelt", ".", "In", "Gruppe", "1", "konnten", "49", "Patienten", "und", "in", "Gruppe", "2", "45", "Patienten", "klinisch", "standardisiert", "nachuntersucht", "werden", ".", "Hinsichtlich", "der", "objektivierbaren", "Untersuchungsbefunde", "ergab", "sich", "zwischen", "beiden", "Gruppen", "kein", "signifikanter", "Unterschied", ".", "Ein", "signifikant", "guenstigeres", "Ergebnis", "der", "Laserpatienten", "fand", "sich", "in", "der", "Schmerzwahrnehmung", ",", "gemessen", "mit", "der", "visuellen", "Analogskala", ".", "Die", "subjektiven", "anamnestischen", "Daten", ",", "erhoben", "mittels", "des", "Lysholm", "-", "Scores", "bzw", ".", "eines", "individuell", "erstellten", "Fragebogens", ",", "zeigten", "in", "einigen", "Kriterien", "statistisch", "signifikant", "bessere", "Ergebnisse", "in", "der", "Lasergruppe", "(", "Gesamtwert", "des", "Lysholm", "-", "Scores", ",", "schmerzfreies", "Treppensteigen", ",", "subjektive", "Schmerzwahrnehmung", ",", "Bereitschaft", "zur", "Operationswiederholung", ")", "." ]

[ "umlsterm" ]

Age is a Person, 65 - 79 is a Value, History is a Observation, coronary artery disease is a Condition, MI / heart attack , stroke , heart failure , or peripheral artery disease is a Scope, Cancer is a Condition, no is a Negation, active treatment is a Procedure, in the last year is a Temporal, MCI is a Condition, MoCA > 18<26 is a Scope, Decline physical function is a Condition, walking speed < 1 m / s is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hypertension is a Condition, treated or resting blood pressure > 140/90 is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hyperlipidemia is a Condition, treated or fasting total cholesterol > 240 is a Scope, English literacy is a Observation, Willing to is a Mood, provide informed consent is a Observation

NCT02986659_inc_task0

Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Value, Person, Observation, Procedure, Negation, Scope, Mood

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]

Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent

[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]

Age is a Person, 65 - 79 is a Value, History is a Observation, coronary artery disease is a Condition, MI / heart attack , stroke , heart failure , or peripheral artery disease is a Scope, Cancer is a Condition, no is a Negation, active treatment is a Procedure, in the last year is a Temporal, MCI is a Condition, MoCA > 18<26 is a Scope, Decline physical function is a Condition, walking speed < 1 m / s is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hypertension is a Condition, treated or resting blood pressure > 140/90 is a Scope, Abdominal obesity is a Condition, > 88 cm women , > 102 cm men is a Scope, hyperlipidemia is a Condition, treated or fasting total cholesterol > 240 is a Scope, English literacy is a Observation, Willing to is a Mood, provide informed consent is a Observation

NCT02986659_inc_task1

Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please typing these entity words according to sentence: Age, 65 - 79, History, coronary artery disease, MI / heart attack , stroke , heart failure , or peripheral artery disease, Cancer, no, active treatment, in the last year, MCI, MoCA > 18<26, Decline physical function, walking speed < 1 m / s, Abdominal obesity, > 88 cm women , > 102 cm men, hypertension, treated or resting blood pressure > 140/90, Abdominal obesity, > 88 cm women , > 102 cm men, hyperlipidemia, treated or fasting total cholesterol > 240, English literacy, Willing to, provide informed consent Options: Temporal, Condition, Value, Person, Observation, Procedure, Negation, Scope, Mood

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]

Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent

[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]

Age, 65 - 79, History, coronary artery disease, MI / heart attack , stroke , heart failure , or peripheral artery disease, Cancer, no, active treatment, in the last year, MCI, MoCA > 18<26, Decline physical function, walking speed < 1 m / s, Abdominal obesity, > 88 cm women , > 102 cm men, hypertension, treated or resting blood pressure > 140/90, Abdominal obesity, > 88 cm women , > 102 cm men, hyperlipidemia, treated or fasting total cholesterol > 240, English literacy, Willing to, provide informed consent

NCT02986659_inc_task2

Sentence: Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent Instructions: please extract entity words from the input sentence

[ "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Observation", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Negation", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Observation", "I-Observation", "B-Mood", "I-Mood", "B-Observation", "I-Observation", "I-Observation", "O" ]

Age 65 - 79 History of coronary artery disease (MI/heart attack, stroke, heart failure, or peripheral artery disease) Cancer, with no active treatment in the last year MCI (MoCA >18<26 -inclusive of 1 point if <12 years of education Group 2 Decline physical function (walking speed < 1 m/s) Group 3 (Either or both) Abdominal obesity (>88cm women, >102cm men) AND hypertension (treated or resting blood pressure >140/90 Abdominal obesity (>88cm women, >102cm men) AND hyperlipidemia (treated or fasting total cholesterol >240 English literacy Willing to provide informed consent

[ "Age", "65", "-", "79", "\n", "History", "of", "coronary", "artery", "disease", "(", "MI", "/", "heart", "attack", ",", "stroke", ",", "heart", "failure", ",", "or", "peripheral", "artery", "disease", ")", "\n", "Cancer", ",", "with", "no", "active", "treatment", "in", "the", "last", "year", "\n", "MCI", "(", "MoCA", ">", "18<26", "-inclusive", "of", "1", "point", "if", "<", "12", "years", "of", "education", "Group", "2", "\n", "Decline", "physical", "function", "(", "walking", "speed", "<", "1", "m", "/", "s", ")", "Group", "3", "(", "Either", "or", "both", ")", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hypertension", "(", "treated", "or", "resting", "blood", "pressure", ">", "140/90", "\n", "Abdominal", "obesity", "(", ">", "88", "cm", "women", ",", ">", "102", "cm", "men", ")", "AND", "hyperlipidemia", "(", "treated", "or", "fasting", "total", "cholesterol", ">", "240", "English", "literacy", "Willing", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Condition", "Measurement", "Observation", "Procedure", "Temporal", "Mood", "Value", "Person", "Negation" ]

profilin is a Individual_protein, actin is a Individual_protein, extracellular matrix proteins is a Individual_protein

290_task0

Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.

[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]

[ "Individual_protein" ]

profilin is a Individual_protein, actin is a Individual_protein, extracellular matrix proteins is a Individual_protein

290_task1

Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please typing these entity words according to sentence: profilin, actin, extracellular matrix proteins Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.

[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]

[ "Individual_protein" ]

profilin, actin, extracellular matrix proteins

290_task2

Sentence: Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "B-Individual_protein", "I-Individual_protein", "I-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Furthermore, a simultaneous expression of profilin, actin and extracellular matrix proteins was observed during the regeneration of rat liver, that is, all mRNAs of these proteins showed biphasic peaks around 6 h and 48 h after partial hepatectomy.

[ "Furthermore", ",", "a", "simultaneous", "expression", "of", "profilin", ",", "actin", "and", "extracellular", "matrix", "proteins", "was", "observed", "during", "the", "regeneration", "of", "rat", "liver", ",", "that", "is", ",", "all", "mRNAs", "of", "these", "proteins", "showed", "biphasic", "peaks", "around", "6", "h", "and", "48", "h", "after", "partial", "hepatectomy", "." ]

[ "Individual_protein" ]

cytochrome P450 1 is a GENE-N, Cyp1 is a GENE-N, vanadium is a CHEMICAL

23423713_task0

Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.

[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

cytochrome P450 1 is a GENE-N, Cyp1 is a GENE-N, vanadium is a CHEMICAL

23423713_task1

Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please typing these entity words according to sentence: cytochrome P450 1, Cyp1, vanadium Options: GENE-N, CHEMICAL

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.

[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

cytochrome P450 1, Cyp1, vanadium

23423713_task2

Sentence: Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "B-GENE-N", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Modulation of cytochrome P450 1 (Cyp1) by vanadium in hepatic tissue and isolated hepatocyte of C57BL/6 mice.

[ "Modulation", "of", "cytochrome", "P450", "1", "(", "Cyp1", ")", "by", "vanadium", "in", "hepatic", "tissue", "and", "isolated", "hepatocyte", "of", "C57BL/6", "mice", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Pneumonien is an umlsterm

DerAnaesthesist.80470925.ger.abstr_task0

Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .

[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]

[ "umlsterm" ]

Pneumonien is an umlsterm

DerAnaesthesist.80470925.ger.abstr_task1

Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please typing these entity words according to sentence: Pneumonien Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .

[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]

[ "umlsterm" ]

Pneumonien

DerAnaesthesist.80470925.ger.abstr_task2

Sentence: Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die offiziellen deutschen Richtlinien zur Praevention nosokomialer Pneumonien durch das fruehere Bundesgesundheitsamt ( jetzt Robert-Koch-Institut ) sind mittlerweile 12 Jahre alt . Die kuerzlich publizierten offiziellen Empfehlungen der amerikanischen Centers for Disease Control and Prevention ( CDC ) beruhen auf vorhandenen wissenschaftlichen Daten und sind daraufhin bezueglich ihrer Wertigkeit kategorisiert . Diese umfassenden Empfehlungen sind wesentlich ausfuehrlicher als die offiziellen deutschen Richtlinien und weisen zu diesen teilweise betraechtliche Unterschiede auf . Mit dieser kurzen Darstellung der amerikanischen Richtlinien soll dem Kliniker fuer die eigene praktische Taetigkeit bezueglich vieler alltaeglicher , aber keineswegs nebensaechlicher Probleme eine fundierte Entscheidungshilfe zur Verfuegung gestellt werden .

[ "Die", "offiziellen", "deutschen", "Richtlinien", "zur", "Praevention", "nosokomialer", "Pneumonien", "durch", "das", "fruehere", "Bundesgesundheitsamt", "(", "jetzt", "Robert", "-", "Koch", "-", "Institut", ")", "sind", "mittlerweile", "12", "Jahre", "alt", ".", "Die", "kuerzlich", "publizierten", "offiziellen", "Empfehlungen", "der", "amerikanischen", "Centers", "for", "Disease", "Control", "and", "Prevention", "(", "CDC", ")", "beruhen", "auf", "vorhandenen", "wissenschaftlichen", "Daten", "und", "sind", "daraufhin", "bezueglich", "ihrer", "Wertigkeit", "kategorisiert", ".", "Diese", "umfassenden", "Empfehlungen", "sind", "wesentlich", "ausfuehrlicher", "als", "die", "offiziellen", "deutschen", "Richtlinien", "und", "weisen", "zu", "diesen", "teilweise", "betraechtliche", "Unterschiede", "auf", ".", "Mit", "dieser", "kurzen", "Darstellung", "der", "amerikanischen", "Richtlinien", "soll", "dem", "Kliniker", "fuer", "die", "eigene", "praktische", "Taetigkeit", "bezueglich", "vieler", "alltaeglicher", ",", "aber", "keineswegs", "nebensaechlicher", "Probleme", "eine", "fundierte", "Entscheidungshilfe", "zur", "Verfuegung", "gestellt", "werden", "." ]

[ "umlsterm" ]

Dokumentation is an umlsterm, Lymphknotenbefundes is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm, thoraxchirurgischen is an umlsterm, Gesellschaft is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten - Sampling is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm

DerChirurg.70680601.ger.abstr_task0

Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .

[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]

[ "umlsterm" ]

Dokumentation is an umlsterm, Lymphknotenbefundes is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm, thoraxchirurgischen is an umlsterm, Gesellschaft is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten is an umlsterm, Lymphknoten - Sampling is an umlsterm, Lymphknotendokumentation is an umlsterm, Lymphadenektomie is an umlsterm

DerChirurg.70680601.ger.abstr_task1

Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please typing these entity words according to sentence: Dokumentation, Lymphknotenbefundes, Lymphknotendokumentation, Lymphadenektomie, thoraxchirurgischen, Gesellschaft, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten - Sampling, Lymphknotendokumentation, Lymphadenektomie Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .

[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]

[ "umlsterm" ]

Dokumentation, Lymphknotenbefundes, Lymphknotendokumentation, Lymphadenektomie, thoraxchirurgischen, Gesellschaft, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten, Lymphknoten - Sampling, Lymphknotendokumentation, Lymphadenektomie

DerChirurg.70680601.ger.abstr_task2

Sentence: Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fuer die chirurgische Dokumentation des Lymphknotenbefundes bei Bronchialcarcinomen stehen verschiedene Schemata zur Verfuegung . Die Benutzung eines reproduzierbaren Schemas ist eine wesentliche Grundlage fuer die korrekte Bestimmung des TNM-Status und fuer die Vergleichbarkeit der Behandlungsergebnisse verschiedener Zentren . Um das gegenwaertige Vorgehen der Lymphknotendokumentation und Lymphadenektomie zu erfragen , haben wir an 90 thoraxchirurgischen Abteilungen eine Umfrage durchgefuehrt . Auswertbare Antworten erhielten wir von 61 ( 67,7 % ) Abteilungen . Die Mehrzahl der Kliniken ( 43 % ) benutzt das Dokumentationsschema der Deutschen Gesellschaft fuer THG/Pneumologie , 23 % das Schema nach Naruke , weitere 25 % nehmen eine individuelle Benennung der entnommenen Lymphknoten vor . Die Anzahl der untersuchten Lymphknoten wird bei 75 % der Kliniken angegeben , der Quotient von befallenen/nichtbefallenen Lymphknoten bei 33 % der Abteilungen . Unter Beruecksichtigung des intraoperativen Aspekts der Lymphknoten wird ein mediastinales " Lymphknoten-Sampling " bei 59 % der Abteilungen durchgefuehrt , eine systematische mediastinale En-bloc-Resektion bei 41 % der Kliniken . Die Ergebnisse dieser Umfrage geben ein Bild des derzeitigen Stands der Lymphknotendokumentation und Lymphadenektomie bei Bronchialcarcinomen wieder und koennten als Grundlage zur Fortentwicklung eines einheitlichen Dokumentationsschemas dienen .

[ "Fuer", "die", "chirurgische", "Dokumentation", "des", "Lymphknotenbefundes", "bei", "Bronchialcarcinomen", "stehen", "verschiedene", "Schemata", "zur", "Verfuegung", ".", "Die", "Benutzung", "eines", "reproduzierbaren", "Schemas", "ist", "eine", "wesentliche", "Grundlage", "fuer", "die", "korrekte", "Bestimmung", "des", "TNM", "-", "Status", "und", "fuer", "die", "Vergleichbarkeit", "der", "Behandlungsergebnisse", "verschiedener", "Zentren", ".", "Um", "das", "gegenwaertige", "Vorgehen", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "zu", "erfragen", ",", "haben", "wir", "an", "90", "thoraxchirurgischen", "Abteilungen", "eine", "Umfrage", "durchgefuehrt", ".", "Auswertbare", "Antworten", "erhielten", "wir", "von", "61", "(", "67,7", "%", ")", "Abteilungen", ".", "Die", "Mehrzahl", "der", "Kliniken", "(", "43", "%", ")", "benutzt", "das", "Dokumentationsschema", "der", "Deutschen", "Gesellschaft", "fuer", "THG", "/", "Pneumologie", ",", "23", "%", "das", "Schema", "nach", "Naruke", ",", "weitere", "25", "%", "nehmen", "eine", "individuelle", "Benennung", "der", "entnommenen", "Lymphknoten", "vor", ".", "Die", "Anzahl", "der", "untersuchten", "Lymphknoten", "wird", "bei", "75", "%", "der", "Kliniken", "angegeben", ",", "der", "Quotient", "von", "befallenen", "/", "nichtbefallenen", "Lymphknoten", "bei", "33", "%", "der", "Abteilungen", ".", "Unter", "Beruecksichtigung", "des", "intraoperativen", "Aspekts", "der", "Lymphknoten", "wird", "ein", "mediastinales", "\"", "Lymphknoten", "-", "Sampling", "\"", "bei", "59", "%", "der", "Abteilungen", "durchgefuehrt", ",", "eine", "systematische", "mediastinale", "En", "-", "bloc", "-", "Resektion", "bei", "41", "%", "der", "Kliniken", ".", "Die", "Ergebnisse", "dieser", "Umfrage", "geben", "ein", "Bild", "des", "derzeitigen", "Stands", "der", "Lymphknotendokumentation", "und", "Lymphadenektomie", "bei", "Bronchialcarcinomen", "wieder", "und", "koennten", "als", "Grundlage", "zur", "Fortentwicklung", "eines", "einheitlichen", "Dokumentationsschemas", "dienen", "." ]

[ "umlsterm" ]

E2F - HDAC is a Complex, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone H3 is a Gene_or_gene_product, lysine 9 is a Simple_chemical, histone H3 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, 6 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, chromatin is a Cellular_component, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone deacetylase is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, trichostatin A is a Simple_chemical, TSA is a Simple_chemical, ARHI is a Gene_or_gene_product, luciferase is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, TSA is a Simple_chemical, E2F - HDAC is a Complex, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, retinoblastoma protein is a Gene_or_gene_product, pRB is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F4 is a Gene_or_gene_product, pRB is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, ARHI is a Gene_or_gene_product

148_task0

Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component

[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]

E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.

[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]

E2F - HDAC is a Complex, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone H3 is a Gene_or_gene_product, lysine 9 is a Simple_chemical, histone H3 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F2 is a Gene_or_gene_product, 6 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, E2F is a Gene_or_gene_product, chromatin is a Cellular_component, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, histone deacetylase is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, trichostatin A is a Simple_chemical, TSA is a Simple_chemical, ARHI is a Gene_or_gene_product, luciferase is a Gene_or_gene_product, E2F is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, TSA is a Simple_chemical, E2F - HDAC is a Complex, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, retinoblastoma protein is a Gene_or_gene_product, pRB is a Gene_or_gene_product, ARHI is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, E2F4 is a Gene_or_gene_product, pRB is a Gene_or_gene_product, E2F1 is a Gene_or_gene_product, 4 is a Gene_or_gene_product, HDAC is a Gene_or_gene_product, ARHI is a Gene_or_gene_product

148_task1

Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please typing these entity words according to sentence: E2F - HDAC, ARHI, ARHI, ARHI, histone H3, lysine 9, histone H3, ARHI, ARHI, E2F, E2F1, 4, E2F2, 6, E2F, E2F1, 4, E2F, chromatin, E2F1, 4, ARHI, histone deacetylase, HDAC, trichostatin A, TSA, ARHI, luciferase, E2F, E2F1, 4, ARHI, TSA, E2F - HDAC, E2F1, 4, retinoblastoma protein, pRB, ARHI, E2F1, E2F4, pRB, E2F1, 4, HDAC, ARHI Options: Simple_chemical, Complex, Gene_or_gene_product, Cellular_component

[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]

E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.

[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]

E2F - HDAC, ARHI, ARHI, ARHI, histone H3, lysine 9, histone H3, ARHI, ARHI, E2F, E2F1, 4, E2F2, 6, E2F, E2F1, 4, E2F, chromatin, E2F1, 4, ARHI, histone deacetylase, HDAC, trichostatin A, TSA, ARHI, luciferase, E2F, E2F1, 4, ARHI, TSA, E2F - HDAC, E2F1, 4, retinoblastoma protein, pRB, ARHI, E2F1, E2F4, pRB, E2F1, 4, HDAC, ARHI

148_task2

Sentence: E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells. Instructions: please extract entity words from the input sentence

[ "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Simple_chemical", "I-Simple_chemical", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Simple_chemical", "O", "O", "O", "O", "O", "O", "B-Complex", "I-Complex", "I-Complex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]

E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer. ARHI is a maternally imprinted tumor suppressor gene whose expression is markedly downregulated in breast cancer. Reactivation of ARHI expression in breast cancer cells is associated with increased histone H3 acetylation and decreased lysine 9 methylation of histone H3. An ARHI promoter segment that spanned bases -420 to +58 (designated the P2 region) exhibits significantly higher promoter activity in normal cells than in cancer cells. To better understand the molecular mechanisms contributing to this differential transcriptional activity, we sought to identify transcription factors that bind to the P2 region of the ARHI promoter and regulate its activity. Sequence analysis and oligonucleotide competition in electrophoretic mobility shift assays identified an A2 fragment containing an E2F-binding site. Using specific antibodies in supershift assays, we have shown that anti-E2F1 and 4 antibodies can supershift the A2-protein complexes, whereas anti-E2F2 and 6 antibodies cannot, demonstrating that the A2 fragment interacts with specific members of the E2F family proteins. When compared with normal breast epithelial cells, breast cancer cells have significantly elevated expression of E2F1, 4 and increased E2F DNA-binding activity. Moreover, chromatin immunoprecipitation experiments revealed that both E2F1 and 4 bind to the ARHI promoter in breast cancer cells in vivo. This binding was reduced when the cells were treated with the histone deacetylase (HDAC) inhibitor--trichostatin A (TSA). When SKBr3 cells were cotransfected with an ARHI/luciferase reporter and E2F-expression vectors, E2F1 and 4 reduced ARHI promoter activity 2-3-fold, and this reduction could be reversed by TSA treatment. The negative regulation by E2F-HDAC complexes could also be reduced by small interfering RNA of E2F1 and 4. While the retinoblastoma protein, pRB, alone had no effect on ARHI promoter activity, repression by E2F1, but not E2F4, was enhanced by the coexpression of pRB. Taken together, our results suggest that E2F1, 4 and their complexes with HDAC play an important role in downregulating the expression of the tumor suppressor gene ARHI in breast cancer cells.

[ "E2F", "-", "HDAC", "complexes", "negatively", "regulate", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", ".", "\n", "ARHI", "is", "a", "maternally", "imprinted", "tumor", "suppressor", "gene", "whose", "expression", "is", "markedly", "downregulated", "in", "breast", "cancer", ".", "Reactivation", "of", "ARHI", "expression", "in", "breast", "cancer", "cells", "is", "associated", "with", "increased", "histone", "H3", "acetylation", "and", "decreased", "lysine", "9", "methylation", "of", "histone", "H3", ".", "An", "ARHI", "promoter", "segment", "that", "spanned", "bases", "-420", "to", "+58", "(", "designated", "the", "P2", "region", ")", "exhibits", "significantly", "higher", "promoter", "activity", "in", "normal", "cells", "than", "in", "cancer", "cells", ".", "To", "better", "understand", "the", "molecular", "mechanisms", "contributing", "to", "this", "differential", "transcriptional", "activity", ",", "we", "sought", "to", "identify", "transcription", "factors", "that", "bind", "to", "the", "P2", "region", "of", "the", "ARHI", "promoter", "and", "regulate", "its", "activity", ".", "Sequence", "analysis", "and", "oligonucleotide", "competition", "in", "electrophoretic", "mobility", "shift", "assays", "identified", "an", "A2", "fragment", "containing", "an", "E2F", "-", "binding", "site", ".", "Using", "specific", "antibodies", "in", "supershift", "assays", ",", "we", "have", "shown", "that", "anti", "-", "E2F1", "and", "4", "antibodies", "can", "supershift", "the", "A2-protein", "complexes", ",", "whereas", "anti", "-", "E2F2", "and", "6", "antibodies", "cannot", ",", "demonstrating", "that", "the", "A2", "fragment", "interacts", "with", "specific", "members", "of", "the", "E2F", "family", "proteins", ".", "When", "compared", "with", "normal", "breast", "epithelial", "cells", ",", "breast", "cancer", "cells", "have", "significantly", "elevated", "expression", "of", "E2F1", ",", "4", "and", "increased", "E2F", "DNA", "-", "binding", "activity", ".", "Moreover", ",", "chromatin", "immunoprecipitation", "experiments", "revealed", "that", "both", "E2F1", "and", "4", "bind", "to", "the", "ARHI", "promoter", "in", "breast", "cancer", "cells", "in", "vivo", ".", "This", "binding", "was", "reduced", "when", "the", "cells", "were", "treated", "with", "the", "histone", "deacetylase", "(", "HDAC", ")", "inhibitor", "--", "trichostatin", "A", "(", "TSA", ")", ".", "When", "SKBr3", "cells", "were", "cotransfected", "with", "an", "ARHI", "/", "luciferase", "reporter", "and", "E2F", "-", "expression", "vectors", ",", "E2F1", "and", "4", "reduced", "ARHI", "promoter", "activity", "2", "-", "3-fold", ",", "and", "this", "reduction", "could", "be", "reversed", "by", "TSA", "treatment", ".", "The", "negative", "regulation", "by", "E2F", "-", "HDAC", "complexes", "could", "also", "be", "reduced", "by", "small", "interfering", "RNA", "of", "E2F1", "and", "4", ".", "While", "the", "retinoblastoma", "protein", ",", "pRB", ",", "alone", "had", "no", "effect", "on", "ARHI", "promoter", "activity", ",", "repression", "by", "E2F1", ",", "but", "not", "E2F4", ",", "was", "enhanced", "by", "the", "coexpression", "of", "pRB", ".", "Taken", "together", ",", "our", "results", "suggest", "that", "E2F1", ",", "4", "and", "their", "complexes", "with", "HDAC", "play", "an", "important", "role", "in", "downregulating", "the", "expression", "of", "the", "tumor", "suppressor", "gene", "ARHI", "in", "breast", "cancer", "cells", ".", "\n" ]

[ "Gene_or_gene_product", "Simple_chemical", "Cellular_component", "Complex" ]

woman is an umlsterm, blood loss is an umlsterm, injuries is an umlsterm, PTT is an umlsterm, factor XII is an umlsterm, deficiency is an umlsterm, symptoms is an umlsterm, von Willebrands disease is an umlsterm, patient is an umlsterm, protein C is an umlsterm, concentration is an umlsterm, homocysteine is an umlsterm, blood plasma is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, mutation is an umlsterm, methylenetetrahydrofolate reductase is an umlsterm, -gene is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, point mutation is an umlsterm, promoter region is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, factor XII is an umlsterm, woman is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, mutation is an umlsterm, women is an umlsterm, old is an umlsterm, blood loss is an umlsterm, coagulation is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, von Willebrands disease is an umlsterm, factor XII is an umlsterm, factor XII deficiency is an umlsterm, APC resistance is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, Mother is an umlsterm, father is an umlsterm, factor XII deficiency is an umlsterm, mutation is an umlsterm, gene is an umlsterm, mother is an umlsterm, mutation is an umlsterm, factor V is an umlsterm, gene is an umlsterm, family members is an umlsterm, D - dimer is an umlsterm, concentrations is an umlsterm, plasma is an umlsterm

MonatsschriftKinderheilkunde.91470104.eng.abstr_task0

Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .

[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]

[ "umlsterm" ]

woman is an umlsterm, blood loss is an umlsterm, injuries is an umlsterm, PTT is an umlsterm, factor XII is an umlsterm, deficiency is an umlsterm, symptoms is an umlsterm, von Willebrands disease is an umlsterm, patient is an umlsterm, protein C is an umlsterm, concentration is an umlsterm, homocysteine is an umlsterm, blood plasma is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, mutation is an umlsterm, methylenetetrahydrofolate reductase is an umlsterm, -gene is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, point mutation is an umlsterm, promoter region is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, factor XII is an umlsterm, woman is an umlsterm, mutation is an umlsterm, factor XII is an umlsterm, gene is an umlsterm, mutation is an umlsterm, women is an umlsterm, old is an umlsterm, blood loss is an umlsterm, coagulation is an umlsterm, analysis is an umlsterm, factor XII is an umlsterm, von Willebrands disease is an umlsterm, factor XII is an umlsterm, factor XII deficiency is an umlsterm, APC resistance is an umlsterm, factor V is an umlsterm, mutation is an umlsterm, Mother is an umlsterm, father is an umlsterm, factor XII deficiency is an umlsterm, mutation is an umlsterm, gene is an umlsterm, mother is an umlsterm, mutation is an umlsterm, factor V is an umlsterm, gene is an umlsterm, family members is an umlsterm, D - dimer is an umlsterm, concentrations is an umlsterm, plasma is an umlsterm

MonatsschriftKinderheilkunde.91470104.eng.abstr_task1

Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please typing these entity words according to sentence: woman, blood loss, injuries, PTT, factor XII, deficiency, symptoms, von Willebrands disease, patient, protein C, concentration, homocysteine, blood plasma, factor V, mutation, mutation, methylenetetrahydrofolate reductase, -gene, analysis, factor XII, gene, point mutation, promoter region, mutation, factor XII, gene, factor XII, woman, mutation, factor XII, gene, mutation, women, old, blood loss, coagulation, analysis, factor XII, von Willebrands disease, factor XII, factor XII deficiency, APC resistance, factor V, mutation, Mother, father, factor XII deficiency, mutation, gene, mother, mutation, factor V, gene, family members, D - dimer, concentrations, plasma Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .

[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]

[ "umlsterm" ]

woman, blood loss, injuries, PTT, factor XII, deficiency, symptoms, von Willebrands disease, patient, protein C, concentration, homocysteine, blood plasma, factor V, mutation, mutation, methylenetetrahydrofolate reductase, -gene, analysis, factor XII, gene, point mutation, promoter region, mutation, factor XII, gene, factor XII, woman, mutation, factor XII, gene, mutation, women, old, blood loss, coagulation, analysis, factor XII, von Willebrands disease, factor XII, factor XII deficiency, APC resistance, factor V, mutation, Mother, father, factor XII deficiency, mutation, gene, mother, mutation, factor V, gene, family members, D - dimer, concentrations, plasma

MonatsschriftKinderheilkunde.91470104.eng.abstr_task2

Sentence: A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

A young woman presenting with marked menstrual blood loss and prolonged bleeding after only minimal injuries was investigated . Because of an extremely prolonged PTT ( more than 200 s ) we measured the factor XII activity and found a severe deficiency . The bleeding symptoms however could be ascribed to the existence of von Willebrands disease type 1. In addition , the patient had an elevated resistance against activated protein C ( APC-resistance ) and a moderately elevated concentration of homocysteine in her blood plasma . At the genomic level we found heterozygosity for the factor V mutation G 1691 A and the mutation C 677 T in the methylenetetrahydrofolate reductase ( MTHFR ) -gene . The analysis of the factor XII gene revealed the existence of a point mutation in the promoter region ( G- > C transversion , nt-8). The same mutation could be found in the paternal factor XII gene . The low factor XII activity in the woman seems to be the result of a second mutation originating from the maternal factor XII gene ( compound heterozygosity ) . However , this second mutation could not be found up to now . In the sister of the women , a 15 year old girl , there is also a marked menstrual blood loss . The coagulation analysis revealed reduced activities of the factor XII and also von Willebrands disease type 1. The reduced factor XII activity seems to be compatible with the heterozygous state of factor XII deficiency . In the girl there was also an increased APC resistance , corresponding with heterozygosity for the factor V mutation G 1691 A. Mother and father are heterozygous for the factor XII deficiency and the mutation C 677 T in the MTHFR gene . In the mother homozygosity for the mutation in the factor V gene ( 1691 AA ) could be found . All family members investigated exhibited elevated D-dimer concentrations in the plasma .

[ "A", "young", "woman", "presenting", "with", "marked", "menstrual", "blood", "loss", "and", "prolonged", "bleeding", "after", "only", "minimal", "injuries", "was", "investigated", ".", "Because", "of", "an", "extremely", "prolonged", "PTT", "(", "more", "than", "200", "s", ")", "we", "measured", "the", "factor", "XII", "activity", "and", "found", "a", "severe", "deficiency", ".", "The", "bleeding", "symptoms", "however", "could", "be", "ascribed", "to", "the", "existence", "of", "von", "Willebrands", "disease", "type", "1", ".", "In", "addition", ",", "the", "patient", "had", "an", "elevated", "resistance", "against", "activated", "protein", "C", "(", "APC", "-", "resistance", ")", "and", "a", "moderately", "elevated", "concentration", "of", "homocysteine", "in", "her", "blood", "plasma", ".", "At", "the", "genomic", "level", "we", "found", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A", "and", "the", "mutation", "C", "677", "T", "in", "the", "methylenetetrahydrofolate", "reductase", "(", "MTHFR", ")", "-gene", ".", "The", "analysis", "of", "the", "factor", "XII", "gene", "revealed", "the", "existence", "of", "a", "point", "mutation", "in", "the", "promoter", "region", "(", "G-", ">", "C", "transversion", ",", "nt-8", ")", ".", "The", "same", "mutation", "could", "be", "found", "in", "the", "paternal", "factor", "XII", "gene", ".", "The", "low", "factor", "XII", "activity", "in", "the", "woman", "seems", "to", "be", "the", "result", "of", "a", "second", "mutation", "originating", "from", "the", "maternal", "factor", "XII", "gene", "(", "compound", "heterozygosity", ")", ".", "However", ",", "this", "second", "mutation", "could", "not", "be", "found", "up", "to", "now", ".", "In", "the", "sister", "of", "the", "women", ",", "a", "15", "year", "old", "girl", ",", "there", "is", "also", "a", "marked", "menstrual", "blood", "loss", ".", "The", "coagulation", "analysis", "revealed", "reduced", "activities", "of", "the", "factor", "XII", "and", "also", "von", "Willebrands", "disease", "type", "1", ".", "The", "reduced", "factor", "XII", "activity", "seems", "to", "be", "compatible", "with", "the", "heterozygous", "state", "of", "factor", "XII", "deficiency", ".", "In", "the", "girl", "there", "was", "also", "an", "increased", "APC", "resistance", ",", "corresponding", "with", "heterozygosity", "for", "the", "factor", "V", "mutation", "G", "1691", "A.", "Mother", "and", "father", "are", "heterozygous", "for", "the", "factor", "XII", "deficiency", "and", "the", "mutation", "C", "677", "T", "in", "the", "MTHFR", "gene", ".", "In", "the", "mother", "homozygosity", "for", "the", "mutation", "in", "the", "factor", "V", "gene", "(", "1691", "AA", ")", "could", "be", "found", ".", "All", "family", "members", "investigated", "exhibited", "elevated", "D", "-", "dimer", "concentrations", "in", "the", "plasma", "." ]

[ "umlsterm" ]

Differentialdiagnose is an umlsterm, pulmonaler Rundherde is an umlsterm, Metastasen is an umlsterm, Tuberkulose is an umlsterm, Sarkoidose is an umlsterm, Silikose is an umlsterm, Amyloidtumoren is an umlsterm, Diagnosefindung is an umlsterm, radiologischer is an umlsterm, Aetiologie is an umlsterm

DerPathologe.60170301.ger.abstr_task0

Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .

[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]

[ "umlsterm" ]

Differentialdiagnose is an umlsterm, pulmonaler Rundherde is an umlsterm, Metastasen is an umlsterm, Tuberkulose is an umlsterm, Sarkoidose is an umlsterm, Silikose is an umlsterm, Amyloidtumoren is an umlsterm, Diagnosefindung is an umlsterm, radiologischer is an umlsterm, Aetiologie is an umlsterm

DerPathologe.60170301.ger.abstr_task1

Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please typing these entity words according to sentence: Differentialdiagnose, pulmonaler Rundherde, Metastasen, Tuberkulose, Sarkoidose, Silikose, Amyloidtumoren, Diagnosefindung, radiologischer, Aetiologie Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .

[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]

[ "umlsterm" ]

Differentialdiagnose, pulmonaler Rundherde, Metastasen, Tuberkulose, Sarkoidose, Silikose, Amyloidtumoren, Diagnosefindung, radiologischer, Aetiologie

DerPathologe.60170301.ger.abstr_task2

Sentence: Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die Differentialdiagnose multipler pulmonaler Rundherde umfasst neben Metastasen auch die Tuberkulose , Sarkoidose und Silikose . Seltenere Erkrankungen wie Amyloidtumoren , Rheumaknoten und Plasmazellgranulome koennen sich - je nach klinischer Situation - hinter diesem Befund verbergen . Am Beispiel des Krankheitsbildes der lymphomatoiden Granulomatose wird die Problematik der klinisch-pathologischen Diagnosefindung unter Einsatz radiologischer bronchoskopischer , mediastinoskopischer und thorakoskopischer Untersuchungsverfahren , dargestellt . Aetiologie und Morphologie einschliesslich differentialdiagnostischer Abgrenzungen zu nekrotisierenden entzuendlichen und neoplastischen Erkrankungen sowie therapeutische Ansaetze werden behandelt .

[ "Die", "Differentialdiagnose", "multipler", "pulmonaler", "Rundherde", "umfasst", "neben", "Metastasen", "auch", "die", "Tuberkulose", ",", "Sarkoidose", "und", "Silikose", ".", "Seltenere", "Erkrankungen", "wie", "Amyloidtumoren", ",", "Rheumaknoten", "und", "Plasmazellgranulome", "koennen", "sich", "-", "je", "nach", "klinischer", "Situation", "-", "hinter", "diesem", "Befund", "verbergen", ".", "Am", "Beispiel", "des", "Krankheitsbildes", "der", "lymphomatoiden", "Granulomatose", "wird", "die", "Problematik", "der", "klinisch", "-", "pathologischen", "Diagnosefindung", "unter", "Einsatz", "radiologischer", "bronchoskopischer", ",", "mediastinoskopischer", "und", "thorakoskopischer", "Untersuchungsverfahren", ",", "dargestellt", ".", "Aetiologie", "und", "Morphologie", "einschliesslich", "differentialdiagnostischer", "Abgrenzungen", "zu", "nekrotisierenden", "entzuendlichen", "und", "neoplastischen", "Erkrankungen", "sowie", "therapeutische", "Ansaetze", "werden", "behandelt", "." ]

[ "umlsterm" ]

RelA is a Protein, c - Rel is a Protein, I kappa B alpha is a Protein, IL-2 is a Protein, IL-2R alpha is a Protein, IL-4 is a Protein, IL-10 is a Protein, IFN - gamma is a Protein, IL-2 is a Protein

187_task0

Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.

[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]

[ "Protein" ]

RelA is a Protein, c - Rel is a Protein, I kappa B alpha is a Protein, IL-2 is a Protein, IL-2R alpha is a Protein, IL-4 is a Protein, IL-10 is a Protein, IFN - gamma is a Protein, IL-2 is a Protein

187_task1

Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please typing these entity words according to sentence: RelA, c - Rel, I kappa B alpha, IL-2, IL-2R alpha, IL-4, IL-10, IFN - gamma, IL-2 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.

[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]

[ "Protein" ]

RelA, c - Rel, I kappa B alpha, IL-2, IL-2R alpha, IL-4, IL-10, IFN - gamma, IL-2

187_task2

Sentence: In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. To understand the role of NF-kappa B complexes in T cell development and activation, we have generated transgenic mice in which RelA and c-Rel complexes were selectively inhibited in the T-lineage cells by specific expression of a trans-dominant form of I kappa B alpha. Transgene expression did not affect the thymic development, but led to lowered numbers of splenic T cells and to a dramatic decrease in the ex vivo proliferative response of splenic T lymphocytes. Analysis of IL-2 and IL-2R alpha expression demonstrated that the perturbation of the proliferation response was not attributable to an abnormal expression of these genes. In contrast, expression of IL-4, IL-10, and IFN-gamma was strongly inhibited in the transgenic T cells. The proliferative deficiency of the transgenic T cells was associated with an increased apoptosis. These results point out the involvement of NF-kappa B/Rel family proteins in growth signaling pathways by either regulating proteins involved in the IL-2 signaling or by functionally interfering with the cell cycle progression.

[ "In", "vivo", "inhibition", "of", "NF", "-", "kappa", "B", "in", "T", "-", "lineage", "cells", "leads", "to", "a", "dramatic", "decrease", "in", "cell", "proliferation", "and", "cytokine", "production", "and", "to", "increased", "cell", "apoptosis", "in", "response", "to", "mitogenic", "stimuli", ",", "but", "not", "to", "abnormal", "thymopoiesis", ".", "\n", "To", "understand", "the", "role", "of", "NF", "-", "kappa", "B", "complexes", "in", "T", "cell", "development", "and", "activation", ",", "we", "have", "generated", "transgenic", "mice", "in", "which", "RelA", "and", "c", "-", "Rel", "complexes", "were", "selectively", "inhibited", "in", "the", "T", "-", "lineage", "cells", "by", "specific", "expression", "of", "a", "trans", "-", "dominant", "form", "of", "I", "kappa", "B", "alpha", ".", "Transgene", "expression", "did", "not", "affect", "the", "thymic", "development", ",", "but", "led", "to", "lowered", "numbers", "of", "splenic", "T", "cells", "and", "to", "a", "dramatic", "decrease", "in", "the", "ex", "vivo", "proliferative", "response", "of", "splenic", "T", "lymphocytes", ".", "Analysis", "of", "IL-2", "and", "IL-2R", "alpha", "expression", "demonstrated", "that", "the", "perturbation", "of", "the", "proliferation", "response", "was", "not", "attributable", "to", "an", "abnormal", "expression", "of", "these", "genes", ".", "In", "contrast", ",", "expression", "of", "IL-4", ",", "IL-10", ",", "and", "IFN", "-", "gamma", "was", "strongly", "inhibited", "in", "the", "transgenic", "T", "cells", ".", "The", "proliferative", "deficiency", "of", "the", "transgenic", "T", "cells", "was", "associated", "with", "an", "increased", "apoptosis", ".", "These", "results", "point", "out", "the", "involvement", "of", "NF", "-", "kappa", "B", "/", "Rel", "family", "proteins", "in", "growth", "signaling", "pathways", "by", "either", "regulating", "proteins", "involved", "in", "the", "IL-2", "signaling", "or", "by", "functionally", "interfering", "with", "the", "cell", "cycle", "progression", "." ]

[ "Protein" ]

Laila is a NOMBRE_SUJETO_ASISTENCIA, Alonso Lestayo is a NOMBRE_SUJETO_ASISTENCIA, 736980 is a ID_SUJETO_ASISTENCIA, Barakaldo is a TERRITORIO, 48903 is a TERRITORIO, 15/08/2015 is a FECHAS, España is a PAIS, 16 meses is a EDAD_SUJETO_ASISTENCIA, 13/12/2015 is a FECHAS, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, 48 48 46560 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, hijo is a FAMILIARES_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, abuelo materno is a FAMILIARES_SUJETO_ASISTENCIA, Padre is a FAMILIARES_SUJETO_ASISTENCIA, Primo de rama paterna is a FAMILIARES_SUJETO_ASISTENCIA, 7 meses is a EDAD_SUJETO_ASISTENCIA, 14 meses is a EDAD_SUJETO_ASISTENCIA, 10 meses is a EDAD_SUJETO_ASISTENCIA, 15 meses is a EDAD_SUJETO_ASISTENCIA, 16 meses is a EDAD_SUJETO_ASISTENCIA, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, Hospital de Cruces is a HOSPITAL, Plaza de Cruces , s / n is a CALLE, 48903 is a TERRITORIO, Cruces is a TERRITORIO, Barakaldo is a TERRITORIO, España is a PAIS, mariasanlo@terra.es is a CORREO_ELECTRONICO

201_task0

Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Laila is a NOMBRE_SUJETO_ASISTENCIA, Alonso Lestayo is a NOMBRE_SUJETO_ASISTENCIA, 736980 is a ID_SUJETO_ASISTENCIA, Barakaldo is a TERRITORIO, 48903 is a TERRITORIO, 15/08/2015 is a FECHAS, España is a PAIS, 16 meses is a EDAD_SUJETO_ASISTENCIA, 13/12/2015 is a FECHAS, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, 48 48 46560 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, hijo is a FAMILIARES_SUJETO_ASISTENCIA, padres is a FAMILIARES_SUJETO_ASISTENCIA, Madre is a FAMILIARES_SUJETO_ASISTENCIA, abuelo materno is a FAMILIARES_SUJETO_ASISTENCIA, Padre is a FAMILIARES_SUJETO_ASISTENCIA, Primo de rama paterna is a FAMILIARES_SUJETO_ASISTENCIA, 7 meses is a EDAD_SUJETO_ASISTENCIA, 14 meses is a EDAD_SUJETO_ASISTENCIA, 10 meses is a EDAD_SUJETO_ASISTENCIA, 15 meses is a EDAD_SUJETO_ASISTENCIA, 16 meses is a EDAD_SUJETO_ASISTENCIA, María Sánchez López is a NOMBRE_PERSONAL_SANITARIO, Hospital de Cruces is a HOSPITAL, Plaza de Cruces , s / n is a CALLE, 48903 is a TERRITORIO, Cruces is a TERRITORIO, Barakaldo is a TERRITORIO, España is a PAIS, mariasanlo@terra.es is a CORREO_ELECTRONICO

201_task1

Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please typing these entity words according to sentence: Laila, Alonso Lestayo, 736980, Barakaldo, 48903, 15/08/2015, España, 16 meses, 13/12/2015, María Sánchez López, 48 48 46560, Mujer, hijo, padres, Madre, abuelo materno, Padre, Primo de rama paterna, 7 meses, 14 meses, 10 meses, 15 meses, 16 meses, María Sánchez López, Hospital de Cruces, Plaza de Cruces , s / n, 48903, Cruces, Barakaldo, España, mariasanlo@terra.es Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, FAMILIARES_SUJETO_ASISTENCIA, HOSPITAL, CALLE, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

Laila, Alonso Lestayo, 736980, Barakaldo, 48903, 15/08/2015, España, 16 meses, 13/12/2015, María Sánchez López, 48 48 46560, Mujer, hijo, padres, Madre, abuelo materno, Padre, Primo de rama paterna, 7 meses, 14 meses, 10 meses, 15 meses, 16 meses, María Sánchez López, Hospital de Cruces, Plaza de Cruces , s / n, 48903, Cruces, Barakaldo, España, mariasanlo@terra.es

201_task2

Sentence: Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "I-FAMILIARES_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "B-TERRITORIO", "B-PAIS", "O", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Datos del paciente. Nombre: Laila. Apellidos: Alonso Lestayo. NHC: 736980. Domicilio: C/ Madrid, 23, 1 A. Localidad/ Provincia: Barakaldo. CP: 48903. Datos asistenciales. Fecha de nacimiento: 15/08/2015. País de nacimiento: España. Edad: 16 meses Sexo: M. Fecha de Ingreso: 13/12/2015. Médico: María Sánchez López NºCol: 48 48 46560. Informe clínico del paciente: Mujer nacida a término por parto vaginal. Antecedentes familiares y personales: Primer hijo de padres no consanguíneos. Madre y abuelo materno con poliquistosis renal. Padre con trastorno de personalidad en tratamiento. Primo de rama paterna con esquizofrenia. Detección intraútero en ecografía de control de ventriculomegalia bilateral leve en la semana 21 de gestación que persiste en controles sucesivos. No se observan otras incidencias durante el embarazo. La puntuación en el test de Apgar fue 3/10, 4/10 y 8/10 a los 1, 10 y 20 minutos respectivamente, precisando intubación endotraqueal en la sala de partos. El peso al nacimiento fue 3.480 gramos, la talla 55 cm y perímetro craneal 39,5 cm. Al nacimiento presenta rasgos dismórficos: fascies tosca, hipertelorismo, narinas antevertidas, microrretrognatia y asimetría frontal con prominencia izquierda. Hipotonía generalizada que progresa hacia hipertonía generalizada con reflejos vivos, clonus y episodios convulsivos generalizados. No hay seguimiento visual. Durante el período neonatal, se realiza un electroencefalograma presentando una discreta lentificación difusa. En la ecografia cerebral se observa ventriculomegalia asimétrica de predominio izquierdo y asimetría hemisférica a favor del lado izquierdo. En la tomografía computarizada craneal presenta una prominencia del sistema ventricular. En la resonancia nuclear magnética se observa displasia cortical con focos de heterotopía nodular. El despistaje metabólico e infeccioso es normal. Cariotipo 46XX. A los 7 meses de edad es remitida al servicio de oftalmología por esotropía del ojo derecho de 15º. Presenta dominancia de ojo izquierdo, nistagmus en abducción en ambos ojos. La retina muestra un aspecto distrófico con desorganización difusa y anomalías pigmentarias retinianas. Hipoplasia de nervio óptico. Presenta miopía de -13,00 dioptrías (-2 a 90º) en ojo derecho y -14,00 dioptrías (-2 a 180º) en ojo izquierdo. Se prescribe corrección óptica. Los potenciales evocados visuales resultan patológicos con un aumento del período de latencia. No se puede realizar un electrorretinograma por falta de colaboración. A los 14 meses, la gran hipertofia hemicraneal izquierda imposibilita portar gafas, se recetan lentes de contacto que son bien toleradas. A los 10 meses, presenta un importante retraso psicomotor, hipertonía de extremidades e hipotonía cervicoaxial. No hay control cefálico ni sedestación. Mejora el contacto visual con mayor interacción con el ambiente y sonrisa social. Los controles electroencefalográficos muestran una asimetría interhemisférica del trazado, sin paroxismos irritativos. Presenta un progresivo aumento del hemicuerpo izquierdo, plagiocefalia y descenso de la órbita ipsilateral. Aparición progresiva de deformidades: tibia vara, coxa valga y adelgazamiento femoral bilateral. A los 15 meses, presenta aspecto macrocefálico con afectación del macizo craneofacial. Nevus epidérmicos y hemangiomas dispersos con predominio en el lado izquierdo. Espasticidad como respuesta a estímulos. A los 16 meses de edad, se realiza traqueostomía por laringotraqueomalacia. Fallece al sexto día del postoperatorio por neumonía. Responsable clínico: María Sánchez López Hospital de Cruces Plaza de Cruces, s/n 48903 Cruces/Barakaldo España E-mail: mariasanlo@terra.es

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Laila", ".", "\n", "Apellidos", ":", "Alonso", "Lestayo", ".", "\n", "NHC", ":", "736980", ".", "\n", "Domicilio", ":", "C/", "Madrid", ",", "23", ",", "1", "A.", "\n", "Localidad/", "Provincia", ":", "Barakaldo", ".", "\n", "CP", ":", "48903", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "15/08/2015", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "16", "meses", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "13/12/2015", ".", "\n", "Médico", ":", "María", "Sánchez", "López", "NºCol", ":", "48", "48", "46560", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "nacida", "a", "término", "por", "parto", "vaginal", ".", "\n", "Antecedentes", "familiares", "y", "personales", ":", "\n", "Primer", "hijo", "de", "padres", "no", "consanguíneos", ".", "\n", "Madre", "y", "abuelo", "materno", "con", "poliquistosis", "renal", ".", "\n", "Padre", "con", "trastorno", "de", "personalidad", "en", "tratamiento", ".", "\n", "Primo", "de", "rama", "paterna", "con", "esquizofrenia", ".", "\n", "Detección", "intraútero", "en", "ecografía", "de", "control", "de", "ventriculomegalia", "bilateral", "leve", "en", "la", "semana", "21", "de", "gestación", "que", "persiste", "en", "controles", "sucesivos", ".", "No", "se", "observan", "otras", "incidencias", "durante", "el", "embarazo", ".", "La", "puntuación", "en", "el", "test", "de", "Apgar", "fue", "3/10", ",", "4/10", "y", "8/10", "a", "los", "1", ",", "10", "y", "20", "minutos", "respectivamente", ",", "precisando", "intubación", "endotraqueal", "en", "la", "sala", "de", "partos", ".", "El", "peso", "al", "nacimiento", "fue", "3.480", "gramos", ",", "la", "talla", "55", "cm", "y", "perímetro", "craneal", "39,5", "cm", ".", "Al", "nacimiento", "presenta", "rasgos", "dismórficos", ":", "fascies", "tosca", ",", "hipertelorismo", ",", "narinas", "antevertidas", ",", "microrretrognatia", "y", "asimetría", "frontal", "con", "prominencia", "izquierda", ".", "Hipotonía", "generalizada", "que", "progresa", "hacia", "hipertonía", "generalizada", "con", "reflejos", "vivos", ",", "clonus", "y", "episodios", "convulsivos", "generalizados", ".", "No", "hay", "seguimiento", "visual", ".", "Durante", "el", "período", "neonatal", ",", "se", "realiza", "un", "electroencefalograma", "presentando", "una", "discreta", "lentificación", "difusa", ".", "En", "la", "ecografia", "cerebral", "se", "observa", "ventriculomegalia", "asimétrica", "de", "predominio", "izquierdo", "y", "asimetría", "hemisférica", "a", "favor", "del", "lado", "izquierdo", ".", "En", "la", "tomografía", "computarizada", "craneal", "presenta", "una", "prominencia", "del", "sistema", "ventricular", ".", "En", "la", "resonancia", "nuclear", "magnética", "se", "observa", "displasia", "cortical", "con", "focos", "de", "heterotopía", "nodular", ".", "\n", "El", "despistaje", "metabólico", "e", "infeccioso", "es", "normal", ".", "Cariotipo", "46XX", ".", "\n", "A", "los", "7", "meses", "de", "edad", "es", "remitida", "al", "servicio", "de", "oftalmología", "por", "esotropía", "del", "ojo", "derecho", "de", "15º.", "Presenta", "dominancia", "de", "ojo", "izquierdo", ",", "nistagmus", "en", "abducción", "en", "ambos", "ojos", ".", "La", "retina", "muestra", "un", "aspecto", "distrófico", "con", "desorganización", "difusa", "y", "anomalías", "pigmentarias", "retinianas", ".", "Hipoplasia", "de", "nervio", "óptico", ".", "\n", "Presenta", "miopía", "de", "-13,00", "dioptrías", "(", "-2", "a", "90º", ")", "en", "ojo", "derecho", "y", "-14,00", "dioptrías", "(", "-2", "a", "180º", ")", "en", "ojo", "izquierdo", ".", "Se", "prescribe", "corrección", "óptica", ".", "Los", "potenciales", "evocados", "visuales", "resultan", "patológicos", "con", "un", "aumento", "del", "período", "de", "latencia", ".", "No", "se", "puede", "realizar", "un", "electrorretinograma", "por", "falta", "de", "colaboración", ".", "A", "los", "14", "meses", ",", "la", "gran", "hipertofia", "hemicraneal", "izquierda", "imposibilita", "portar", "gafas", ",", "se", "recetan", "lentes", "de", "contacto", "que", "son", "bien", "toleradas", ".", "\n", "A", "los", "10", "meses", ",", "presenta", "un", "importante", "retraso", "psicomotor", ",", "hipertonía", "de", "extremidades", "e", "hipotonía", "cervicoaxial", ".", "No", "hay", "control", "cefálico", "ni", "sedestación", ".", "Mejora", "el", "contacto", "visual", "con", "mayor", "interacción", "con", "el", "ambiente", "y", "sonrisa", "social", ".", "Los", "controles", "electroencefalográficos", "muestran", "una", "asimetría", "interhemisférica", "del", "trazado", ",", "sin", "paroxismos", "irritativos", ".", "Presenta", "un", "progresivo", "aumento", "del", "hemicuerpo", "izquierdo", ",", "plagiocefalia", "y", "descenso", "de", "la", "órbita", "ipsilateral", ".", "\n", "Aparición", "progresiva", "de", "deformidades", ":", "tibia", "vara", ",", "coxa", "valga", "y", "adelgazamiento", "femoral", "bilateral", ".", "A", "los", "15", "meses", ",", "presenta", "aspecto", "macrocefálico", "con", "afectación", "del", "macizo", "craneofacial", ".", "Nevus", "epidérmicos", "y", "hemangiomas", "dispersos", "con", "predominio", "en", "el", "lado", "izquierdo", ".", "Espasticidad", "como", "respuesta", "a", "estímulos", ".", "A", "los", "16", "meses", "de", "edad", ",", "se", "realiza", "traqueostomía", "por", "laringotraqueomalacia", ".", "Fallece", "al", "sexto", "día", "del", "postoperatorio", "por", "neumonía", ".", "\n", "Responsable", "clínico", ":", "María", "Sánchez", "López", "Hospital", "de", "Cruces", "Plaza", "de", "Cruces", ",", "s", "/", "n", "48903", "Cruces", "/", "Barakaldo", "España", "E", "-", "mail", ":", "mariasanlo@terra.es", "\n" ]

[ "FAMILIARES_SUJETO_ASISTENCIA", "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "HOSPITAL", "NOMBRE_SUJETO_ASISTENCIA", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "PAIS", "ID_SUJETO_ASISTENCIA", "SEXO_SUJETO_ASISTENCIA" ]

LEGO therapy is a Intervention_Psychological, social use of language programme is a Intervention_Psychological, social skills interventions is a Intervention_Psychological, children is a Participant_Age, high functioning autism is a Participant_Condition, Asperger Syndrome is a Participant_Condition, Social Use of Language Programme ( SULP ) is a Intervention_Psychological, 6 - 11 is a Participant_Age, no - intervention control group is a Intervention_Control, autism - specific social interaction scores ( Gilliam Autism Rating Scale ) is a Outcome_Mental, Maladaptive behaviour is a Outcome_Mental, communication and socialisation skills is a Outcome_Mental

36069_task0

Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Mental

[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]

LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .

[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]

[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]

LEGO therapy is a Intervention_Psychological, social use of language programme is a Intervention_Psychological, social skills interventions is a Intervention_Psychological, children is a Participant_Age, high functioning autism is a Participant_Condition, Asperger Syndrome is a Participant_Condition, Social Use of Language Programme ( SULP ) is a Intervention_Psychological, 6 - 11 is a Participant_Age, no - intervention control group is a Intervention_Control, autism - specific social interaction scores ( Gilliam Autism Rating Scale ) is a Outcome_Mental, Maladaptive behaviour is a Outcome_Mental, communication and socialisation skills is a Outcome_Mental

36069_task1

Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please typing these entity words according to sentence: LEGO therapy, social use of language programme, social skills interventions, children, high functioning autism, Asperger Syndrome, Social Use of Language Programme ( SULP ), 6 - 11, no - intervention control group, autism - specific social interaction scores ( Gilliam Autism Rating Scale ), Maladaptive behaviour, communication and socialisation skills Options: Intervention_Psychological, Intervention_Control, Participant_Condition, Participant_Age, Outcome_Mental

[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]

LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .

[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]

[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]

LEGO therapy, social use of language programme, social skills interventions, children, high functioning autism, Asperger Syndrome, Social Use of Language Programme ( SULP ), 6 - 11, no - intervention control group, autism - specific social interaction scores ( Gilliam Autism Rating Scale ), Maladaptive behaviour, communication and socialisation skills

36069_task2

Sentence: LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Age", "I-Participant_Age", "I-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O" ]

LEGO therapy and the social use of language programme : an evaluation of two social skills interventions for children with high functioning autism and Asperger Syndrome . LEGO therapy and the Social Use of Language Programme ( SULP ) were evaluated as social skills interventions for 6-11 year olds with high functioning autism and Asperger Syndrome . Children were matched on CA , IQ , and autistic symptoms before being randomly assigned to LEGO or SULP . Therapy occurred for 1 h/week over 18 weeks . A no-intervention control group was also assessed . Results showed that the LEGO therapy group improved more than the other groups on autism-specific social interaction scores ( Gilliam Autism Rating Scale ) . Maladaptive behaviour decreased significantly more in the LEGO and SULP groups compared to the control group . There was a non-significant trend for SULP and LEGO groups to improve more than the no-intervention group in communication and socialisation skills .

[ "LEGO", "therapy", "and", "the", "social", "use", "of", "language", "programme", ":", "an", "evaluation", "of", "two", "social", "skills", "interventions", "for", "children", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "LEGO", "therapy", "and", "the", "Social", "Use", "of", "Language", "Programme", "(", "SULP", ")", "were", "evaluated", "as", "social", "skills", "interventions", "for", "6", "-", "11", "year", "olds", "with", "high", "functioning", "autism", "and", "Asperger", "Syndrome", ".", "Children", "were", "matched", "on", "CA", ",", "IQ", ",", "and", "autistic", "symptoms", "before", "being", "randomly", "assigned", "to", "LEGO", "or", "SULP", ".", "Therapy", "occurred", "for", "1", "h", "/", "week", "over", "18", "weeks", ".", "A", "no", "-", "intervention", "control", "group", "was", "also", "assessed", ".", "Results", "showed", "that", "the", "LEGO", "therapy", "group", "improved", "more", "than", "the", "other", "groups", "on", "autism", "-", "specific", "social", "interaction", "scores", "(", "Gilliam", "Autism", "Rating", "Scale", ")", ".", "Maladaptive", "behaviour", "decreased", "significantly", "more", "in", "the", "LEGO", "and", "SULP", "groups", "compared", "to", "the", "control", "group", ".", "There", "was", "a", "non", "-", "significant", "trend", "for", "SULP", "and", "LEGO", "groups", "to", "improve", "more", "than", "the", "no", "-", "intervention", "group", "in", "communication", "and", "socialisation", "skills", "." ]

[ "Outcome_Mental", "Intervention_Psychological", "Intervention_Control", "Participant_Condition", "Participant_Age" ]

muscarinic M3 receptor is a GENE-Y

19498041_task0

Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.

[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

muscarinic M3 receptor is a GENE-Y

19498041_task1

Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please typing these entity words according to sentence: muscarinic M3 receptor Options: GENE-Y

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.

[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

muscarinic M3 receptor

19498041_task2

Sentence: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O" ]

Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor.

[ "Exploring", "the", "mechanism", "of", "agonist", "efficacy", ":", "a", "relationship", "between", "efficacy", "and", "agonist", "dissociation", "rate", "at", "the", "muscarinic", "M3", "receptor", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

polychlorinated biphenyl is a CHEMICAL

23147987_task0

Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.

[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]

[ "CHEMICAL" ]

polychlorinated biphenyl is a CHEMICAL

23147987_task1

Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please typing these entity words according to sentence: polychlorinated biphenyl Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.

[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]

[ "CHEMICAL" ]

polychlorinated biphenyl

23147987_task2

Sentence: Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effects-based marine ecological risk assessment at a polychlorinated biphenyl-contaminated site in Saglek, Labrador, Canada.

[ "Effects", "-", "based", "marine", "ecological", "risk", "assessment", "at", "a", "polychlorinated", "biphenyl", "-", "contaminated", "site", "in", "Saglek", ",", "Labrador", ",", "Canada", "." ]

[ "CHEMICAL" ]

Lichtes is an umlsterm, Haut is an umlsterm, karzinogene is an umlsterm, DNS is an umlsterm, Tierexperimenten is an umlsterm, Plattenepithelkarzinomen is an umlsterm, Melanomen is an umlsterm, therapeutischen Anwendung is an umlsterm, maligner Melanome is an umlsterm, karzinogene is an umlsterm, Menschen is an umlsterm, Risiken is an umlsterm

DerHautarzt.40450517.ger.abstr_task0

Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .

[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]

[ "umlsterm" ]

Lichtes is an umlsterm, Haut is an umlsterm, karzinogene is an umlsterm, DNS is an umlsterm, Tierexperimenten is an umlsterm, Plattenepithelkarzinomen is an umlsterm, Melanomen is an umlsterm, therapeutischen Anwendung is an umlsterm, maligner Melanome is an umlsterm, karzinogene is an umlsterm, Menschen is an umlsterm, Risiken is an umlsterm

DerHautarzt.40450517.ger.abstr_task1

Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please typing these entity words according to sentence: Lichtes, Haut, karzinogene, DNS, Tierexperimenten, Plattenepithelkarzinomen, Melanomen, therapeutischen Anwendung, maligner Melanome, karzinogene, Menschen, Risiken Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .

[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]

[ "umlsterm" ]

Lichtes, Haut, karzinogene, DNS, Tierexperimenten, Plattenepithelkarzinomen, Melanomen, therapeutischen Anwendung, maligner Melanome, karzinogene, Menschen, Risiken

DerHautarzt.40450517.ger.abstr_task2

Sentence: Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Zusammenfassung . Die Anwendung des ultravioletten ( UV ) Lichtes zur kosmetisch erwuenschten Braeunung der Haut ist weit verbreitet . Eine moegliche Karzinogenitaet des UV-Lichtes ist bekannt , wird aber vorwiegend dem kurzwelligen UV-Anteil ( UVB ) zugeschrieben . Neuere Studien lieferten jedoch Hinweise auf eine karzinogene Potenz auch des langwelligen UV-Anteils ( UVA ) . In-vitro-Studien zeigten , dass UVA die DNS schaedigen kann . In mehreren Tierexperimenten fuehrte UVA z . , T. in Verbindung mit UVB , z . T. aber UVA allein , zur Entstehung von Plattenepithelkarzinomen und Melanomen . Belege ueber die moegliche Karzinogenitaet des UVA ergeben sich auch aus der therapeutischen Anwendung des UVA-Lichtes in Verbindung mit Psoralenen ( PUVA ) . Neuere epidemiologische Studien zeigten ferner Beziehungen zwischen Solarienbenutzung und der Entstehung maligner Melanome auf . Die Gesamtbetrachtung ergibt , dass eine karzinogene Wirkung der UVA-Strahlung beim Menschen nicht gesichert ist , jedoch aufgrund der vorliegenden experimentellen und epidemiologischen Daten keinesfalls ausgeschlossen werden kann . Wegen der weitreichenden Risiken ist vor laengerer UVA-Exposition Zurueckhaltung geboten .

[ "Zusammenfassung", ".", "Die", "Anwendung", "des", "ultravioletten", "(", "UV", ")", "Lichtes", "zur", "kosmetisch", "erwuenschten", "Braeunung", "der", "Haut", "ist", "weit", "verbreitet", ".", "Eine", "moegliche", "Karzinogenitaet", "des", "UV", "-", "Lichtes", "ist", "bekannt", ",", "wird", "aber", "vorwiegend", "dem", "kurzwelligen", "UV", "-", "Anteil", "(", "UVB", ")", "zugeschrieben", ".", "Neuere", "Studien", "lieferten", "jedoch", "Hinweise", "auf", "eine", "karzinogene", "Potenz", "auch", "des", "langwelligen", "UV", "-", "Anteils", "(", "UVA", ")", ".", "In", "-", "vitro", "-", "Studien", "zeigten", ",", "dass", "UVA", "die", "DNS", "schaedigen", "kann", ".", "In", "mehreren", "Tierexperimenten", "fuehrte", "UVA", "z", ".", ",", "T.", "in", "Verbindung", "mit", "UVB", ",", "z", ".", "T.", "aber", "UVA", "allein", ",", "zur", "Entstehung", "von", "Plattenepithelkarzinomen", "und", "Melanomen", ".", "Belege", "ueber", "die", "moegliche", "Karzinogenitaet", "des", "UVA", "ergeben", "sich", "auch", "aus", "der", "therapeutischen", "Anwendung", "des", "UVA", "-", "Lichtes", "in", "Verbindung", "mit", "Psoralenen", "(", "PUVA", ")", ".", "Neuere", "epidemiologische", "Studien", "zeigten", "ferner", "Beziehungen", "zwischen", "Solarienbenutzung", "und", "der", "Entstehung", "maligner", "Melanome", "auf", ".", "Die", "Gesamtbetrachtung", "ergibt", ",", "dass", "eine", "karzinogene", "Wirkung", "der", "UVA", "-", "Strahlung", "beim", "Menschen", "nicht", "gesichert", "ist", ",", "jedoch", "aufgrund", "der", "vorliegenden", "experimentellen", "und", "epidemiologischen", "Daten", "keinesfalls", "ausgeschlossen", "werden", "kann", ".", "Wegen", "der", "weitreichenden", "Risiken", "ist", "vor", "laengerer", "UVA", "-", "Exposition", "Zurueckhaltung", "geboten", "." ]

[ "umlsterm" ]

Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Kehlkopfentfernung is an umlsterm, Patienten is an umlsterm, Rachenhinterwandkarzinom is an umlsterm, Hypopharynx is an umlsterm, Tumorausdehnung is an umlsterm, kehlkopferhaltendes is an umlsterm, Patienten is an umlsterm, Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Unterarmlappen is an umlsterm, Duenndarmtransplantat is an umlsterm, Tumorausdehnungen is an umlsterm, Patienten is an umlsterm, Schluckfunktion is an umlsterm, Ernaehrung is an umlsterm, Patient is an umlsterm, Patient is an umlsterm, Aspirationen is an umlsterm, Nahrungsaufnahme is an umlsterm, Patienten is an umlsterm, Laryngektomie is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Rehabilitation is an umlsterm, Rachenhinterwandkarzinome is an umlsterm, Patienten is an umlsterm

HNO.80460135.ger.abstr_task0

Sentence: Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten .

[ "Bei", "der", "chirurgischen", "Entfernung", "von", "ausgedehnten", "Karzinomen", "der", "hypopharyngealen", "Rachenhinterwand", "stellt", "sich", "die", "Frage", "der", "Kehlkopfentfernung", "in", "erster", "Linie", "aus", "funktionellen", "Gruenden", ".", "Zwischen", "1994", "und", "1997", "wurde", "allen", "Patienten", "mit", "einem", "Rachenhinterwandkarzinom", "des", "Hypopharynx", "und", "einer", "geschaetzten", "Tumorausdehnung", "von", "mehr", "als", "6", "cm", "ein", "kehlkopferhaltendes", "chirurgisches", "Behandlungskonzept", "vorgeschlagen", ".", "Bei", "9", "Patienten", "mit", "T2", "(", "n=2", ")", "und", "T4", "(", "n=7", ")", "Karzinomen", "erfolgte", "nach", "lateraler", "Pharyngotomie", "eine", "Rekonstruktion", "der", "Rachenhinterwand", "mit", "freien", "Lappen", "(", "8", "Unterarmlappen", "und", "1", "Duenndarmtransplantat", ")", ".", "Die", "maximalen", "Tumorausdehnungen", "reichten", "von", "6,5", "-", "12,5", "cm", ".", "Bei", "der", "Praeparation", "wurde", "versucht", ",", "den", "N.", "laryngeus", "superior", "zu", "erhalten", "und", "bei", "der", "Einnaht", "der", "freien", "Lappen", "fand", "die", "exakte", "Anpassung", "des", "Lappens", "an", "den", "Defekt", "besondere", "Beachtung", ".", "Bei", "7", "Patienten", "war", "innerhalb", "von", "3", "Monaten", "die", "Schluckfunktion", "so", "wiederhergestellt", ",", "dass", "die", "Ernaehrung", "oral", "erfolgen", "konnte", ".", "Ein", "Patient", "benoetigte", "hierzu", "4", "Monate", "und", "ein", "Patient", "war", "12", "Monate", "postoperativ", "aufgrund", "von", "Aspirationen", "weiterhin", "nicht", "zur", "ausreichenden", "oralen", "Nahrungsaufnahme", "faehig", ",", "6", "Patienten", "wurden", "bisher", "dekanueliert", "und", "in", "keinem", "Fall", "war", "in", "der", "Beobachtungszeit", "eine", "Laryngektomie", "aufgrund", "von", "Komplikationen", "oder", "auf", "Wunsch", "des", "Patienten", "erforderlich", ".", "Die", "funktionelle", "Rehabilitation", "nach", "der", "Entfernung", "ausgedehnter", "Rachenhinterwandkarzinome", "gelingt", "mit", "Hilfe", "von", "freien", "Lappen", "bei", "einem", "Grossteil", "der", "Patienten", "." ]

[ "umlsterm" ]

Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Kehlkopfentfernung is an umlsterm, Patienten is an umlsterm, Rachenhinterwandkarzinom is an umlsterm, Hypopharynx is an umlsterm, Tumorausdehnung is an umlsterm, kehlkopferhaltendes is an umlsterm, Patienten is an umlsterm, Karzinomen is an umlsterm, Rachenhinterwand is an umlsterm, Unterarmlappen is an umlsterm, Duenndarmtransplantat is an umlsterm, Tumorausdehnungen is an umlsterm, Patienten is an umlsterm, Schluckfunktion is an umlsterm, Ernaehrung is an umlsterm, Patient is an umlsterm, Patient is an umlsterm, Aspirationen is an umlsterm, Nahrungsaufnahme is an umlsterm, Patienten is an umlsterm, Laryngektomie is an umlsterm, Komplikationen is an umlsterm, Patienten is an umlsterm, Rehabilitation is an umlsterm, Rachenhinterwandkarzinome is an umlsterm, Patienten is an umlsterm

HNO.80460135.ger.abstr_task1

Sentence: Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten . Instructions: please typing these entity words according to sentence: Karzinomen, Rachenhinterwand, Kehlkopfentfernung, Patienten, Rachenhinterwandkarzinom, Hypopharynx, Tumorausdehnung, kehlkopferhaltendes, Patienten, Karzinomen, Rachenhinterwand, Unterarmlappen, Duenndarmtransplantat, Tumorausdehnungen, Patienten, Schluckfunktion, Ernaehrung, Patient, Patient, Aspirationen, Nahrungsaufnahme, Patienten, Laryngektomie, Komplikationen, Patienten, Rehabilitation, Rachenhinterwandkarzinome, Patienten Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Bei der chirurgischen Entfernung von ausgedehnten Karzinomen der hypopharyngealen Rachenhinterwand stellt sich die Frage der Kehlkopfentfernung in erster Linie aus funktionellen Gruenden . Zwischen 1994 und 1997 wurde allen Patienten mit einem Rachenhinterwandkarzinom des Hypopharynx und einer geschaetzten Tumorausdehnung von mehr als 6 cm ein kehlkopferhaltendes chirurgisches Behandlungskonzept vorgeschlagen . Bei 9 Patienten mit T2 ( n=2) und T4 ( n=7) Karzinomen erfolgte nach lateraler Pharyngotomie eine Rekonstruktion der Rachenhinterwand mit freien Lappen ( 8 Unterarmlappen und 1 Duenndarmtransplantat ) . Die maximalen Tumorausdehnungen reichten von 6,5-12,5 cm . Bei der Praeparation wurde versucht , den N. laryngeus superior zu erhalten und bei der Einnaht der freien Lappen fand die exakte Anpassung des Lappens an den Defekt besondere Beachtung . Bei 7 Patienten war innerhalb von 3 Monaten die Schluckfunktion so wiederhergestellt , dass die Ernaehrung oral erfolgen konnte . Ein Patient benoetigte hierzu 4 Monate und ein Patient war 12 Monate postoperativ aufgrund von Aspirationen weiterhin nicht zur ausreichenden oralen Nahrungsaufnahme faehig , 6 Patienten wurden bisher dekanueliert und in keinem Fall war in der Beobachtungszeit eine Laryngektomie aufgrund von Komplikationen oder auf Wunsch des Patienten erforderlich . Die funktionelle Rehabilitation nach der Entfernung ausgedehnter Rachenhinterwandkarzinome gelingt mit Hilfe von freien Lappen bei einem Grossteil der Patienten .

[ "Bei", "der", "chirurgischen", "Entfernung", "von", "ausgedehnten", "Karzinomen", "der", "hypopharyngealen", "Rachenhinterwand", "stellt", "sich", "die", "Frage", "der", "Kehlkopfentfernung", "in", "erster", "Linie", "aus", "funktionellen", "Gruenden", ".", "Zwischen", "1994", "und", "1997", "wurde", "allen", "Patienten", "mit", "einem", "Rachenhinterwandkarzinom", "des", "Hypopharynx", "und", "einer", "geschaetzten", "Tumorausdehnung", "von", "mehr", "als", "6", "cm", "ein", "kehlkopferhaltendes", "chirurgisches", "Behandlungskonzept", "vorgeschlagen", ".", "Bei", "9", "Patienten", "mit", "T2", "(", "n=2", ")", "und", "T4", "(", "n=7", ")", "Karzinomen", "erfolgte", "nach", "lateraler", "Pharyngotomie", "eine", "Rekonstruktion", "der", "Rachenhinterwand", "mit", "freien", "Lappen", "(", "8", "Unterarmlappen", "und", "1", "Duenndarmtransplantat", ")", ".", "Die", "maximalen", "Tumorausdehnungen", "reichten", "von", "6,5", "-", "12,5", "cm", ".", "Bei", "der", "Praeparation", "wurde", "versucht", ",", "den", "N.", "laryngeus", "superior", "zu", "erhalten", "und", "bei", "der", "Einnaht", "der", "freien", "Lappen", "fand", "die", "exakte", "Anpassung", "des", "Lappens", "an", "den", "Defekt", "besondere", "Beachtung", ".", "Bei", "7", "Patienten", "war", "innerhalb", "von", "3", "Monaten", "die", "Schluckfunktion", "so", "wiederhergestellt", ",", "dass", "die", "Ernaehrung", "oral", "erfolgen", "konnte", ".", "Ein", "Patient", "benoetigte", "hierzu", "4", "Monate", "und", "ein", "Patient", "war", "12", "Monate", "postoperativ", "aufgrund", "von", "Aspirationen", "weiterhin", "nicht", "zur", "ausreichenden", "oralen", "Nahrungsaufnahme", "faehig", ",", "6", "Patienten", "wurden", "bisher", "dekanueliert", "und", "in", "keinem", "Fall", "war", "in", "der", "Beobachtungszeit", "eine", "Laryngektomie", "aufgrund", "von", "Komplikationen", "oder", "auf", "Wunsch", "des", "Patienten", "erforderlich", ".", "Die", "funktionelle", "Rehabilitation", "nach", "der", "Entfernung", "ausgedehnter", "Rachenhinterwandkarzinome", "gelingt", "mit", "Hilfe", "von", "freien", "Lappen", "bei", "einem", "Grossteil", "der", "Patienten", "." ]

[ "umlsterm" ]